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ABSTRACT 
 
Background: Missing treatment effect estimates for particular outcomes in a study have the potential 
to affect the conclusions in a meta-analysis (MA), especially if missingness is a result of outcome 
reporting bias (ORB). ORB comes from the results-based selection for publication of a subset of the 
original measured outcome variables and can result in overestimating treatment effects, resulting in 
bias. As well as missing treatment effect estimates at the study level, outcome data may also be 
missing within studies at the individual participant level. Multivariate meta-analysis (MVMA) of 
individual participant data (IPD) has the potential to overcome the impact of both these problems, by 
utilising the correlation between outcomes.  
 
Methods: An assessment of ORB was carried out in a cohort of systematic reviews (SR) with a core 
set of outcomes investigating pharmacological treatments for rheumatoid arthritis (RA). Novel IPD- 
MVMA methods to borrow strength across correlated outcomes were applied and evaluated through 
simulation, with the aim to show and quantify how this approach can reduce bias and improve 
precision of MA results, compared to traditional univariate methods, when there is missing outcome 
data as a result of both ORB and missing participant data. ORB assessments and the MVMA methods 
were applied to examples in RA.     
 
Results: Of the 167 assessable trials from 21 Cochrane RA reviews, 23% contained high suspicion of 
ORB in at least one of the core outcomes. Results from the simulations showed that the ‘borrowing of 
strength’ (BoS) in a multivariate model can reduce the magnitude of bias and increase precision in the 
pooled estimates. Results showed that when an ORB mechanism is introduced or there was missing 
IPD, MVMA tends to reduce the bias, increase the precision and improve the coverage when 
compared to a univariate analysis. In some instances, these benefits observed were also found in 
applying MVMA to the RA reviews.  
 
Conclusions: MVMA is not the solution to all missing data related problems within review meta-
analyses, but, informed by this thesis, it can unquestionably be seen as a route to address missing 
outcome data in SRs. The BoS, reduction in bias and increase in precision can all be seen as 
promising.
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Chapter 1 – Introduction 
 
1.1 Evidence-based medicine 
 
It is well established that evidence-based medicine (EBM) is a hot topic for clinicians, public 
health practitioners, purchasers, planners, and the public [1]. EBM is defined as the 
conscientious, explicit and judicious use of current best evidence in making decisions about 
the care of patients [1].  
 
It is essential at this point of this thesis to begin with an understanding of what we mean by 
EBM.. The aim of EBM  is to help physicians find the information that will ensure they can 
provide optimum management for their patients [2]. In essence, EBM consists of five linked 
ideas: identifying the clinical issues and questions, obtaining the clinical evidence, making 
recommendations from the evidence (evidence synthesis), making an informed clinical 
decision for patients and evaluating the performance of the decisions made [2].  
 
In other words, the practice of EBM involves converting the need for information into a 
question and identifying the best evidence in order to answer that question. It consists of 
integrating individual clinical expertise with the best available external clinical evidence from 
systematic research [2].  
 
Therefore, in accordance with the definition and its targets, it can be said, as suggested by 
Sackett et al. [1], that EBM is a hot topic for clinicians, public health practitioners, 
purchasers, planners and the public.  
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1.2 Randomised controlled trials 
 
A randomised controlled trial (RCT) could be defined as a planned experiment involving the 
random assignment of participants to interventions [3]. For example, in a two-arm parallel 
group RCT of rheumatoid arthritis (RA), participants allocated to the treatment group may 
receive a biologic treatment (intervention) and those allocated to the alternative group may 
receive a standard disease-modifying anti-rheumatic drug (control). If an RCT is designed 
and conducted correctly, randomisation reduces bias by allowing the investigators to control 
for factors, both known and unknown, that would otherwise confound the results [3].   
 
The strength of evidence for decisions about the effects of an intervention can be thought of 
as a pyramid (Figure 1.1 http://sladen.hfhs.org/library/staff/ebm-resource-pyramid.htm), with 
randomised trials and systematic reviews (SRs) of these providing the strongest evidence 
[1]. EBM incorporates the best available research evidence, and RCTs are seen as the gold 
standard of study designs to evaluate the effectiveness of a treatment in medical research in 
humans. 
 
 
 
              
 
Nevertheless, in some situations it may not be possible or ethical to conduct an RCT to 
answer a specific research question. For example, non-randomised observational studies 
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may be more appropriate to investigate serious, rare and long term harmful or unintended 
effects of treatment [3].  
 
A report of an RCT should enable readers to understand the conduct of the trial and to 
assess the validity of its results. The Consolidated Standards of Reporting Trials 
(CONSORT) Statement is intended to improve the reporting of a randomised controlled trial 
[4]. It comprises a checklist of 22 essential items to be reported and a flow diagram. 
 
1.3 Systematic reviews  
 
When conducting a trial, similar studies may be considered alongside the trial but they are 
often analysed and reported in isolation [5]. In this section, we introduce the systematic 
review (SR) as a means to appraise and synthesise the research evidence from the 
individual studies that aim to answer the same question. Focus is given to the Cochrane 
Musculoskeletal Group (CMSG) SR for RA [6], which is considered in more detail as the 
motivating example of this thesis. 
 
1.3.1 Need for systematic reviews in scientific research 
 
Healthcare providers, consumers, researchers, and policy makers are inundated with 
unmanageable amounts of information, including evidence from healthcare research [1]. It is 
unlikely that all will have the time, skills and resources to find, appraise and interpret this 
evidence and to incorporate it into healthcare decisions. Cochrane reviews respond to this 
challenge by identifying, appraising and synthesising research-based evidence and 
presenting it in an accessible format [7]. 
 
A SR attempts to collate all empirical evidence that fits pre-specified eligibility criteria in 
order to answer a specific research question. It uses explicit, systematic methods that are 
selected with a view to minimising bias, thus providing more reliable findings from which 
conclusions can be drawn and decisions made [7]. The key characteristics of a SR are: 
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 a clearly stated set of objectives with pre-defined eligibility criteria for studies; 
 
 an explicit, reproducible methodology; 
 
 a systematic search that attempts to identify all studies that would meet the eligibility 
criteria; 
 
 an assessment of the validity of the findings of the included studies, for example, 
through the assessment of risk of bias; and 
 
 a systematic presentation, and synthesis, of the characteristics and findings of the 
included studies. 
  
Many SRs contain meta-analyses. Meta-analysis (MA) is the use of statistical methods to 
summarise the results of independent studies [7]. By combining information from all relevant 
studies, meta-analyses can provide more precise estimates of the effects of healthcare than 
those derived from the individual studies included within a review. They also facilitate 
investigation of the consistency of evidence across studies and the exploration of differences 
across studies. 
 
1.3.2 Cochrane Collaboration and systematic reviews 
 
The Cochrane Collaboration (http://www.cochrane.org) is an international organisation 
whose primary aim is to help people make well-informed decisions about healthcare by 
preparing, maintaining and promoting the accessibility of SRs of the evidence that underpins 
them. By providing a reliable synthesis of the available evidence on a given topic, SRs 
adhere to the principle that science is cumulative and facilitate decisions considering all the 
evidence on the effect of an intervention. Since it was founded in 1993, The Cochrane 
Collaboration has grown to include over 15,000 contributors from more than 100 countries, 
making it easily the largest organisation involved in this kind of work [7].  
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The work of The Cochrane Collaboration orbits around 53 Cochrane Review Groups 
(CRGs), responsible for preparing and maintaining reviews within specific areas of 
healthcare. Cochrane reviews are published online in the Cochrane Database of Systematic 
Reviews (CDSR), which is a core component of The Cochrane Library. The CDSR is 
published 12 times a year, each time with new reviews and updates of existing reviews. The 
Library currently contains (March 2011) more than 4500 Cochrane reviews and 2000 
protocols for reviews in progress. 
 
1.3.3 Cochrane Reviews of Rheumatoid Arthritis - Musculoskeletal Group  
 
The CMSG represents one of the 53 CRGs. The targets of the CMSG include: gout, lupus 
erythematosus, osteoarthritis (OA), osteoporosis, paediatric rheumatology, RA, soft tissue 
rheumatism, spondyloarthropathy, systemic sclerosis and vasculitis.  
 
As of May 2014, the CMSG had produced 171 reviews and 105 protocols. They had 
registered 15 titles, and contributed 1023 studies to the CENTRAL register 
(http://musculoskeletal.cochrane.org/welcome) edition of the CDSR.   
 
The focus of this thesis is on RA, for which there were 59 published reviews as of Issue 9, 
2012 (http://onlinelibrary.wiley.com/book/10.1002/14651858/topics). 
 
1.4 Meta-analysis  
 
It is now widely recognised that MA is a vital part of a SR in order to analyse, interpret and 
communicate a collection of clinical trials. For the last few years, MA has been of increasing 
interest in medicine. One of the principal reasons for conducting a MA within a SR is that by 
combining information from all relevant studies it increases the power and precision of 
estimates of the treatment effect [8].  
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The aim of this section is to explain what MA is and introduce the statistical models used. At 
this stage of the thesis we will provide the univariate model for MA where it is assumed that 
all outcomes (endpoints) are analysed separately. 
 
In general, MA is a two-stage process [9]:  
 
 Obtain the treatment effect estimate and variability (e.g. standard error (SE)) in each 
study.  
 
 Combine the treatment effect estimates from each study using a weighted average 
to obtain a pooled estimate of treatment effect and appropriate confidence interval. 
 
Assume that we have n studies (i =1 to n). The general formula for a pooled estimate is [10]:  
 
(1.1)
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Where iyˆ  is the pooled treatment effect estimate, the weight is denoted as iw  and the 
specific study effect estimate as i . 
 
The studies in the MA are weighted so that studies that contain the most information and 
have estimated the treatment effect more precisely (narrow confidence intervals) are given 
the most weight. The weight is generally consistent with sample size such that larger studies 
have a larger weight and therefore a smaller confidence interval width [11]. For binary 
outcomes the confidence interval width also depends on the frequency of the event. 
Therefore, a smaller trial may have a larger weight if the frequency of events is high [11]. 
 
The weight given to a study is calculated as the reciprocal of the variance of the effect size,  
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(1.2)
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In formula the variance is denoted as 
2
i . Therefore, studies with more information have 
small variances and are given a larger weight [10]. 
 
1.4.1 Definition of heterogeneity and importance to assess it in systematic reviews 
 
The studies that are brought together in a SR could differ for various reasons leading to 
variability among the studies. All the types of variability among studies in a SR can be 
defined as heterogeneity [9]. It is possible to differentiate between different types of 
heterogeneity. The first type of heterogeneity is due to the variability in the participants, 
interventions and outcomes studied. This is defined as clinical diversity [9]. A second type of 
heterogeneity is due to the variability in study design and risk of bias, and is defined as 
methodological diversity [9]. It is essential to assess these two types of heterogeneity, as 
only if studies are assessed to be clinical and methodological homogeneous is it possible to 
combine these studies in a MA and explore statistical heterogeneity [9].    
 
1.4.2 Statistical heterogeneity 
 
Statistical heterogeneity is one of the most troublesome aspects of many SRs. The 
interpretative problems depend on how substantial the heterogeneity is, since this 
determines the extent to which it might influence the conclusions of the MA. It is therefore 
important to be able to quantify the extent of heterogeneity among a collection of studies [9]. 
An obvious means of achieving this is by estimating the between-study variance of the 
parameters of interest [11]. This is performed as part of random-effects meta-analysis 
(REMA) [11]. There are two approaches for detecting heterogeneity: graphical and 
statistical.  
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The graphical approach is called a ‘Forest plot’; that is, a graphical display of results from 
individual studies on a common scale [12]. In this approach the effect estimate is usually 
represented by a square and the size of this square is representative of the weight the study 
has in the MA. Associated with each estimate there will be also a graphical visualisation of 
the confidence intervals calculated. Clearly, a less informative trial will have a wider 
confidence interval, meaning that the estimate of the treatment effect is less precise. This 
plot allows a visual examination of the degree of heterogeneity between studies. The more 
the confidence intervals overlap, the less heterogeneity there is.  
 
Considering the statistical approach, there are two different methods. The first method is the 
heterogeneity statistic called Cochran’s Q given by [13]: 
 
)3.1()ˆ( 2  iiwQ .  
 
In equation 1.3, ˆ refers to the pooled true treatment effect estimate, while as described in 
the previous paragraph iw  denotes the weight, and i  denotes the specific study effect 
estimate. 
 
P-values are obtained by comparing the statistic Q with a 
2  distribution with n−1 degrees 
of freedom, where n is the number of studies. This test however is known to have low power 
to detect heterogeneity and it is suggested to use a value of 0.1 as a cut-off for significance. 
Indeed, low p-values (p<0.1) indicate statistical heterogeneity [13]. Conversely, Q has too 
much power as a test of heterogeneity if the number of studies is large [13]. 
 
An alternative method to calculate the effect of heterogeneity, providing a measure of the 
degree of inconsistency in the studies’ results, is the
2I . As suggested by Higgins et al. [9], 
the 
2I statistic evaluates the percentage of total variation across the study that is not 
attributable to chance alone. The formula of Higgins and Thompson [11] to calculate 
2I will 
be explained and reported in details in Chapter 5 in section 5.3.6.1.   
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1.4.3 Quality of reporting in randomised controlled trials 
 
One of the issues when conducting a MA is the quality of reporting of RCTs. In 1996 a group 
of clinical epidemiologists, clinicians, statisticians, editors and researchers met and set up 
the Preferred Reporting Items for SRs and Meta-Analysis (PRISMA) group [14], with the aim 
of improving the quality of MA reporting. Over the years, several medical journals have 
accepted the PRISMA statement to improve the reporting of SRs that they publish. 
 
1.4.4 Fixed-effects meta-analysis 
 
In fixed-effects meta-analysis (FEMA) it is assumed that all studies are estimating the same 
true effect. It is also assumed that the variability between studies results is due solely to the 
sample of people within each study. Another important assumption is that precision depends 
mainly on study size [15].  
 
For each study i, a set of m treatment effects )....( 1 imi2i yyy  and their within-study 
(w/s) variances )sss(
2
im
2
i2
2
i1 .... are required.  
 
In the univariate fixed-effects meta-analysis (UFMA) each outcome is analysed separately, 
and assumes that the obtained estimates of the treatment effect from the ith study are 
normally distributed about a common fixed true effect ( imi21i  .... respectively for 
outcomes 1, 2…, m) and variances, which are assumed to be known; therefore, for the ith 
study and, the general UFMA could be written as follows [16]: 
 
 
 
 2immim
2
i22i2
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i11i1
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N
.  
 
In this model, we are interested in the estimate of the common fixed true effect. The model 
parameters are often estimated using the method of maximum likelihood (ML). 
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1.4.5 Random-effects meta-analysis 
 
For REMA the model assumes that the treatment effects for the individual studies are 
assumed to vary around a global treatment effect. 
 
In each study, the overall treatment effects )....( imi2i1 yyy are assumed to be an 
estimate of a true value )....( imi2i1 μμμ ; and in a hierarchical structure each true 
value is assumed to follow a Normal distribution.  
 
The general univariate random-effect meta-analysis (URMA) could be written as follows [17]: 
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In this model, the objective is to obtain the mean effect )....( 21 m  and the 
between-studies )....(
22
2
2
1 m
 variances and possibly the true values-specific 
effects )....( imi2i1 μμμ  [17].  
 
The model parameters are usually estimated using the method of restricted maximum 
likelihood (REML). 
 
1.5 Individual participant data meta-analysis 
 
The purpose of this section is to provide a general introduction of the concept of individual 
participant data meta-analyses (IPD-MA) approaches and their definitions. A more detailed 
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description will be given in the methodology chapters which will present the models and their 
formulas with reference to the simulation work conducted in this thesis.  
 
The IPD-MA models are widely considered the gold standard of MA and involve the re-
analysis of all the individual participant data (IPD) from the included studies [18]. Most often 
meta-analyses are aggregate but there are advantages to using IPD [18]. However, 
availability of IPD and lack of resources often mean that aggregate meta-analyses are more 
common [18]. In this thesis, both aggregate and IPD meta-analyses approaches are 
explored.  
 
When IPD are available from each of the studies, the MA can proceed in either a one-step or 
a two-step framework. The one-stage approach simultaneously models the IPD from all of 
the studies. The two-stage approach first fits a model to the IPD from each study separately, 
and then the study parameter estimates are combined in a MA [19].  
 
1.5.1 One-stage individual participant data meta-analysis  
 
In the one-stage approach, the IPD from all studies are modelled simultaneously while 
accounting for the clustering of participants within studies.  
 
A one-stage model [18] can be used to estimate intervention effects while stratifying or 
otherwise accounting for differences between trials [20]. This is typically a regression model 
such as linear, logistic, or Cox regression, with either a separate term for each trial or one 
that varies across trials via a random effect. 
 
1.5.2 Two-stage individual participant data meta-analysis 
 
In this section a general description of two-stage IPD-MA will be provided. Further details 
with formula and an application to the simulation that was conducted in this thesis work will 
be provided in Chapter 3 and Chapter 4.  
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 In the first stage of the two-step IPD-MA approach, each study is analysed 
separately.  
 
 The second stage requires a univariate MA framework or a multivariate MA 
approach. 
 
Two-stage IPD-MA are clearly more laborious, but in the second stage the models allow the 
use of traditional, well-known MA techniques such as those used by the Cochrane 
Collaboration (for example, inverse variance FE or RE approach, or the Mantel-Haenszel 
method). 
 
One-stage IPD-MA approach and two-stage IPD–MA approach could lead to different results 
due to some assumptions that will be described in detail in Chapter 3 of this thesis. 
 
In this work of thesis the two-stage approach has been used because it allowed the analysis 
of separate outcomes in each trials at the first stage, reducing the IPD to aggregate data 
(AD). Furthermore having the results from each single study two-stage approach allowed us 
to calculate the w/s correlation at the first stage needed to fit the model at the second stage 
of the two-stage IPD-MA. 
 
1.6 Rheumatoid arthritis 
  
Rheumatoid arthritis is one of the most prevalent chronic inflammatory diseases. It primarily 
involves the joints, but should be considered a syndrome that includes extra-articular 
manifestations, such as rheumatoid nodules, pulmonary involvement or vasculitis, and 
systemic comorbidities [21]. Rheumatoid arthritis is the medical condition that motivates the 
statistical analyses performed in this thesis and therefore, by way of introduction, some 
background is now provided on the condition itself.  
 
RA affects the immune system, which normally fights infection, attacking the lining of the 
joints. As a disease, it is characterised by persistent synovitis, systemic inflammation, and 
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autoantibodies (particularly to rheumatoid factor and citrullinated peptide) [22]. This makes 
joints swollen, stiff and painful. The small joints of the hands and feet are usually affected 
first. 
 
1.6.1 Epidemiology 
 
Findings of population-based studies show RA affects between 0.5% and 1.0% of adults in 
developed countries. The disease is three times more frequent in women than men [22]. The 
prevalence of RA rises with age and is highest in women older than 65 years, suggesting 
hormonal factors could have a pathogenic role [23]. Prevalence of RA varies geographically 
[22]. The disease is common in northern Europe and North America compared with parts of 
the developing world, such as rural West Africa [23]. These variations are indicative of 
different genetic risks and environmental exposures. Some evidence suggests incidence of 
RA might be declining, with onset happening later in life [22]. 
 
1.6.2 Management 
 
Several national and regional guidelines for management of RA exist, including 
recommendations from the American College of Rheumatology (ACR) [24], European 
League Against Rheumatism (EULAR) [25], and the UK’s National Institute for Health and 
Clinical Excellence (NICE) [22].  
 
 Treatment of symptoms. Analgesics reduce pain, and non-steroidal anti-inflammatory 
drugs (NSAIDs) lessen pain and stiffness. Both groups of drugs are used widely to 
control symptoms of RA. Evidence for use of analgesics is modest but uncontroversial; 
support for use of NSAIDs is considerably stronger [22]. However, NSAIDs have lost 
their historical role as first-line treatment because of concerns about their limited 
effectiveness, inability to modify the long-term course of disease, and gastrointestinal 
and cardiac toxic effects [22].  
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 Disease-modifying antirheumatic drugs. DMARDs are a heterogeneous collection of 
agents for the treatment of RA [22]. They reduce joint swelling and pain, decrease 
acute-phase markers, limit progressive joint damage and improve function. Methotrexate 
(MTX) is the dominant DMARD. Sulfasalazine and Leflunomide are also widely used. 
Their efficacy has been established in placebo-controlled trials [22]. Adverse effects of 
DMARDs include those that are minor (e.g., nausea) and serious (e.g., hepatotoxicity, 
blood dyscrasias, and interstitial lung disease) [22].  
 
 Biological agents. Biological agents are another class of treatments used for RA therapy. 
TNF inhibitors were the first licensed biological agents, followed by Abatacept, 
Rituximab, and Tocilizumab: they are highly effective [22]. The efficacy of biological 
agents is most obvious in short-term studies in late disease, when placebo responses 
are low; it is generally less clear-cut in early disease, when active comparators can 
achieve good responses. Biological agents are combined conventionally with MTX. 
Adverse events include span reactions and infections at infusion and injection sites. 
Concerns have also been raised about demyelination and cancer [22]. 
 
 Glucocorticoids. Short-term glucocorticoids reduce synovitis. In the long term, they 
decrease joint damage [22] but incur substantial adverse risks, such as infections and 
osteoporosis, and their overall risk/benefit ratio is deemed unfavourable [22]. However, 
they can be especially useful in two settings. First, short-term use during flare-ups in 
disease can lead to rapid improvement and allow other treatments, such as DMARDs, 
which have a slower onset of action, to be adjusted. Use of steroids in this way is low 
risk. Oral or intramuscular glucocorticoids are administered by many centres in this 
setting. Second, intra-articular glucocorticoids are a highly effective local treatment for 
individual active joints [22]. 
 
 New treatments. New biological agents in development include drugs that target 
proximal effects on the immune response and growth factors for T-cell subsets (such as 
interleukin-17) [16]. New conventional drugs with DMARD-like properties might also 
15 
 
have important future roles. Clinical trials of inhibitors of the kinases have provided 
promising data, and other targets are under investigation [22]. 
 
There are also non-pharmacological treatments such as supportive treatment, for example, 
effective non-drug treatments, joint protection, foot care and psychological support [22]. 
Patients’ education is also of crucial importance. All these strategies are best delivered by a 
multidisciplinary team of rheumatologists, nurses, therapists, and podiatrists. Management 
of comorbidities is important, as they reflect both the disease process and its treatment. 
Comorbidities include cardiac disease, bone disease and depression. Surgical treatment, 
particularly joint replacement surgery, is vital to maintain function when joints fail, and 
collaboration with orthopaedic specialists is required [22]. 
 
1.7 Core outcome set  
 
1.7.1 General definition and application of core outcome set 
 
In an RCT, the effectiveness of an intervention is usually determined by comparing 
outcomes that reflect beneficial and harmful effects. Selection of appropriate outcomes or 
domains is crucial when designing clinical trials to compare directly the effects of different 
interventions in ways that minimise bias [26].  
 
There is a growing recognition that insufficient attention has been paid to the outcomes 
measured in clinical trials [26]. Difficulties caused by heterogeneity in outcome measurement 
are well known to systematic reviewers. Empirical research provides strong evidence that 
outcome reporting bias (ORB), defined as the results-based selection for publication of a 
subset of the original measured outcome variables, is an important problem in randomised 
trials [27] that affects the conclusions in a substantial proportion of Cochrane Reviews [28]. 
ORB is likely to affect SRs more widely, as well as published research in general. 
 
These issues could be addressed through the development and use of an agreed 
standardised collection of outcomes, known as a core outcome set (COS), which should be 
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measured and reported in all trials for a specific clinical area [29]. It is not compulsory that 
outcomes in a particular trial should be restricted to those in the COS but there is an 
expectation that the core outcomes will always be collected and reported, and that 
researchers will continue to explore other outcomes. The central idea behind the COS is that 
they should be reflective of the outcomes important to both health care professionals and 
patients. Examples exist where patients identified an outcome important to them as a group 
that might not have been considered by practitioners on their own [26]. It should be 
remembered here that the importance of incorporating health service user opinion in COS 
development is increasing, but involvement has been limited to date. 
 
The Core Outcome Measures in Effectiveness Trials (COMET) initiative [26] brings together 
researchers interested in the development, application and promotion of COS, derived using 
rigorous consensus methods, for effectiveness trials. The objectives of COMET are to collect 
and stimulate the development of relevant resources, both applied and methodological, to 
facilitate exchange of ideas and information, to work with patients, the public and their 
representatives, to develop material to improve health service user engagement, and to 
increase methodological research in the area of COS [30]. Information on relevant individual 
studies, both published and ongoing, are being included in a free, publically available 
internet-based resource. This is a unique resource, which is updated periodically, and which 
should serve to minimise duplication of effort in the development of COS. 
 
The COMET initiative provides a focus for the continued development of a framework for 
outcome measurement, first in relation to domains and outcomes within domains, 
subsequently in terms of definitions and measurement instruments, and finally in relation to 
the timing of measurement. There is an increasing awareness of the need for greater 
attention to be given to the outcomes measured in clinical trials, in terms of standardisation 
and reporting [26]. 
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1.7.2 Core outcome set for rheumatoid arthritis  
  
One of the most remarkable works regarding outcome standardisation has been in the area 
of RA. The Outcome Measures for Rheumatology Clinical Trials (OMERACT) collaboration 
was established in 1992; it advocates the use of COS in clinical trials in rheumatology [30]. 
In 1994, the OMERACT group ratified one of the first COS for RA [8]: tender joint count 
(TJC), swollen joint count (SJC), pain, physician global assessment (Phy.Global), patient 
global assessment (Pat.Global), function and acute phase reactant (APR). In studies lasting 
at least one year, an additional recommendation was for radiographs of the joints to be 
taken to assess radiological damage (RD). 
 
Previous work conducted by other researchers analysed a review of 350 trials for the 
treatment of RA of rheumatology trials published up to 2009 [31] identified through The 
Cochrane Library. Findings of this research were particularly interesting. Indeed, it was 
discovered firstly that between 60% and 70% of trialists conducting trials in RA measured 
the core outcomes, and secondly that 90% of trialists contacted said they would consider 
measuring the RA COS if they were to lead a new trial in RA. However, the fact that it is 
established that an outcome has been measured does not imply that it has been 
appropriately reported in the publication of the study. Furthermore, composite outcomes are 
often reported in place of the individual core outcomes; examples include Disease Activity 
Score (DAS) [32] and ACR criteria [23]. The CMSG ratifies the use of the COS in its reviews. 
The consequence of this type of reporting is that many meta-analyses of the individual core 
outcomes will contain missing data, when it is known that the individual outcomes were 
measured and possibly analysed. As part of this thesis, these missing data are investigated 
and it is determined whether or not they impact on the review meta-analyses. 
 
1.8 Thesis structure 
 
ORB is a missing data problem and is a threat to the validity of SRs. There are a number of 
statistical approaches for adjusting for ORB in meta-analyses but this thesis focuses on the 
use of multivariate meta-analysis (MVMA). MVMA allows the joint synthesis of outcomes 
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simultaneously and utilises correlations across studies which has the potential to reduce the 
impact of ORB. The aims of this thesis were two. The first objective was to apply the 
methods to assess the presence of outcome reporting bias with multiple outcomes. The 
second objective was to understand the use of MVMA through simulation studies and 
application of the method to reviews of RA, in order to improve statistical analysis methods 
for MA research, especially when considering the risk of bias of the available evidence.  In 
Chapter Two a framework for assessing ORB in SRs is presented and the methods applied 
to a cohort of Cochrane reviews in RA using the core set of outcomes for this condition.  The 
prevalence of high risk ORB in the trials included within these reviews is estimated. Chapter 
Three presents an IPD FE MA simulation study to compare the performance of the MVMA 
method against univariate meta-analysis (UVMA) under a range of different study-level 
missing data (ORB) scenarios. Chapter Four presents a similar simulation study   to 
compare the performance of the MVMA method against UVMA when there is missing 
individual patient-level missing data (missing data in the IPD). In Chapter Five, MVMA is 
applied to the RA examples where ORB was assessed in Chapter 2. The results are 
compared to univariate approaches and the advantages and disadvantages of each 
approach are discussed. The impact the missing data have on the original MA results in 
term of the statistical conclusions is also quantified and discussed. Chapter Six contains a 
discussion, conclusions and recommendations for further work. This research is the first to 
assess the prevalence of ORB against a set of core correlated outcomes. It also 
demonstrates the feasibility of using a MVMA approach to examine the robustness of MA 
results when there is high-suspicion of ORB. Finally, the real novel aspect of this work is 
that, under the generation of IPD, we can also explore the benefit MVMA might have on 
missingness at the patient level, which cannot be investigated in AD MA. 
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Chapter 2 – Outcome reporting bias 
 
2.1 Background 
 
In Chapter 1, the fundamental concepts of EBM, clinical trials, MA and SRs were introduced.  
 
From the literature, it is clear that different types of bias could affect the results of a MA, 
particularly when outcome data are missing [34, 35]. Study publication bias (where whole 
studies are not published) and w/s selective outcome reporting (where a subset of the 
originally recorded outcomes has been selectively reported) have been recognised as two 
missing data problems that can affect EBM. If selective reporting or non-reporting is driven 
by the significance and/or direction of the effect size (for example non-significant outcomes 
are reported only as p-value > 0.05 or are suppressed altogether) then this is known as 
selective reporting bias or ORB [36]. 
 
Empirical evidence suggests that there is strong evidence of an association between 
significant results and publication; studies that report positive or significant results are more 
likely to be published and outcomes that are statistically significant have higher odds of 
being fully reported (FR) (range of odds ratios: 2.2 to 4.7) [37]. In this chapter the focus is on 
ORB, although it is important to note that study publication bias and ORB often impact 
review meta-analyses in the same way. Impact assessment is addressed in Chapter 6. A 
recent study has suggested that the amount of missing participant data from unpublished 
studies (15%) is greater than that from published studies (4%) [33]. However, if partially 
reported data is considered to be unpublished then the amount of missing data from 
published studies increases to 38%. Considering partially reported data as missing is an 
important consideration since it reflects the fact that the data cannot be included in a review 
MA. Furthermore, partial reporting has previously been associated with a high risk of ORB 
[37].  
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Results from the Outcome Reporting Bias in Trials (ORBIT) study [28] have shown that over 
half of SRs did not include full data for a single review primary outcome of interest from all 
eligible trials and half of the trials assessed with missing data were under high suspicion of 
ORB [37]. 
 
One way to reduce the problem of ORB is the introduction of an agreed minimum set of 
standardised outcomes, to be measured and reported in all trials for a particular disease or 
condition, referred to as a COS [30]. In Chapter 1, a COS for RA which was defined by 
OMERACT in 1994 [28] was introduced. Only one previous study has assessed ORB for all 
review outcomes in cystic fibrosis [38]. This study showed that all eligible trials from all 
published reviews from the Cochrane Cystic Fibrosis group did not include full data when 
looking across all review outcomes; that is, both primary and secondary outcomes [38].  
 
In these SRs a core set of outcomes has been endorsed by trialists and the Cochrane 
Review Group. While uptake of this COS has been shown to be improving over time (up to 
70% of trialists measuring the full set of core outcomes in 2010), reporting of the outcomes 
appeared to be less well performed, making the studies prone to potential ORB [27].    
 
The aim of this chapter is to present the methods to determine how to detect and assess 
suspected ORB in SRs and to estimate the prevalence of ORB in the Cochrane RA reviews 
by considering all eight outcomes in the COS.    
 
2.2 How to assess outcome reporting bias in a systematic review 
 
A tutorial for assessing the potential for ORB in a review exists [28], although the tools 
available, particularly the impact methods (to be addressed in Chapter 6) to systematic 
reviewers to help them complete the assessments have largely been updated since the 
tutorial was published. In this section, a review of the most recent methodologies and tools 
available for assessing ORB in reviews is presented in a series of steps. The methods 
require the use of two important tools, an outcome matrix for detecting missing data and a 
classification system for assessing the potential risk of ORB.   
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This methodology has already been successfully implemented by some systematic 
reviewers [40].    
 
2.2.1 Steps for addressing missing outcome data in a review 
 
Step 1: Exclusion criteria 
 
The first step is to ensure that no potentially eligible studies are excluded from the review for 
the sole reason of not reporting on any review outcomes of interest. If a study report does 
not give results for or mention particular outcomes, this does not necessarily mean that they 
were not measured or analysed. For this reason, studies must not be excluded if they do not 
report any of the relevant review outcomes. For example, the review ‘Methotrexate 
monotherapy versus methotrexate combination therapy with non-biologic disease modifying 
antirheumatic drugs for RA’ [41] excluded from the assessment the study Mottaghi 2005 [42] 
and the reason for exclusions was that this trial contained “no outcome of interest”.  
 
Step 2: Constructing the outcome matrix from the study reports 
 
The outcome matrix is constructed by listing all the eligible studies as rows and all the 
review outcomes of interest as columns in the matrix. Outcomes can be distinguished in 
terms of review primary and secondary outcomes and as benefit or harm outcomes. 
Outcomes that are not of interest in the review but are reported in the reports for eligible 
trials are also listed. This has been found to be useful when assigning the risk of bias. For 
example, in RA, composite disease activity criteria are often reported, e.g. ACR response 
criteria. The ACR criteria [43] considers TJC, SJC and three of the following five outcomes: 
patient’s assessment of pain, patient’s global assessment, and Phy.Global, patient’s 
assessment of physical function and acute-phase reactant. For this reason, if ACR criteria 
are reported then it is known that all of the RA core outcomes (with the exception of RD) 
have been measured, even if they are not reported. Furthermore, some outcomes are often 
routinely measured together so that, if one outcome is reported but not the other, this may 
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raise suspicion that selective reporting has occurred, e.g. TJC and SJC. A tool for 
constructing the outcome matrix (ORBIT matrix generator) is freely available 
(http://ctrc.liv.ac.uk/orbit/) [28].  
 
Step 3: Completing the outcome matrix 
 
Once the outcome matrix has been constructed, it can be filled in (the matrix can also be 
filled in using the ORBIT matrix generator) [28]. For each study, a reviewer should indicate 
which outcomes (benefits and harms) were reported and differentiate between ‘full 
reporting’, ‘partial reporting’, ‘not reported – not clear whether measured or not’ and ‘not 
measured’. Guidance on what constitutes the different levels of reporting can be found 
below.   
 
a) Full Reporting. Studies that ‘fully report’ an outcome should be denoted by a tick in the 
matrix. Typically, if a study includes enough information on the outcome to be included 
in a review MA (without contact for extra information from the trialists), then the outcome 
is FR and there is no risk of non-reporting bias. If a MA is not appropriate, then the 
outcome can still be considered FR. Some guidance on what constitutes full reporting 
for each of the different outcome types (e.g. binary, continuous and time to event) is 
provided in Box 1 below.   
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Box 1. Data Required for meta-analysis of Fully Reported Outcomes [44] 
 
For Unpaired Continuous Data 
Sample size in each group and magnitude of treatment effect (group means/medians or 
difference in means/medians) and measure of precision or variability (confidence interval, 
standard deviation, or SE for means; interquartile or other range for medians) or the precise 
p-value* 
 
For Unpaired Binary Data 
Sample size in each group and either the numbers (or percentages) of participants with the 
event for each group, or the odds ratio or relative risk with a measure of precision or 
variability (confidence interval, standard deviation, or SE) or the precise p-value* 
 
For Paired Continuous Data 
Sample size in each group and either the raw data for each participant, or the mean 
difference (MD) between groups and a measure of its precision or variability or the precise 
p-value* 
 
For Paired Binary Data 
Sample size in each group and paired numbers of participants with and without events 
 
For Survival Data 
Either a Kaplan-Meier curve or similar, with numbers of patients at risk over time, or a 
hazard ratio with a measure of precision and sample size in each group 
 
*Sample sizes, treatment effect and precise p-value enable the calculation of a SE if a 
measure of precision or variability is not reported. 
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b) Partial Reporting. Studies that ‘partially report’ an outcome should be denoted by an 
open circle in the matrix. For partial reporting, it is clear that the review outcome of 
interest has been analysed in the eligible studies but there is not enough information 
reported for the outcome to be considered FR. Some suggestions for partially reported 
outcomes include: 
 
 p-value reported only (with no treatment-effect size indicated) (high risk of bias) 
 
 No measure of variance/precision reported (low risk of bias) 
 
 Percentage data given for both groups but denominators unclear (binary data) 
(low risk of bias) 
 
 Results are reported graphically only (accurate data extraction not possible) 
(low risk of bias) 
 
 Treatment-effect estimate reported from a statistical model only (low risk of 
bias) (this would be accepted as full reporting if the SE of the estimate is also 
given). 
 
c) Not reported. This means that it is not clear whether the outcome has been measured 
or not. If a study does not report on a review outcome, it should be denoted with a 
cross in the matrix. Reviewers should compare all sections of the study reports to the 
results section, by looking at which other outcomes were measured and reported and 
accounting for knowledge of the clinical area. Reviewers should be suspicious of high 
risk of bias, if it is either clear or assumed that the outcome had been measured and 
possible that non-reporting could have been influenced by the results.  
 
d) Not measured. This means that in some situations it will be clear from the study reports 
that outcomes were not measured. In these situations, studies should be denoted with 
a star in the matrix. If it is clear from the study report that outcomes were not 
25 
 
measured, then this eliminates any risk of non-reporting bias. For example, in RA, 
studies that last for less than one year often do not measure RD (as damage 
progression is long term). If a study therefore reported “radiographic assessments were 
not made in this study” then it is clear that RD was not measured. 
 
Step 4: Contacting trialists 
 
After the outcome matrix has been completed, reviewers should make an attempt to contact 
the trialists from the studies included in the review that partially reported the review 
outcomes of interest or where it was not clear whether the outcome was measured or not. 
The purpose of this contact is to try and obtain missing outcome data to include in the review 
analysis or to confirm that the outcomes of interest were not measured. The matrix should 
be updated accordingly in light of the extra information obtained. 
 
Step 5: Outcome reporting bias assessment: classification system 
 
Once the outcome matrix is complete and trialists have been contacted for missing data, a 
reviewer should then assess the potential risk of ORB as a result of outcomes being partially 
reported or not reported using the ORBIT nine-point classification system for benefit 
outcomes (Table 2.1) [28]. Each outcome with missing or partially reported data should be 
given a classification. Each classification should be justified with a reason, using verbatim 
study report text whenever appropriate. The classification is determined by comparing all 
sections of the study reports to the results section of the trial report, by looking at which 
other outcomes were measured and reported and accounting for knowledge of the clinical 
area. As with data extraction and risk of bias assessment, this task should be completed by 
at least two researchers independently and differences should be discussed to agree on an 
overall classification for each review outcome that is missing for each study. If available, 
review authors should also seek to obtain study protocols or trial registry entries for eligible 
studies in order to compare pre-specified outcomes with those reported in the final study 
report. The comparison between what was planned (in terms of outcome specification) and 
what was actually measured has the potential to simplify the risk of bias assessment for 
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each outcome. The classification system was developed to assess the risk of bias when a 
trial was excluded from a MA either because the data for the outcome were not reported or 
because the data were reported incompletely (for example, just as “non-significant”). The 
categories reflect the stages of assessing whether an outcome was measured, whether an 
outcome was analysed, and, finally, the nature of the results presented. The system 
identifies whether there is evidence that the outcome was measured and analysed but only 
partially reported (A to C classifications), whether the outcome was measure and analysed 
but not reported at all (D classification), whether the outcome was measured but not 
necessarily analysed (E and F), if it is unclear whether the outcome was measured (G and 
H), or if it is clear that the outcome was not measured (I).  
 
 A “high risk” classification is assigned when it is either known or suspected that the 
results were partially or not reported because the treatment comparison for the 
outcome of interest was statistically non-significant (p-value > 0.05).  
 
 A “low risk” classification is set when it is suspected but not actually known that the 
outcome was either not measured, measured but not analysed, or measured and 
analysed but either partially reported or not reported for a reason unrelated to the 
results obtained.  
 
 A “no risk” classification is reserved for cases where it is known that the outcome 
was not measured, known that it was measured but not analysed, or known that it 
was measured and analysed but the reason for partial or no reporting is not because 
the results were statistically significant.  
   
For the cases where the outcome was measured but not necessarily analysed, 
judgment is needed as to whether it was likely (E) or unlikely (F) that the measured 
outcome was analysed and not reported because of non-significant results. When it 
is unclear whether the outcome was measured, judgment is also needed as to 
whether it is likely that the outcome was measured and analysed but not reported on 
the basis of non-significant results (G) or unlikely that the outcome was measured at 
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all (H). In the original ORBIT study [28], two separate sensitivity and specificity 
analyses were performed. The first analysis considered only G and H classifications 
and aimed to determine how good the classification system was at judging whether 
the primary outcome of interest in the review had been measured when it was not 
mentioned in the trial report. The second analysis looked at how well the bias could 
be predicted when a judgment was required. The truth was obtained by contacting 
the trialist to determine whether the outcome was measured or not and, if it was 
measured, was the outcome analysed, and what was the justification for non-
reporting. The sensitivity and specificity results were high, demonstrating that the 
classification system was able to distinguish satisfactorily between an outcome 
being measured or not and being able to predict bias reliably.      
 
Trial classified as A/D/E/G, C/F/H, and B/I are assumed to be at high, low and no 
risk of ORB, respectively, in relation to the review outcomes. In a similar way, all 
missing review outcomes from trials excluded from the review but selected for 
assessment should also be assigned an ORBIT classification [28].  
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Table 2.1 ORBIT study classification for benefit outcomes [28] 
Description 
Level of 
reporting 
Risk of 
bias 
Clear that the outcome was measured and analysed 
A 
Trial report states that outcome was analysed but only reports that result was 
not significant (typically stating p-value > 0.05). 
Partial 
High 
Risk 
B 
Trial report states that outcome was analysed but only reports that result was 
significant (typically stating p-value < 0.05). 
Partial 
No  
Risk 
C 
Trial report states that outcome was analysed but insufficient data were 
presented for the trial to be included in meta-analysis or to be considered to 
be fully tabulated. 
Partial 
Low  
Risk 
D Trial report states that outcome was analysed but no results reported. None 
High 
Risk 
Clear that the outcome was measured 
E 
Clear that the outcome was measured. Judgment says outcome likely to have 
been analysed but not reported because of non-significant results. 
None 
High 
Risk 
F 
Clear that the outcome was measured. Judgment says outcome unlikely to 
have been analysed. 
None 
Low  
Risk 
Unclear whether the outcome was measured 
G 
Not mentioned but clinical judgment says likely to have been measured and 
analysed but not reported on the basis of non-significant results. 
None 
High 
Risk 
H 
Not mentioned but clinical judgment says unlikely to have been measured at 
all. 
None 
Low  
Risk 
Clear that the outcome was not measured 
I Clear that the outcome was not measured. NA 
No  
Risk 
Risk of bias arising from the lack of inclusion of non-significant results when a trial was excluded 
from a meta-analysis or non-fully reported in a review because the data were unavailable. 
 
 
2.3 Assessment of outcome reporting bias in Cochrane systematic 
reviews of rheumatoid arthritis 
 
A cohort of SRs published by the CMSG (up to and including the September 2012 issue) 
that considered pharmacological interventions (DMARDs, biologics or glucocorticoids) for 
the treatment of RA were included. Reviews were identified via the Cochrane topics link 
(http://onlinelibrary.wiley.com/book/10.1002/14651858/topics) and were those that were 
indexed under ‘musculoskeletal’, RA, ‘treatment (pharmacological interventions)’ and 
‘biologics/steroids/DMARDs’. The reviews were selected based on previous work conducted 
by Kirkham et al. [39]. Furthermore this assessment was focused on pharmacological 
interventions because the scope of the COS [40] was not specifically designed for non-drug 
trials and does not focus on measures of safety. Therefore systematic reviews that 
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considered non-pharmacological interventions or considered drug safety only were excluded 
from this work of assessment.  I decided to focus on systematic reviews up to 2012 because 
the Cochrane SRs set was the most updated list meeting the eligibility criteria to be included 
in the assessment of ORB. 
 
Overviews and reviews that contained no eligible RCTs (empty reviews) were also excluded, 
as an assessment of primary studies would not be possible. Empty reviews were however 
checked to make sure no studies were excluded due to ‘no relevant outcome data’ (see Step 
1, Section 2,1,1) which could be included in the assessment. Reviews were assessed for 
ORB in relation to eight outcomes for RA. In some cases, it was often problematic to assess 
whether an outcome was measured and clinical judgment was required. If there were any 
uncertainties with the classifications, review authors were consulted. All trials were 
independently classified by two researchers (G.F. and J.J.K.), and disagreements were 
resolved through discussion. The full assessment followed the procedures outlined in 
Section 2.2. Trialists were not contacted for missing outcome data in this instance (Step 4), 
as this had already been carried out by the authors of the included reviews. Such outcomes 
have not previously been addressed when it comes to ORB assessments. Firstly, the 
purpose is to discuss how these outcomes were dealt with in order to provide ‘rules’ for 
assessing the risk of bias that could be consistently applied to all trials. 
 
2.3.1 Outcome reporting bias assessment for composite outcomes   
 
Trials of RA often use composite outcomes to measure disease activity. These composite 
outcomes often encompass a number of the core individual outcome measures. For 
instance, in section 2.2.1 we explained in detail the composite measure called ACR, but 
others also exist, for example, the DAS [45]. The DAS is a composite index that includes the 
combination of the values of TJC and SJC, patient’s global assessment of disease activity, 
and APR measures as erythrocyte sedimentation rate (ESR) value. When composite 
outcome criteria were reported in full, but no data on any of the individual core outcomes 
were reported, then the low-risk F-classification was used (clear that the outcome was 
measured but unlikely that the individual outcomes were analysed) for all core outcomes 
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contained within the composite. The motivation is that it may not have been the trialists’ 
intention to analyse the individual core outcomes. If a trialist selectively reported some of the 
individual core outcomes from the composite, then the high-risk E-classification was used for 
the core outcomes not reported, as in this situation it is more likely that all the core outcomes 
would have been analysed, and the likely reason for some of them not being reported is a 
non-significant result. 
 
2.4 Results 
 
2.4.1 Systematic reviews assessed: eligibility criteria 
 
The CMSG published 56 unique RA reviews up to and including the September 2012 issue 
(Figure 2.1). Thirty-five reviews were excluded: 20 focused on non-pharmacological 
interventions, 13 studied symptom-modifying antirheumatic drugs, one was an overview, and 
one focused on safety.  
 
Of the remaining 21 reviews included in the assessment, 12 reviews considered DMARDs, 
eight considered biologics, and one considered glucocorticoids. All reviews required an ORB 
assessment for at least one eligible trial.  
 
The 21 reviews included a total of 183 trials for assessment (Figure 2.1). All the reports for 
each randomised trial included in the eligible reviews were obtained for evaluation. Among 
the 183 trials included within the 21 reviews, 16 trials could not be assessed further because 
either the articles were not in English (n=10) or the trial reports were unobtainable (n=6). 
Therefore, in this study, 167 trials were assessed, 105 on DMARDs (63%), 46 on biologics 
(28%) and 16 on glucocorticoids (9%) (Figure 2.1). Of the 167 assessable trials (Figure 2.1), 
22 trials (13%) FR the outcome data for all core outcomes, but the data in only ten of these 
were adequately reported in the review. Among these 22 trials, ten studies included all core 
outcome data in the review and for twelve studies the core outcome data were reported only 
in the study but not completely FR in the review.  
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A summary of the studies assessed in each of the 21 SRs is provided in Table 2.2.  
 
Table 2.2 Summary of the 167 RCTs assessed in the 21 SRs 
Systematic Review Objective 
Number of trials not fully 
reporting on all core 
outcomes 
Number 
of trials 
fully 
reporting 
on all 
core 
outcomes 
Included Excluded 
Methotrexate 
monotherapy versus 
methotrexate 
combination therapy 
[41] 
Efficacy and toxicity 19 2 0 
Antimalarials [46] Efficacy and toxicity 4 2 0 
Azathioprine [47] Short-term effects 3 3 0 
Auranofin [48] Efficacy and toxicity 9 1 0 
Cyclophosphamide 
[49] 
Short-term effects 2 0 0 
Cyclosporine [50] 
Short-term (up to one year) 
effects 
2 0 1 
Injectable gold [51] 
Short-term benefit and risk 
of side-effects 
3 0 1 
Methotrexate [52] 
Short term efficacy and 
toxicity 
5 0 0 
Penicillamine [53] Short-term effects 7 0 0 
Sulfasalazine [54] 
Short-term efficacy and 
toxicity 
7 0 0 
Leflunomide [55] Efficacy and toxicity 20 1 4 
Folic acid and 
folinic acid for 
reducing side 
effects in patients 
receiving 
methotrexate [56] 
Effects of folic acid and 
folinic acid in reducing the 
mucosal and 
gastrointestinal (GI) and 
haematologic side effects 
of low-dose of MTX in 
patients with RA and to 
determine whether or not 
folate supplementation 
alters MTX efficacy 
7 2 0 
Adalimumab [57] Efficacy and safety 3 0 3 
Abatacept [58] Efficacy and safety 5 0 2 
Anakinra [59] Effectiveness and safety 3 0 2 
Certolizumab pegol 
[60] 
Effectiveness and safety 3 0 1 
Etanercept [61] 
Update the previous 
Cochrane systematic 
review published in 2003 
assessing the benefits and 
harms 
6 0 3 
Infliximab [62] Efficacy and safety 1 0 1 
Golimumab [63] Efficacy and safety 2 0 2 
Tocilizumab [64] Efficacy and safety 7 1 1 
Glucocorticoids [65] 
Evaluating efficacy in 
inhibiting the progression 
of RD in RA 
15 0 1 
  
133 12 
22 
Total: 145 
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Table 2.2 shows that, not taking into account studies that are fully reporting on all core 
outcomes, the total number of RCTs not fully reporting on all core outcomes that have been 
assessed in these SRs for ORB was 145.  
 
This set of studies contains 133 (92%) trials that were included in the SR. Trials that were 
excluded in the ‘characteristics of excluded studies’ section were also checked for any 
suggestion of ORB. The number of excluded studies was 12 (8%) (see Table 2.2).  
 
2.4.2 Constructing and completing the ORBIT matrix 
 
Using the information from the reviews, the ORBIT matrices [28] were constructed for each 
review. As an example, the matrix is provided for the review of Auranofin [48] for the 
treatment of RA (Table 2.3). In this particular review, none of the included trials reported on 
the full set of core outcomes. The matrix also identifies that no trial reported on RD and Borg 
1991 reported on none of the core outcomes. Borg 1991 was excluded from the original SR 
because no OMERACT outcomes were reported in this article. In the appendix, the ORBIT 
matrices are shown for the remaining 20 SRs assessed (Appendix A, Tables A.1-A.20). 
 
Table 2.3 Constructing the ORBIT matrix - Auranofin for treating rheumatoid 
arthritis [48] 
Study Eligibility TJC SJC Pain 
Pat. 
Global 
Phy.  
Global 
Function APR RD 
Davies  
‘82  
Included 
        
Prouse  
‘82  
        
Palmer  
‘82 
        
Ward  
‘83 
        
Wenger  
‘83 
        
Lewis  
‘84  
        
Bombardier 
‘86 
        
Johnsen  
‘89  
        
Glennas  
‘97 
        
Borg   
‘91 
Excluded         
TJC: Tender joint count; SJC: Swollen joint count; Pat.: Patient; Phy.: Physician; APR: acute phase reactant; RD: 
Radiological Damage 
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2.4.3 Applying the ORBIT classification system: Auranofin for treating rheumatoid arthritis 
 
Table 2.4 shows the outcome matrix (Auranofin for treating RA [48]), which was constructed 
using the outcome data that was included in the SR. The sample size for all participants in 
this review was 1287, ranging from 20 patients in the Palmer 1982 trial to 340 in the Wenger 
1983 trial.  
 
Table 2.4 Completing the ORBIT matrix - Auranofin for treating rheumatoid arthritis 
[48] 
Study Eligibility  TJC SJC Pain 
Pat. 
Global 
Phy.  
Global 
Function APR RD 
Davies  
‘82 
Included 
 (H)  (H) (H) (C) (H) (D) 
Prouse  
‘82  
 (H)  (H) (H) (C)  (E) 
Palmer  
‘82  
  (C)  (H)   (H) 
Ward  
‘83  
     (FR)  (H) 
Wenger  
‘83  
   (H)  (C)  (FR) 
Lewis  
‘84  
(F) (H) (E) (H) (H) (F)  (H) 
Bombardier 
‘86  
       (H) 
Johnsen  
‘89  
    (D) (FR)  (FR) 
Glennas  
‘97  
(G)   (H) (H)   (A) (FR) 
Borg  
‘91  
Excluded (G) (D) (D) (D) (G) (C) (G) (G) 
TJC: Tender joint count; SJC: Swollen joint count; Pat.: Patient; Phy.: Physician; APR: Acute Phase Reactant; RD: 
Radiological Damage; FR Fully Reported 
 
 
In Table 2.4, eight core outcomes for the assessment of the efficacy of RA are presented, 
TJC, SJC, pain, Pat.Global, Phy.Global, function, APR and, finally, RD.  
 
As all the trials had missing data on at least one outcome; all trials were scrutinised and the 
outcome classified using the ORBIT classification system [28] where an outcome was not 
reported in the review. Table 2.4 shows the classifications for the Auranofin review [48], 
taking into account the information from the trial report. This table shows that, for 48% (38) 
of the 80 evaluable outcomes (8 outcomes x 10 trials) carried out in this SR, the set of core 
outcomes was either partially reported or not reported (A to I classification). For 16%, 13 of 
the 80 assessments carried out in this SR, at least one core outcome was classified under 
high suspicion for ORB (A, D, E, or G classification), whereas, for 14% (11 of 80), it was 
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clear the outcomes were measured and analysed (A, B, C, D classification), but the 
reporting of the outcomes meant that the data could not be included in a MA. Some trials did 
report data on function and RD but they were not considered when calculating the pooled 
results of the MA. Notably, the outcome function for the Ward [66] and Johnsen [67] trials 
was classified as ‘FR’. Ward measured, analysed and reported in full the outcome grip 
strength, which was not a validated measure of function for this particular review. However, 
amongst rheumatologists now this method to measure the outcome function is considered a 
consistent measure and it is accepted and therefore function was classified as FR also when 
it has been measured with grip strength. Johnsen on the other hand measured, analysed 
and reported in full a ‘Health Assessment Questionnaire (HAQ)’ but it was not reported in the 
MA. The HAQ was a validated measure of function used in the review; this outcome was 
therefore classed as FR and this was missed by the reviewers. Furthermore, RD for the 
Wenger, Johnsen and Glennas trials was classified as ‘FR’. In detail, Wenger did not use a 
validated scale to measure RD but Johnsen and Glennas used ‘Larsen Dale index’ reporting 
respectively median and Inter Quartile Range (IQR) and median (range) and p-value. While 
this non-parametric data could not have easily been used in the review MA, the reviewer 
should have tabulated this data within their review.  
 
Table 2.5 provides the justification for these classifications. The classifications and the 
remaining 20 reviews can be found in the appendix to this chapter (Appendix A).  
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Table 2.5 Justifications for the ORBIT classifications: Auranofin for treating RA [48] 
Trial Outcome Classification Reason 
Davies  
‘82  
 
SJC H** SJC is not mentioned in this trial 
Pat.Global H** Pat.Global is not mentioned in this trial 
Phy.Global H** Phy.Global is not mentioned in this trial 
Function C Grip strength was partially reported (mean only) 
APR H** APR is not mentioned in this trial 
RD D RD clearly measured but no results were reported 
Prouse  
‘82 
SJC H** SJC is not mentioned in this trial 
Pat.Global H** Pat.Global is not mentioned in this trial 
Phy.Global H** Phy.Global is not mentioned in this trial 
Function C Grip strength was partially reported (graphically) 
RD E** 
RD measured and likely analysed – composite and a 
selective set of outcomes reported 
Palmer  
‘82 
Pain C Pain is reported only graphically 
Phy.Global H** Phy.Global is not mentioned in this trial 
RD H** This study had a duration of 6 months 
Ward  
‘83 
Function FR 
The trialists measured, analysed and reported in full 
functional class  
RD H** This study had a duration of 21 weeks 
Wenger  
‘83  
Pat.Global H** Pat.Global is not mentioned in this trial 
Function C Grip strength was only partially reported (MD only) 
RD FR n/N progressed + radiological score changes reported  
Lewis  
‘84 
TJC F** TJC measured but unlikely analysed 
SJC H** SJC is not mentioned in this trial 
Pain E** 
Outcome measured and likely analysed – composite 
and a selective set of outcomes reported  
Pat.Global H** Pat.Global is not mentioned in this trial 
Phy.Global H** Phy.Global is not mentioned in this trial 
Function F** Function measured but unlikely analysed 
RD H** This study had a duration of 6 months 
Bombardier  
‘86 
RD H** This study had a duration of 6 months 
Johnsen  
‘89 
Phy.Global D Phy.Global measured but no results were reported 
Function FR The trialists measured and reported functional class  
RD FR Reported as median (IQR) for both treatment groups  
Glennas  
‘97 
TJC G** Routine practice to measure TJC  
Pat.Global H** Pat.Global is not mentioned in this trial 
Phy.Global H** Phy.Global is not mentioned in this trial 
APR A 
Outcome measured and analysed: p-value reported 
only as p>0.05 
RD FR Trialists measured and reported functional class 
Borg  
‘91 
TJC G** Routine practice to measure TJC 
SJC D SJC clearly measured but no results were reported 
Pain D Pain clearly measured but no results were reported 
Pat.Global D 
Pat.Global clearly measured but no results were 
reported 
Phy.Global G** Routine practice to measure Phy.Global 
Function C Function is reported only graphically (HAQ) 
APR G** Routine practice to measure APR 
RD G** Routine practice to measure RD in long-term trials 
TJC: Tender joint count; SJC: Swollen joint count; Pat.: Patient; Phy.: Physician; APR: Acute Phase Reactant; RD: 
Radiological Damage; FR: Fully Reported 
**E/F and G/H classifications were confirmed with the reviewer 
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2.4.4 Assessment results: all rheumatoid arthritis reviews 
 
The ORBIT classification [28] for all the assessed trials is shown in Table 2.5. A breakdown 
of the classification by intervention class (DMARDs, biologics, and glucocosteroids) is 
provided in the appendix to this chapter. In the following table (Table 2.6) the clinical trials 
considered for the assessment of ORB are 145 that are derived from the set of 167 studies 
except the 22 studies for which the outcomes were FR.  
 
Table 2.6 Clinical trials assessed for outcome reporting bias  
Class 
Rheumatoid Arthritis Core Set of Outcomes  
TOTAL 
(%)a 
 TJC SJC Pain 
Pat. 
Global 
Phy. 
Global 
Function APR 
RD 
< 52 
wk 
≥ 52 
wk  
A 3 4 1 3 2 2 4 2 2 
21 
(1.7%) 
B 1 1 0 0 1 0 0 0 0 
3  
(0.2%) 
C 21 19 17 20 18 33 36 1 4 
168 
(13.9%) 
D 2 3 8 8 8 8 7 2 2 
46 
(3.8%) 
E 19 16 18 22 20 8 15 2 0 
118 
(9.8%) 
F 10 10 8 7 6 7 8 0 1 
57 
(4.7%) 
G 7 12 20 15 19 7 4 6 6 
90 
(7.5%) 
H 6 8 19 18 24 10 7 89 0 
92 
(7.6%) 
I 0 0 0 0 0 0 0 4 0 
0  
(0%) 
Total: A to I classification 
595 
(49.4%) 
Fully 
reported 
98 94 76 74 69 92 86 25 21 
610 
(51%) 
Total 167 167 167 167 167 167 167 131 36 1205 
TOTAL 
Missing 
Data (A-I) 
(%)b 
69 
(41%) 
73 
(44%) 
91 
(54%) 
93 
(56%) 
98  
(59%) 
75  
(45%) 
81 
(49%) 
N/Ac 
15 
(42%)d 
 
TJC: Tender joint count; SJC: Swollen joint count; Pat.: Patient; Phy.: Physician; APR: acute phase reactant; RD: 
Radiological Damage.   
a The denominator used is 1205. That is the total number of data points if all 145 trials reported on all seven core 
outcomes (TJC, SJC, Pain, Pat. Global, Phy.Global, Function, APR) plus the 36 trials that should have also 
measured and reported on RD due to a follow-up greater than 52 weeks (i.e. (167*7) + (36*1) = 1205). The 
numerator also excludes the assessment of RD for trials less than 52 weeks. 
b The denominator used is the total number of trials where an assessment is possible (167). 
c Not applicable: OMERACT recommends outcome only applicable if follow-up > 52 weeks. 
d The denominator used is the total number of trials where an assessment is possible and the follow-up is greater 
than 52 weeks (36). 
 
 
At the trial level, missing or incomplete reporting of outcome data for each core outcome 
ranged from 41% (69 of 167 trials) for TJC, up to 59% (98 of 167 trials) for Phy.Global. For 
595 (49.4%) of the 1205 evaluable outcomes in this current study, the set of core outcomes 
38 
 
was either partially reported or not reported (A to I classification) (Table 2.6). The 23% (275) 
of the 1205 assessable outcomes were classified under high suspicion for ORB (A, D, E, or 
G classification), whereas for 20% (238 of 1205) it was clear the outcomes were measured 
and analysed (A, B, C, D classification), but the reporting of the outcomes meant that the 
data could not be included in a MA. 
 
2.5 Discussion 
 
This is the first study to consider an assessment of ORB against a well-established core set 
of outcomes. The OMERACT COS was approved for use in clinical trials for RA but is also 
endorsed by the CMSG [6]. Although the uptake of the measurement of the COS for 
rheumatoid arthritis trials has been shown to be increasing [40], the reporting of the 
outcomes for many of these trials remains insufficient, meaning that many meta-analyses 
are unable to include data from all relevant studies. Similar to the study reported by Dwan et 
al [38], who looked at all review outcomes in a cohort of Cochrane Cystic Fibrosis reviews, 
all the reviews considered in this study included at least one study that contained missing 
data in relation to at least one of the core outcomes. Across all core outcomes, there were 
238 items of study data missing from meta-analyses for outcomes that were clearly 
measured and analysed (A-D classifications), and a further 208 items of study data where 
the outcome data were clearly measured (or likely measured) but not reported because of 
non-significant results (E and G classifications). In this assessment, the number of outcomes 
with high suspected bias (A, D, E, and G) was 275 of the 1205 evaluable outcomes 
assessed.  
 
It is important that trialists follow CONSORT 2010 [68] guidance for reporting trial findings. 
Adherence to CONSORT would ensure that all outcomes are reported in full and all pre-
specified outcomes are defined and reported. Many outcomes were not mentioned in the 
trial reports, meaning that clinical judgment was needed to decide whether the outcome of 
interest was likely to have been measured for a particular trial. Reviewers were contacted to 
help with the assessments and to provide their expert judgment in these situations, although 
a limitation of this study is that trialists were not contacted to confirm whether the outcome 
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was measured or not. This was a pragmatic choice, as the median publication date for trials 
included in this review was 1999, meaning there would be difficulties in locating many of the 
trialists.  
 
The original ORBIT study [28] found that the sensitivity and specificity of determining 
whether an outcome was measured or not and detecting bias from unpublished/partially 
reported outcomes was excellent. The work in this chapter however demonstrates that the 
reliability of SRs could be improved if more attention is paid to missing outcomes from the 
source trial reports. If data are missing, in the first instance, reviewers should be encouraged 
to at least attempt to contact the trialists or study sponsors to confirm whether the outcome 
was measured and analysed, and, if so, obtain the results and update the review MA 
accordingly with the newly obtained data. If data are not available, then reviewers should 
consider sensitivity analyses to adjust and assess the impact the biases identified have on 
the pooled effect estimates – a topic covered in Chapter 3.  
 
Another underlying issue in this study is that there are several measurement scales that can 
be used to measure each of the core outcomes, some of which may not have been accepted 
as valid measurement instruments in the individual reviews. The RA COS used in this study 
addresses the issues of ‘what’ outcomes to measure but not ‘how’ to measure them. As part 
of the uptake study [10], acceptable measurement instruments for each core outcome were 
decided in advance by expert rheumatologists. Trials were therefore classed as fully 
reporting the core outcome if they had reported in full one of these acceptable measurement 
instruments to represent the core outcome that was not of interest in the review. The 
motivation here is that, in many cases, it was thought unlikely that trials would use several 
measurement scales to use the same outcome and therefore the risk of non-reporting bias 
would be low. In addition, some of the measurement tools required for the review may not 
have been validated at the time the trial was conducted. However, the risk of bias from 
reported results, i.e. when an outcome is selectively reported based on a subset of the 
analysis undertaken (e.g. selectively reporting the most significant scales from a battery of 
measurements used to measure the same outcome), may remain high. This form of 
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reporting bias was evident in the reporting of composite outcomes which was addressed in 
this study. In an ideal situation, if a composite outcome is used, then all of its individual 
components should also be reported in full for complete transparency.  
 
One final comment is that the RA COS set does not address harm outcomes. This chapter 
outlines a framework for identifying and assessing ORB in SRs. Using a similar framework, 
harms can also be assessed for ORB in reviews, but the classification for assessing the 
reasons for missing data may differ from that for benefit outcomes. For harm outcomes, 
Saini et al [69] propose a different 13-point classifications to be used where the bias is 
associated with the suppression (or inappropriate) reporting of specific harms data that mask 
the harm profile of particular interventions.  
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Chapter 3 - Multivariate fixed-effects meta-analysis to 
adjust for outcome reporting bias: a simulation study  
 
3.1 Background 
  
In Chapter 2 the notion of ORB was defined, describing the potential impact this form of bias 
may have on a SR. Furthermore, the results of the study were presented where ORB was 
assessed in a cohort of reviews in which a core set of outcomes had been endorsed by 
trialists and the related Cochrane Review Group.  
 
The aim of Chapter 2 was to present the methodology to assess suspected ORB in SRs and 
to estimate the prevalence of ORB in the Cochrane RA reviews by considering all eight 
outcomes in the COS.  
 
In summary, from the results, firstly, all 21 reviews contained missing data on at least one of 
the eight core outcomes. Secondly, ORB was highly suspected in 275 (23%) of the 1205 
evaluable outcomes from the 167 assessable trials scrutinised. Finally, ORB is a non-
ignorable missing-data problem that could adversely affect the results of a SR. 
 
In the presence of ORB, it is important to determine how robust MA conclusions are. If there 
is selective reporting and the presence of ORB is suspected, one possible solution is to 
contact the trialists in order to try and obtain the missing outcome data. However, in many 
cases this process is not feasible because missing data are unobtainable from trial authors, 
often because the authors are no longer easily contactable, the trials are old and data are 
not stored or readily available.  
 
The impact of these missing data on the MA result should be examined through the use of a 
sensitivity analysis. In the statistical literature, there are three main statistical methods 
available for assessing the impact of ORB on MA results.  
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The first method has been termed maximum bias bound [70] and consists of calculating a 
pooled-effect estimate from the n studies reporting data and to calculate the bias-adjusted 
estimate by adding the value of this bound to the pooled-effect estimate. This approach 
assumes that larger studies (with small SEs) are more likely to be published than smaller 
studies (with larger SEs).  
 
The second method, proposed by Copas et al. in 2014 [71], consists of checking if a paper 
in the area of interest does not report sufficiently well (or not at all) the particular outcome of 
interest using the ORBIT classification [28] method described in Chapter 2. This method 
explicitly models the ORB missing data mechanism according to the level of suspicion of 
ORB (again using the high/low classifications) from ORBIT.  Fundamental to this approach is 
calculating the likelihood function [71] for each study being considered in the MA, taking into 
account that some of the outcome data are observed, some outcome data are missing due 
to a high ORB suspicion (i.e. the data are presumed missing because the result is not 
statistically significant) and some data are missing due to a reason associated with low 
suspicion of ORB, for example, the result has been measured as reported graphically but 
not necessarily analysed. The level of suspicion (high or low) also comes from the ORBIT 
classification [28] discussed in Chapter 2.  
 
The third method is represented by MVMA, where the study effect estimates (which often 
relate to the treatment effect) for all available outcomes are jointly synthesised, while 
accounting for their w/s and between-study correlations [72]. In the presence of ORB, MVMA 
has been proposed as a possible statistical method to reduce the impact of ORB in a MA 
[72]. The main reason that the focus is on this MVMA method in this thesis is that MVMA 
allows for multiple outcomes to be synthesised simultaneously and the method accounts for 
the correlation across studies, which may add additional information to reduce ORB when 
there are missing outcomes. MVMA in this setting is largely unexplored and therefore sets 
the basis for this thesis.   
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The MVMA method utilises the w/s and (in the REMA setting) between-study correlations of 
the effects for the multiple outcomes in order to jointly synthesise outcomes from 
randomised trials. Furthermore, MVMA takes into account the correlation to gain more 
information than allowed in a traditional, UVMA of each outcome separately. From a 
practical sense, it is desirable to synthesise important outcomes in a review by performing 
one analysis, rather than analysing each outcome separately. 
 
However, the lack of reporting of w/s correlations within trial reports often prevents the 
application of MVMA [73]. Various approaches for estimating the w/s correlation have been 
proposed in the literature. It has been demonstrated that, when IPD are not available, MVMA 
can be carried out by assuming a plausible value for each unknown correlation coefficient 
[74]. For example, there are some situations where the w/s correlation could be assumed as 
equal to zero [75]. These correlation values may also be derived using clinical 
considerations (e.g. elicitation of correlation information). In addition, the empirical 
correlation coefficient observed between treatment effect estimates across studies could be 
used. 
 
If IPD are available for all studies, then the w/s correlations can be derived directly, which 
thus avoids reliance on study reporting [73]. Another simulation study has previously been 
undertaken in the area of MVMA for ORB. This study considered the UFMA and bivariate 
fixed-effects meta-analysis (BFMA) models and their estimation. The objective of the 
research was to demonstrate through a simulation study the estimation properties from 
BFMA when compared with those from two separate UFMA in situations with complete data 
and non-ignorable missing data according to an ORB mechanism [73]. The researchers 
obtained UFMA results that show ORB can substantially bias pooled estimates, and thereby 
over-estimate pooled treatment effects. They found that the results from the BFMA approach 
were encouraging and that the borrowing of strength (BoS), from taking into account the w/s 
correlation between outcomes running the model, can reduce the impact of ORB in a MA 
[72]. However, the researchers concluded that a major limitation of their study was that they 
generated the AD (effect estimates, and their w/s variances and correlations) directly, and so 
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did not generate IPD first. This has potential limitations. Firstly, the w/s correlations were 
always the same in each MA dataset, which in some situations may be unrealistic. Secondly, 
w/s variances were generated as known (i.e. they were not estimated from the IPD itself), 
which is also potentially unrealistic. Therefore, new simulations based on IPD are needed to 
verify the findings in a more realistic setting. 
 
Undeniably, SRs and MA based on IPD are regarded as the gold standard [76] for evidence 
synthesis and have become increasingly common, having several advantages over meta-
analyses based on AD. The advantages related to the use of the IPD in a MA involve all the 
aspects of the SR – from the trial inclusion, to the data quality, risk of bias assessment, 
analysis, and interpretation [77]. For example, the use of IPD would allow any unavailable 
w/s correlations to be calculated directly. Therefore, the use of IPD in MVMA should be 
considered.  
 
The aim of this present study is to investigate the use of MVMA for reducing ORB in IPD 
MA, through simulation. This is the first IPD-based simulation study examining the impact of 
ORB reduction on pooled-effect estimates for meta-analyses.  
 
For this simulation study, continuous patient-level responses are considered. IPD were 
generated for multiple outcomes in order to model the data across multiple studies using 
multivariate fixed-effects meta-analysis (MFMA) methods, for a number of different ORB 
scenarios, with comparison to UVMA.  
 
The simulation study is motivated by the RA reviews that were previously considered in 
Chapter 2. Through the use of performance metrics, the objective is to demonstrate if MVMA 
offers an overall benefit over a standard UVMA approach when the w/s correlations and 
variances from each study can be computed directly.  
 
In this chapter, the model specifications and estimation methods are presented for a UFMA 
model and a MFMA. The two-stage approach and models for fitting and analysing an IPD 
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meta-analytic approach are also described. In later sections, the simulation study structure, 
including the process for generating the data, incorporating missingness as a result of ORB, 
and the simulation performance indicators are both defined and described.  
 
The chapter concludes with the results from the simulation study and discussion of the 
relative benefits of MFMA and any limitations.  
 
3.2 Model specification and estimation 
 
Before describing the MFMA model or considering IPD MA approaches, the standard UFMA 
and its estimation is firstly introduced. The UFMA model was also introduced in Chapter 1 in 
section 1.4.2. For UFMA model it is to be assumed that the effect estimates, their variances 
and correlations for a set of multiple outcomes are available from a set of randomised 
clinical studies to be meta-analysed. In general terms, there are to be n studies 
),.....,1( ni  and m outcomes ),......,1( mk  . 
 
3.2.1 Univariate fixed-effects meta-analysis 
 
For a UVMA, there are two quantities of interest that are required from each study (i) for 
inclusion in the model: the treatment effect estimates and the w/s variance (or equivalently 
the SE).  
 
Assume that for each study i there is a set of m treatment effect 
estimates ),........,,( 21 imii yyy . Similarly, for each study i there is a set of m w/s variances for 
each outcome (say
22
2
2
1 ,........,, imii sss ). 
 
Therefore the UFMA model assumes that the obtained estimates of the treatment effect for 
the ith study are normally distributed about a common, fixed, true effect and variance, which 
are assumed to be known.  
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Of prime interest is estimating this fixed true effect value. For (m) separate outcomes, there 
are (m) separate normal distributions, as Equation 3.1 demonstrates [17]: 
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Each model parameter (for each outcome separately) is typically estimated using ML 
estimation. The final (pooled) estimate of the MA is a weighted average of the estimates of 
the individual studies. In UFMA, model weights are a function of the variability of each study; 
in other words, the inverse of the variance. For example, for outcome one, the formula for 
the overall pooled estimate for outcome one is the following [17]: 
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3.2.2 Multivariate fixed-effects meta-analysis 
 
For MFMA, all outcomes are analysed simultaneously [76]. In addition to the two quantities 
required for a UVMA from each study (treatment effect estimate and the w/s variance), the 
w/s correlations are also required. The w/s correlations indicate the strength of the 
association between the outcome estimates within a study, and these are assumed to be 
known. These w/s correlations are rarely reported in primary studies, but, in Section 3.3, a 
process for deriving these quantities from each study is described when IPD are available. 
Therefore, the general form of the MFMA model follows the multivariate normal distribution 
and is shown in Equation 3.3 [76]: 
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In Equation 3.3 
i
Y  represents the vector for the treatment effect estimates, while μ  is the 
vector of the fixed true treatment effects for the outcomes and 
i
S represents the w/s 
variance-covariance matrix of the effects’ estimates. For m outcomes, the model in Equation 
3.3 is equivalent to: 
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The entries of the matrix 
i
S  on the main diagonal are the w/s variances ),.......,,(
22
2
2
1 imii
sss , 
which are assumed to be known. The entries outside the main diagonal are the w/s 
covariances, which are also assumed to be known.  
 
ML estimation method can again be used to estimate the vector of pooled estimates ˆ , for 
example, using the STATA MVMA module ‘MVMETA’ [78]. One of the benefits of the model 
in Equation 3.3 is that it can accommodate studies that do not report on data for all 
outcomes by utilising the w/s correlation. In the field of MVMA, the impact the w/s correlation 
has on the estimation of the treatment effects is often termed borrowing of strength. BoS can 
typically depend on the strength of the w/s correlations and also the size of the w/s 
variances between outcomes [76]. In the presence of missing study data, BoS can be 
particularly large, as this is equivalent to arbitrarily setting a w/s variance of infinity for 
missing outcomes in such studies. The concept of ‘borrowing strength’ is returned to in 
Section 3.9, where it is considered as an important performance indicator in the simulation 
study. 
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3.3 Individual participant data multivariate meta-analysis 
 
The motivating RA example underpinning this thesis considers only multiple continuous 
outcomes and hence this thesis considers only facilitating both the univariate and 
multivariate models (Equations 3.1 and 3.3 respectively) for this particular scenario. 
Consequently, the IPD will be used to obtain the effect estimates, their within study 
variances and covariances from each study under the assumption that all outcomes are 
continuous. Focus is also given to the two-stage IPD-MA approach suggested by Riley et al. 
2010 [76], although a one-stage approach is also possible.   
 
Under a two-stage approach, when IPD are available from n studies, in the first stage, each 
of these studies is analysed separately to obtain the AD from each study, and then, in the 
second stage, the models in Equation 3.1 and Equation 3.2 can be applied.  
  
3.3.1 First-stage  
 
As with many RA trials, most are two-arm, parallel group trials comparing a treatment (T) 
against a comparator drug (C). The model specification for the first stage of an IPD-MA is 
dependent on the specific metric of analysis. The following considers the final score analysis 
that will be used in the simulation, but other specifications are also available, for example, 
change from baseline [79]. 
 
At the end of each study, for a final score analysis, the jth patient in the ith study will provide a 
final score for each outcome. Each individual patient response will be referred to as ijkz , 
i.e. the response value for outcome (k) from patient (j) in the ith study. For each outcome and 
each trial separately, the general form of the model for the final score analysis becomes: 
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In Equation 3.5, ik is the control group effect (intercept) for outcome k, ik is the treatment 
effect for outcome (k) and study (i), while ijT identifies the treatment group indicator for the 
ith study and the jth patient. In this joint model (Equation 3.5), the residual errors are equally 
distributed as a Normal with mean 0 and variance
2
ik , which represents the residual 
variance of outcome k in trial i, after accounting for the treatment effect. The residual errors 
are also correlated and the covariance mmimmi ),1()1( ),cov(    is different from 0 and 
equal to mm ),1(  .  
 
In the simulation study, just three continuous outcomes will be considered (k=3), where k=1 
for the outcome TJC, k=2 for the outcome SJC and k=3 for pain, as an example from the RA 
core set of outcomes defined in Chapter 2. Consideration of only three outcomes is for 
simplicity. For the motivating example, the model in Equation 3.5 can be fitted as a trivariate 
model with a joint model specification, where each patient contributes to three follow-up 
responses (one for each outcome k), to a single model containing all the three outcome 
jointly [79]. Therefore, the joint model fitted in each trial – taking into account all three 
outcomes as in this example – assumes the following structure: 
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Of interest from the model shown in Equation 3.6 are the estimation of the treatment effects 
vector iβ , the associated SEs of iβ and the patient’s level (residual) variance-covariance 
parameters iΣ . At the second stage of the IPD model, the SEs will be used to calculate the 
variances to run the MFMA model in Equation 3.2. It should be noted that, for the future 
implementation of UFMA or MFMA models, the vector of iβ estimates in Equation 3.6 
contains exactly the same values contained in the vector of the treatment effect estimates 
iY  of Equation 3.2. In order to estimate these quantities, the model in Equation 3.3 (and 
Equation 3.4) can be fitted using SAS ‘proc mixed’ using REML as the method of estimation. 
 
At this stage of the IPD-MA it is fundamental to recall that, having calculated the 
covariances, for example, for outcome one and outcome two, 12i , between the patient 
outcome responses, and the SEs 1i  and 2i , it is also possible to calculate the w/s 
correlations 12wi between individual outcome responses [80], as follows:  
 
 (3.7)
21
12
12
ii
i
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
 .    
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3.3.2 Second-stage 
 
From stage one, the treatment effect estimates for each outcome k in each study i, and their 
w/s variance-covariance matrices (containing their variances and w/s correlations, see 
Equation 3.7) are obtained. Having estimated these parameters it is possible to run the 
UFMA model (Equation 3.1 and Equation 3.2) [79] and therefore obtain the pooled-effect 
estimates, their SEs and the 95% confidence intervals. It is also possible to apply and fit the 
MFMA model (Equation 3.3 and Equation 3.4) [79] and again obtain the pooled-effect 
estimates, their SEs and the 95% confidence intervals.  
 
3.4 Description of the simulation study 
 
As previously mentioned, in this simulation study, three continuous correlated outcomes 
from the COS [25] endorsed by the RA SRs are considered (outcome 1: TJC, outcome 2: 
SJC and outcome 3: pain). TJC and SJC are discrete numerical variables (treated and 
analysed as continuous outcomes), while pain is measured on a continuous scale. For all 
these outcomes, the treatment effect is defined as the MD between the groups of patients 
randomised to control group treatment (C) and the group of patients receiving active 
treatment (T). In order to introduce correlated patient data there is also a need to define true 
patient-level correlations ( p ) between the outcomes. This simulation study considers a 
variety of different patient-level correlations between outcomes, including a set of 
correlations for the outcomes considered from a real IPD dataset of RA. Differing numbers of 
studies in the MA may also have an important factor on results (in this study we consider five 
and ten studies, as these reflect the range of studies found in reviews of RA) as well as 
different severities of missingness according to known ORB mechanisms. The simulation 
study examines 25 different scenarios in total, categorised (i) to (xxv) (Table 3.1). The 
details on how the data were generated and missing data introduced are provided in 
Sections 3.5 and 3.7 respectively.    
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Table 3.1 Scenario used in the simulation 
Scenario 
Assumed patient-level 
correlation: p   
Description 
Complete    
i 0  
No missing data 
ii 0.2  
iii 0.5  
iv 0.8  
v 
RA correlations from a real clinical 
trial (RA_corr) 
ORB   
vi 0  
Set missing all the study results showing 
a benefit to alternative treatment (i.e. 
study outcome with a positive MD) 
vii 0.2  
viii 0.5  
ix 0.8  
x 
RA correlations from a real clinical 
trial (RA_corr) 
xi 0  
Set missing 15%, 20% and 30% 
respectively for outcomes Y1, Y2 and Y3 
of the study results non-significant after 
‘first stage’ IPD-MA 
xii 0.2  
xiii 0.5  
xiv 0.8  
xv 
RA correlations from a real clinical 
trial (RA_corr) 
xvi 0  
Set missing all the study results that are 
non-significant after the ‘first stage’ IPD-
MA 
xvii 0.2  
xviii 0.5  
xix 0.8  
xx 
RA correlations from a real clinical 
trial (RA_corr) 
xxi 0  
Set missing all the study results that are 
either non-significant or showing a 
benefit to alternative treatment 
xxii 0.2  
xxiii 0.5  
xxiv 0.8  
xxv 
RA correlations from a real clinical 
trial (RA_corr) 
RA_corr: 0.67 (Y1 & Y2), 0.55 (Y1 & Y3), 0.38 (Y2 & Y3) 
 
 
3.5 Generating the simulated data 
 
The purpose of this section is to explain how the IPD were generated for each of the 1000 
MA simulation datasets nsim )1000....,,.........1( nsim . 
 
The true effect estimates (MDs) were set equal to -5 for outcome one (TJC), -3 for outcome 
two (SJC) and -6 for outcome three (pain). While the choice of treatment effect estimates 
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maybe seen as an arbitrary one in a simulation study, typically these were set such that they 
were the ‘average’ treatment effect values observed in the RA reviews. As an example, for 
TJCs, an interpretation of a MD of -5 would reflect that ‘on average’ five fewer TJCs were 
observed in the treatment group than in the control group. 
 
The number of studies (n) within each MA and each simulation scenario was fixed at five 
studies and ten studies. In five-study scenarios, the sample sizes (N) for each study ranged 
from 30 to 70 in each treatment arm, and this was from 10 to 100 in each treatment arm for 
meta-analyses containing ten studies. Sample sizes were fixed for each study across all 
simulations. For scenarios where n = 5 studies were simulated, the first study contained 30 
patients in each treatment arm, increasing in increments of 10 additional patients up to study 
5, which had 70 patients. When considering scenarios where n = 10 studies were simulated, 
the first trial had 10 patients in each treatment arm, and then went up in increments of 10, 
where study 10 had 100 patients in each arm. The ratio between the sample sizes of 
patients in each treatment arm was set as 1:1.  
     
Based on the number of studies and sample sizes, two sets of data were generated for each 
outcome, one for the group receiving treatment (T), and the patients receiving placebo in the 
control group (C). The response variable for each outcome was then simulated from a 
multivariate normal distribution and a vector of MDs (representing the final score) for the 
three outcomes generated. The MDs between the group of patients treated and the control 
group of patients were fixed as described above.   
 
The multivariate normal distribution through the specification of a variance-covariance matrix 
structure allowed the IPD for the three outcomes generated for each study to be correlated 
within each simulation. The patient-level correlations pi  were fixed across all studies and 
simulations and set to be 0, 0.2, 0.5, and 0.8 between each pair of the three outcomes. An 
additional patient-level correlation scenario was also considered (RA_Corr). This resembled 
the actual patient-level correlation between the three outcomes from a real RA IPD dataset. 
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These patient-level correlations were as follows: (TJC/SJC =0.67; TJC/pain=0.55; 
SJC/pain=0.38).  
 
Furthermore, MVMA needs the variance-covariance matrix to be defined. In this simulation, 
different size of variances were considered for each study, where study one, with the lower 
sample size, has been allocated the lower variances for each outcome and study five, with 
the higher sample size, has been allocated the higher variances for each outcome 
considered. 
 
Considering the variance-covariance matrix, the idea was to generate IPD as similar as 
possible to the actual data observed during the analysis of the SRs. First of all, as in the 
analysed SRs, where it had been noticed that each outcome was characterised by different 
variability, three different variances were considered for each outcome of this simulation 
study. Secondly, in analysing the SRs it had been observed that the treated group of 
patients and the control group of patients were presenting different variability. Therefore, 
considering each single outcome, the IPD were simulated taking into account this difference, 
setting two different sets of variances for treated and control group. As shown in the 
Appendix B, for studies with higher sample sizes, higher variances were considered for the 
groups of patients considered in the simulated randomised trials.  
  
The SAS code to generate the DATA is provided in Appendix B. A fuller specification of the 
parameters used including the covariance parameters is included. 
      
3.6 First stage of individual participant data meta-analysis 
 
After simulating the IPD for each study and each simulation, of interest is the calculation of 
the estimates associated with the treatment groups. Furthermore, the attention needs to be 
paid to the estimate of the MD, across the groups of patients randomised to treatment or 
control group, for the outcomes considered. Also needed are the estimated w/s variances 
and w/s correlations defined in Equation 3.5 under the w/s variance-covariance matrix. At 
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this stage, the aim is to apply the joint fixed model (Equation 3.6 or Equation 3.7 as in the 
motivation example of this work of simulation there are three outcomes considered) as 
described in Section 3.3.1, through the introduction of dummy indicator variables, which 
identify which patient belongs to which group. 
 
3.7 Generating the missing outcome data 
 
Following on from Section 3.5, at this stage, the IPD data generated are complete. Missing 
data are generated according to the varying degrees of ORB severity mechanisms outlined 
in Table 3.1. The mechanism in scenarios xi-xv resembles the proportion of missing study 
data found in previously analysed RA reviews for the outcomes considered. Scenarios xxi to 
xxv are the most extreme cases of ORB missingness.    
 
Once the estimates of the effects (MD) for each study and each simulation and SEs and p-
values associated with them (from stage 1 of the IPD-MA) had been obtained, missing data 
at the study level were introduced, according to the various scenarios. In other words, 
introducing missing data at the study level means that some of the results of the studies 
included in the MA that have been simulated are omitted. The objective was to replicate, as 
far as possible, realistic scenarios of ORB. Therefore, missing study data in the 1000 
simulated datasets were simulated.  
 
For example, for scenarios vi to x (Table 3.1), as it has been defined, the objective was to 
introduce missingness in correspondence to all the study results showing a benefit to 
alternative treatment (i.e. those with a positive MD). To introduce this type of missingness, 
following the results from the first stage of the IPD-MA, all the study-level results showing a 
positive MD for all 1000 simulated datasets were omitted. Study data for all other scenarios 
were omitted according to the mechanisms described in Table 3.1. 
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3.8 Fitting the meta-analysis model 
 
The first stage therefore provides treatment effects’ estimates and their variances, for each 
outcome in each study, and their w/s correlations. After the introduction of missing data at 
the study level (except in the case of the complete case analysis), it is then possible to 
implement the UFMA model following Equation 3.1 or MFMA using Equation 3.3. UFMA and 
MFMA models will give the pooled-effect estimates and their SEs for each outcome 
considered for each of the 1000 simulated MA datasets. 
 
For computational convenience, some studies were incorporated into the MA by allocating 
them an arbitrary value (e.g. set the treatment effect to zero) with a very large within-
variance (e.g. 1,000,000) and w/s correlation equal to zero. This technique is called data 
augmentation and replaces the missing outcome value with values that have negligible 
weight and information during estimation.    
 
Confidence intervals and hypothesis tests immediately followed using the conventional 
procedure by assuming that the estimates 
^
k  obtained from the UFMA model in Equation 
3.1 or the MFMA model in Equation 3.2 are normally distributed. 
 
3.9 Assessment of performance 
 
The performance of the estimates was assessed in terms of bias, mean SE, mean square 
error (MSE), coverage, power and BoS.  
 
Considering )1000....,,.........1( nsim  the number of simulations and )3,,.........1( k  the 
number of outcomes, the bias for outcome k is defined as [17]:   
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Therefore, the bias is calculated as the average of the differences between the estimator 
expected value knsim
^
  for each simulation and each outcome and the true value of the 
parameter k being estimated.  
 
Furthermore, the average standard error (SEsim) and mean squared error (MSEsim) were 
calculated to assess precision, taking the average of all the SEs and all the mean squared 
errors associated with the estimates obtained for each simulation with reference to the 
outcomes analysed.  
 
Then the coverage and the power associated with the overall estimates were calculated.  
 
The coverage was calculated as the percentage of simulated datasets for which the 95% 
confidence interval for an outcome’s treatment effect estimate contained the true effect 
estimate k .  
 
Power was calculated as the percentage of simulated datasets for which the 95% 
confidence interval for an outcome’s treatment effect estimate did not contain zero [17].  
 
For all scenarios, the BoS was also calculated with the objective to compare the results 
obtained from UFMA and MFMA to see how much influence the utilisation of the w/s 
correlation has on the BoS at the MVMA level. For this,  kMFMAVar needed to be defined 
as the average of the estimated variances for outcome k for the MFMA model and 
 kUFMAVar as the average of the estimated variances for outcome k from the UFMA 
model. The formula that we used to calculate BoS is reported in Jackson et al. [80]. In the 
following formula (Equation 3.12), the BoS will be calculated as a percentage, as follows:  
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It is know from the literature that large w/s correlations allow BoS across outcomes, and this 
produces slightly narrower ‘confidence intervals’ as a result of smaller SEs [18]. 
 
3.10 Simulation Results 
 
The aim is to study the impact of bias in the pooled treatment effect estimates for multiple 
outcomes using UFMA and MFMA, and to determine whether the BoS from MVMA can 
reduce the impact of ORB.  
 
The results of the simulation studies are provided in a separate appendix (Appendix C). 
Table C.1 in this appendix provides the simulation results for scenarios with no missing data. 
The results for scenarios with missing data at the study level, as a result of ORB, are shown 
in Tables C.2 to C.5 of this appendix.  
 
The purpose is now to discuss the new findings from this present simulation study, in 
particular focusing on the utilisation of w/s correlation. The trend in the parameters 
considered for the evaluation of the results will be described, and in particular the variation 
and the trend in the bias of the estimates, SEs (SEsim), coverage, mean squared error 
(MSEsim) and power will be examined. The variation of percentage of BoS for all outcomes 
will also be presented and discussed.  
 
Data augmentation was needed for a number of the simulated MA datasets; the number of 
datasets this method was applied to, increased, as the amount of missingness became more 
severe (Tables C.1-C.5 in Appendix C). In the tables of the appendix C, 1 refers to the 
outcome 1 (TJC), 2 refers to the outcome 2 (SJC) and finally 3 refers to the outcome 3 
(pain). 
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3.10.1 Comparison between univariate fixed-effects meta-analysis and multivariate fixed-
effects meta-analysis 
 
For all scenarios, complete cases and missing ORB mechanisms, there were no discernible 
differences in power; hence, it was difficult to make a judgement on the benefit of MFMA 
using this performance criterion. Notably, the level of power achieved was high, and in many 
cases 100% power was achieved. The high levels of power observed are perhaps the 
consequence of performing IPD-MA with true effect sizes far from zero. 
 
For complete-case data, the estimates for all outcomes were relatively unbiased for both 
UFMA and MFMA (Table C.1 Appendix C). As the missing ORB data mechanism became 
more severe, the estimates became more biased. The negative biases observed in this 
instance were indicative of the pooled treatment effect overestimating the true treatment 
effect. The most severe biases occurred when both non-significant results and results 
showing benefit to the alternative treatment were excluded (Table C.5 Appendix C). There 
was a tendency for the biases to be greater for the estimates obtained in scenarios where 
there were ten studies compared to those with five studies. It is expected that this is a result 
of the additive effect of excluding more studies from the meta-analyses, resulting in more 
biased pooled estimates. Similarly, there was a tendency for outcome three to be more 
biased than outcome two and outcome two to be more biased than outcome one, a result of 
differing levels of missingness in each outcome. In terms of bias reduction, there was a 
benefit from using MFMA over UFMA in all scenarios where at least all non-significant study 
results were removed from the MA (Tables C.4 and C.5 in Appendix C). The benefit seemed 
to be greater as the patient-level correlation between outcomes increased and marginally 
improved when there were fewer studies in the MA (five studies as opposed to ten). As an 
example, from Table C.5 Appendix C, where five studies were simulated for each simulation, 
with a patient-level correlation of 0.8 between outcomes, the bias reduction in outcome two 
was about 26% when comparing the UFMA estimate (-1.129) with the MFMA estimate (-
0.838). When a lower patient-level correlation value of 0.2 between outcomes was used, the 
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bias reduction was about 2% when comparing the UFMA result (-1.160) with the MFMA 
result (-1.140).  
 
When the missing ORB data mechanism was less severe (Tables C.2 and C.3 in Appendix 
C), the MFMA still outperformed the UFMA in the majority of cases. There were some 
instances when the UFMA was slightly improved, but this nearly always occurred in outcome 
one where the bias was generally smaller due to fewer studies being missing from the 
analysis. The benefit gain in the UFMA was also only negligible.  
 
In terms of standard errors (SEsim) and MSEsim, the pooled estimates were always more 
precise using MFMA, resulting in smaller standard errors and mean square errors, with 
larger gains when there were missing data as a result of ORB and when the patient level 
correlation was increased. As an example, considering outcome two, for ten studies with a 
patient-level correlation of 0.8 (Table C.5 in Appendix C), the average standard error for the 
UFMA approach was 1.178 compared with 0.950 for MFMA, an increase in precision of 
19%. These findings are consistent with those found in previous simulation studies, albeit 
these considered BFMA.  
 
This pattern in the increase in precision is also reflected in the BoS performance indicator 
that was not previously considered in other simulation studies. The more severe the ORB 
missing data mechanism and the stronger the patient-level correlation, the bigger the gain in 
BoS when applying the MFMA method. For example, considering the most severe ORB 
scenario (Table C.5 in Appendix C), where the patient-level correlation is set to 0.8 and the 
number of studies at ten, the %BoS is 8.6%, 31.7% and 19.3% for outcomes one through to 
three respectively. Considering the same level of studies and same patient-level correlation 
for a less severe ORB mechanism, the %BoS is much lower, for example, 4.3%, 7.6% and 
5.6% for the three outcomes respectively (Table C.5 in Appendix C). Considering the impact 
on the patient-level correlation comparing the most extreme ORB mechanism, again with ten 
studies but with a patient-level correlation set to 0.2, the %BoS is 1.7%, 3.3% and 2.3% 
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(Table C.5 in Appendix C) for the three outcomes, far lower than the 8.6%, 31.7% and 
19.3% for a patient-level correlation of 0.8.     
 
For complete-case scenarios, coverages were hovering around the nominal 95% for both 
UFMA and MFMA approaches. Similarly, nominal coverages were maintained for both 
methods when the ORB mechanism was less severe (benefit of alternative treatment 
removed, Table C.2 in Appendix C). There was a marked drop in coverage as the missing 
ORB mechanism became more severe; this was particularly noticeable for ten studies 
compared to five. For these situations, there were quite a few instances where the UFMA 
marginally outperformed the MFMA approach. For example, taking into account the scenario 
where 15/20/30% of study results were suppressed from TJC/SJC/Pain respectively if they 
were non-significant and considering the situation where n = 5 studies, the UFMA coverage 
results were closer to nominal (93.3% for outcome 1, 94.7% for outcome 2 and 92.1% for 
outcome 3) than the MFMA coverage results (93.1% for outcome 1, 94.3% for outcome 2 
and 84.0% for outcome 3). Nevertheless, in scenarios where the ORB mechanism was most 
severe, MFMA was preferable, particularly when the patient-level correlation increased. For 
example, taking into account the scenario where all studies that have non-significant results 
and show benefit of alternative treatment are excluded and considering the situation where n 
= 5 studies, the UFMA coverage results were lower (91.7% for outcome 1, 85.7% for 
outcome 2 and 89.8% for outcome 3) than the MFMA coverage results (91.9% for outcome 
1, 88.8% for outcome 2 and 90.6% for outcome 3).  
 
3.11 Discussion 
 
3.11.1 Research problem 
 
The objective of this present study was to investigate the use of MVMA for reducing ORB in 
IPD-MA, through simulation. This is the first IPD-based simulation study examining the 
impact of ORB reduction on pooled-effect estimates for meta-analyses.  
 
62 
 
3.11.2 Rationale for individual participant data meta-analysis  
 
In this chapter, both the UFMA and MFMA approach for meta-analysing IPD were 
considered. The MVMA approach offers a novel way of jointly synthesising multiple 
outcomes across multiple studies. The added benefit of having access to the IPD is that the 
often-unreported w/s correlations could be computed directly from the data [79]. 
 
The IPD-MA simulation study that was performed demonstrated that the MFMA was 
preferential over UFMA across the majority of performance criteria and scenarios 
considered. The benefit was particularly noticeable as the ORB missing data mechanism 
became more severe and the patient-level correlation between the outcomes increased. 
This study also utilised the BoS performance measure, which has not been previously 
considered in related simulation studies. This enabled the quantification of the relative 
benefit in key performance criteria when comparing UFMA with MFMA.     
 
In this simulation study, a two-stage IPD-MA was applied for convenience and simplicity. 
This approach means that the estimates of the treatment effects, variances and w/s 
correlation at the first stage for each separate study can be first estimated for each separate 
simulation, allowing these estimates to be used in the UFMA or MFMA models at the second 
stage of the IPD-MA. From a statistical perspective, this approach avoided possible 
problems of convergence and is particularly feasible when data are missing in some 
outcomes [79]. Nevertheless, a one-stage MA approach could have been considered, 
analysing all IPD together from all studies to perform a single IPD analysis with a mixed-
effects model [79].   
 
In this thesis study, continuous outcomes were simulated. Other studies have been 
considered and analysed with multivariate IPD-MA; furthermore, other outcomes such as 
binary, survival and mixed have also been considered. 
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3.11.3 Limitations of the study 
 
The first limitation of this study is that we only considered FEMA approach. In many ORB 
scenarios, this may not be a realistic assumption in practice because ORB may hide the true 
extent of any underlying heterogeneity. This may suggest that a REMA approach ought to 
be the default methodology in the presence of severe ORB.  
 
A second limitation of this simulation study is that the number of studies (n) within each MA 
and each simulation scenario was fixed across the five studies and ten studies. This could 
have had an effect on the results, reducing the variability of the response variable between 
studies across all the 1000 simulations considered.  Taking this into consideration, some of 
the differences between five and ten study scenarios may not be directly comparable.  
 
A third limitation of this simulation study is that, when UFMA was applied at the second 
stage of IPD-MA, the known treatment effect estimates that are required to calculate the 
UFMA model are the estimates of the MD calculated from the IPD model implemented at the 
first stage. The same estimates of the MD and the variances were used also to implement 
the MFMA at the second stage.  
 
Chapter 4 will investigate an alternative method to analyse the IPD at the first stage that 
could make the results between UFMA and MFMA more different in terms of performance 
criteria such as Bias or Standard Error.  
 
3.11.4 Conclusion 
 
The main conclusion to be drawn from the simulation study that was performed is that the 
results are encouraging and the use of MFMA over standard UFMA is strongly 
recommended. There is also an argument to suggest that the method is no more complex to 
understand than a standard IPD UVMA, if this is being considered. Nevertheless, in the 
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presence of severe ORB mechanisms, it should be noted that, while MFMA can reduce the 
bias compared to standard UFMA, the results can still remain largely biased.      
 
3.11.5 Future applications of univariate fixed-effects meta-analysis and multivariate fixed-
effects meta-analysis to missing data scenarios simulated at individual participant data level  
 
In Chapter 4, the purpose is to retrace the simulation study by applying the UFMA and 
MFMA methods to scenarios where missing data have been introduced at the level of IPD, 
according to various types of missingness: missing completely at random (MCAR) and 
missing at random (MAR).  
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Chapter 4 - Multivariate fixed-effects meta-analysis to 
adjust for missing data in individual participant data: 
a simulation study 
 
4.1 Background 
 
Chapter 3 considered both the UFMA and MFMA approaches for meta-analysing individual 
IPD. The chapter investigated the use of MVMA for reducing outcome reporting bias (ORB) 
in IPD-MA. A series of ORB scenarios was considered. In particular, an IPD-MA simulation 
study proved that the MFMA was preferable to UFMA across the majority of performance 
criteria and scenarios considered. Furthermore, the previous chapter also showed that the 
results obtained from the application of UFMA and MFMA were encouraging. The conclusion 
was that the use of MFMA would be recommended. However, in the presence of severe 
ORB mechanisms, it has been noted that, while MFMA can reduce the bias compared to 
standard UFMA, the results can still remain largely biased. Ignoring missing data will lead to 
bias if the missing data mechanism is related to both the treatment and the unobserved 
outcome (e.g. missing values are more likely in one treatment arm because it is not 
effective). Missing data is a common issue in randomised controlled trials and threatens a 
trial’s ability to yield definitive conclusions [81]. Missing outcome data in trials can be due to 
many reasons and the explanations for it may follow the three basic missing data 
mechanisms: MCAR, MAR and missing not at random (MNAR) [82].                     
 
In the presence of missing outcome data, trial authors often ignore the missing data and 
perform a complete case analysis [83]. In the CONSORT statement, point 13b states "for 
each group, losses and exclusions after randomisation, together with reasons" should be 
included within the trial report [83]. This is not adhered to in a large number of trials within 
the study [83]. It is difficult to suggest a gold standard for missing data handling, as the 
appropriateness of a method is dependent on the unique nature of missing data within each 
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individual trial [84]. However, by carrying out a complete case analysis or eliminating certain 
patients based on level of missingness or prognostic factor we are making a bold 
assumption that the data we exclude is missing completely at random [84]. This is rarely, if 
ever, the case in practice [84]. For example, in a recent review of 100 clinical trials with a 
longitudinal outcome, nearly a third of the trials (32/100) performed only a complete case 
analysis despite there being missing outcome data [83]. Of those that did apply an 
imputation method, only half were deemed to have used an adequate method, in particular a 
simple imputation called LCOF/FOCB/Baseline Carried Forward [83]. Here, in Chapter 4, 
this work is extended by simulating a different mechanism for dealing with missing data at 
the patient level and applying UFMA and MFMA.  
 
MVMA has been considered and applied in both this chapter and in Chapter 3. The 
importance of its application is due to the following reasons. First of all, MVMA utilises the 
within-study correlations of the effects for the multiple outcomes in order to jointly synthesise 
outcomes from randomised trials. Furthermore, MVMA takes into account the correlation to 
gain more information than allowed in a traditional, UVMA of each outcome separately. In a 
practical sense, it is desirable to synthesise important outcomes in a review by performing 
one analysis, rather than analysing each outcome separately [17]. 
 
The concept of IPD was introduced in the previous chapter and relates to the data recorded 
for each subject in a study. A set of IPD from multiple studies often comprises a large 
sample size of patients. The notion of IPD is in contrast to the term AD, which relates to 
information averaged or estimated across all individuals in a trial. It is important to bear in 
mind that AD are derived from IPD themselves, so IPD can be considered the original 
source material. The objective of IPD-MA is to summarise the evidence on a particular 
clinical question from multiple related studies, such as whether a treatment is effective [76]. 
IPD-MA allows systematic reviewers to obtain the entire within-study variance/covariance 
matrix in each study, alleviating the reliance on this information being reported in the trial 
manuscripts. IPD may be not available for some studies. In this situation, one solution is to 
use the within-study correlations derived from IPD studies to give a likely value of the within-
study correlation in AD studies [17]. It has been discussed in the literature that one of the 
67 
 
potential advantages of using IPD for a MA is that missing data can be observed and 
accounted for at the individual level by applying imputation methods. Examples include 
using simplistic methods such as single imputation, for example, by using mean substitution, 
or more sophisticated methods such as the application of the expectation-maximisation (EM) 
[82] algorithm or multiple imputation [82], prior to synthesising the data. In this way the 
sensitivity of the pooled effects estimates from the imputed data sets can be assessed 
against the available case or complete case data. When only AD is available, systematic 
reviewers have little control over how to adjust for the missing data in their meta-analyses, 
other than to make an assessment of the potential impact of the missing data when 
assessing the risk of bias in the study. This also assumes that the amount of missing data is 
known from the primary study report, which may not always be the case, especially at the 
individual outcome level.     
 
The simulation study presented in Chapter 3 does not take into account missing data at the 
patient level, but it does consider it at the study level. With the existence of IPD, it is possible 
to deal with missing data at the patient level. Therefore, the aim of this current chapter is to 
simulate IPD for each study and within each simulated dataset, to introduce at the patient 
level different mechanisms for missing data, and finally to apply IPD-MA to the simulated 
data set. As in Chapter 3, 4 UFMA and MFMA models will be applied. The purpose of this 
chapter is to demonstrate is that MVMA could improve the estimates in the presence of 
missing data at the participant level. 
 
4.2 Steps of the individual participant data simulation analysis applied 
to missing completely at random and missing at random scenarios  
 
The aim of this section is to describe the present simulation study. The objective of this 
study is to simulate different missing data mechanisms at the IPD level and to analyse these 
missing data with the IPD models that will be described in section 4.3. All the characteristics 
in this simulation study remain the same as those described in Chapter 3; the only difference 
introduced in this chapter is that the missing data mechanism are considered at the 
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individual participant level rather than the study level. These are the steps that have been 
followed to obtain the results that will be presented and discussed in this chapter: 
 
 Step 1: IPD simulation. The first step of IPD-MA must estimate the treatment effects 
for each outcome in each trial. Therefore, IPD for three correlated outcomes 
(outcome 1 was TJC, outcome 2 was SJC count and outcome 3 was pain) were 
simulated following a multivariate normal distribution to simulate continuous 
outcomes. The motivating example for this IPD simulation study was the 
assessment of a Cochrane Systematic Review for the treatment of Rheumatoid 
Arthritis previously analysed. Then different mechanisms – a MCAR mechanism and 
a MAR mechanism – in IPD were simulated and studied. 
 
 Step 2: IPD-MA. The interest was in calculating the estimates associated with the 
treatment effects, measured as a mean difference across the groups of patients 
randomised to treatment or control group, for the three outcomes considered. To 
apply IPD-MA, a two-stage IPD-MA approach was chosen [79]. 
 
i. During the first stage of IPD-MA, it was considered using two different 
approaches. The first method consisted of applying a separate model, which is 
described in section 4.3.1.1 of this chapter. The second approach consisted of 
implementing a joint model, which is described in section 4.3.1.2 of this chapter. 
The first stage therefore provides treatment effect estimates and their variances, 
for each outcome in each study, and their within-study correlations. Treatment 
effects and their variances are estimated from SAS PROC MIXED [85] with the 
REML method (Appendix D). 
 
ii. The first stage therefore provides treatment effect estimates and their variances 
for each outcome in each trial, and their within-study correlations. Then, at the 
second stage of the IPD it was possible to implement the UFMA model 
described in section 4.3.2.1 of this chapter or MFMA, which will be described in 
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section 4.3.2.2. UFMA and MFMA models will give the pooled-effect estimates 
and their standard errors for each outcome considered for each of the 1000 
simulated MA datasets. In applying the UFMA to obtain the pooled mean 
difference estimate at this stage, the results from the two models implemented 
at the first stage have been taken into consideration. The first model was called 
the separate model (UFMAs) and the second model was called the joint model 
(UFMAj). To obtain the desired results, the mvmeta command in STATA [78] 
was utilised. See Appendix D for more details about the STATA code.  
 
 Step 3: the results obtained from the UFMA and MFMA have been summarised with 
performance indicators, as will be described in section 4.7 of this chapter. The 
results are contained in Appendix E and reported in section 4.8 of this chapter and 
discussed in section 4.9. 
 
4.3 Defining individual participant data meta-analysis 
 
In Chapter 3, the two-stage IPD-MA was defined in detail. As defined in the previous 
chapter, the most frequent scenario in many rheumatoid arthritis trials is that most of them 
are two-arm parallel group trials comparing a treatment (T) against a comparator drug or 
control (C). The model specification for the first stage of an IPD-MA is dependent on the 
specific metric of analysis. Again, the final score analysis to be used in this simulation is 
considered. The setup of the simulation study is similar to that in Chapter 3, with the 
difference being only in introducing missingness at the participant level rather than the study 
level; an additional modelling approach is also considered here for comparison.  
 
In Chapter 3, when UFMA was applied, the joint model was considered but in this chapter a 
separate model is also investigated. Here there is the need to introduce the difference 
between the joint model and the separate model because each outcome is investigated 
separately within each study by fitting n different UFMAs, where n is equal to the number of 
the outcomes considered in the simulation study.  
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In situations with a large proportion of incomplete outcome data, as in the scenarios that will 
be considered in this chapter, it is reasonable to assume that applying a separate model 
instead of applying a joint model could lead to different treatment effect estimates and 
variances. In the next sections, the focus will be on the description of the differences 
between these approaches. 
  
4.3.1 First stage: joint model versus separate model 
 
The main difference between these two approaches lies at the first stage of the IPD analysis 
because there are two ways in which the data can be analysed.  
 
The first approach consists of obtaining the estimates, standard errors (SEs) (variances) that 
come from each univariate analysis separately for each outcome (separate model), and the 
second consists of calculating the estimates and SEs taking into account all the outcomes in 
a single model (joint model). 
 
4.3.1.1 Modelling outcomes separately - separate model   
 
Recall at the end of each study for a final score analysis, the jth patient in the ith study will 
provide a final score for each outcome. Each individual patient response will be referred to 
as ijkz , i.e. the response value for outcome (k) from patient (j) in the ith study. For each 
outcome separately and in each trial, the general form of the UFMAs for the final score 
analysis is provided in Equation 4.1.  
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In Equation 4.1, 
ik is the control group effect (intercept) for outcome k, ik is the treatment 
effect for outcome (k) and study (i), while ijT identifies the treatment group indicator for the i
th 
study and the jth patient. 
 
In the separate specification (Equation 4.1), ),cov( )1( immi    is equal to 0 and thus the 
outcomes are considered separately in a separate model. For the motivating example 
(where three continuous outcomes will again be considered), the model in Equation 4.1 can 
therefore be fitted as three separate univariate models, where each patient (j) contributes to 
three separate follow-up responses (one for each outcome k), to three models containing 
each outcome, one at a time [76], for example: 
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4.3.1.2 Modelling outcomes jointly - joint model  
 
For each outcome and each trial separately, the general form of the model for the final score 
analysis becomes: 
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In the joint specification (Equation 4.3), ),cov( )1( immi    is equal to mm ),1(   and thus 
the outcomes are considered jointly in this model. For the motivating example (where three 
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continuous outcomes will again be considered), the model in Equation 4.3 can therefore be 
fitted as a joint univariate model, where each patient (j) contributes to three follow-up 
responses (one for each outcome k), to a single model containing all the three outcomes 
jointly [17], for example: 
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It is fundamental to recall that, having calculated the covariances, for example, for outcome 
one and outcome two, 211212 iipii    between the patient outcome responses, and the 
standard errors 1i  and 2i , it is possible to also calculate the patient-level correlations 
12pi between individual outcome responses [86] as follows:  
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4.3.2 Second stage 
 
The first stage therefore provides treatment effect estimates and their variances for each 
outcome in each trial and their within-study correlations. Having estimated these 
parameters, it is possible to implement the UFMA model [17], obtaining the pooled-effect 
estimates and their standard errors and the 95% confidence intervals. It is also possible to 
apply and fit the MFMA model [17] and once more obtain the pooled-effect estimates, their 
standard errors and the 95% confidence intervals.  
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In section 4.3.2.1, UFMA will be described, explaining the difference between the approach 
that takes into account the estimates and the variances arising from the application of the 
separate model (Equation 4.1 and Equation 4.2) and the approach that considers the 
estimates and the variances deriving from the implementation of the joint model (Equation 
4.3 and Equation 4.4).  
 
In section 4.3.2.2, MFMA will be described, highlighting the theoretical difference with the 
approach that considers the estimates and the variances deriving from the implementation of 
the joint model. 
 
4.3.2.1 Defining the univariate fixed-effects meta-analysis  
 
UFMA was applied and described in Chapter 3, section 3.2.1, in Equation 3.1 and Equation 
3.2. In this section the UFMA model will be recalled taking into consideration the differences 
between the separate model (Equation 4.1 and Equation 4.2) and the joint model (Equation 
4.3 and Equation 4.4) described in the previous sections of this chapter.  
 
For a single outcome (k), the UMFA model assumes that the obtained estimates of the 
treatment effect for the ith study are normally distributed about a common, fixed, true effect 
and variance, which are assumed to be known. 
 
Before going on to describe the simulation study, it is necessary to introduce the difference 
between applying the UFMA using the joint approach, as defined in Equation 3.1 and 
Equation 3.2, and applying the UFMA using the separate approach. The separate approach 
will be defined as UFMAs. In this case, the UFMA takes into account the treatment effect 
estimates and their variances that come from the implementation of the joint model 
(Equation 4.1 and Equation 4.2) described in section 4.2.1.1. The joint approach is the 
model that was already described in Chapter 3 and which will be defined as UFMAj. In This 
case UFMA considers the treatment effect estimates and their variances that come from the 
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implementation of the joint model (Equation 4.3 and Equation 4.4) described in section 
4.2.1.2. 
 
4.3.2.2 Defining the difference between univariate fixed-effects meta-analysis joint approach 
and multivariate fixed-effects meta-analysis 
 
Notably, the difference between UFMAj and MFMA lies in the fact that, while MFMA takes 
into account the estimates, SEs (variances) and the covariances that derive from the model 
estimated at the first stage, the UFMAj model takes into account only the estimates and the 
SEs and assumes that the covariances are fixed and equal to 0 as the hypothesis is that the 
within-study correlation between outcomes is equal to 0 [87].  
 
As was explained in the previous chapter, at the second stage of the IPD-MA the estimates 
of outcome effects and variances were used to obtain the overall results for the UFMA 
separate and joint models and the MFMA approach [79]. 
4.3.2.3 Defining the multivariate fixed-effects meta-analysis model  
 
MVMA was applied and described in Chapter 3, section 3.2.2, in Equation 3.3 and Equation 
3.4. In MVMA, all outcomes are analysed simultaneously.  
 
4.4 Missing individual participant data mechanisms 
 
As mentioned in the previous section, there are three missing data mechanism types. In this 
section, the aim is to recall the missing data mechanism from the statistics literature and to 
relate the theory of the missing data mechanism to the scenarios considered in this 
simulation analysis.  
 
i. The definition of data MCAR is that the likelihood of missing data is unrelated to any 
observed or unobserved outcomes. In the context of RCTs, under MCAR, the chance of 
missing data is the same for individuals in different treatment groups. As an example, in 
rheumatoid arthritis, the core outcome APR is often measured using a laboratory test. If 
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the test result was invalidated as a result of a laboratory error in the sample, then the 
data could be MCAR, as the error is equally likely to occur in any patient in the study 
(i.e. regardless of treatment received) [82]. 
 
ii. When the likelihood of missing data is related to observed outcomes but not to 
unobserved outcomes, the missing data mechanism is referred to as MAR. For example, 
if in a clinical trial the dropout is more likely for high values compared to low values of 
the outcome tested, for example, that patients with more TJC, SJC and high values of 
pain (evaluated on a scale 0-100), but all patients with high values of these tested 
outcomes have the same chance of dropout and all patients with low values of these 
outcomes have the same chance of dropout, the missing data mechanism is MAR [82].  
 
iii. However, as mentioned above, if the missing data are related to the treatment, then the 
missing data mechanism is MNAR, because the missing data depend on the 
unobserved outcome data. As an example, in rheumatoid arthritis, where the disease 
activity outcomes are important, it is quite likely that patients assigned to the control 
group, taking the placebo, with the most active disease will drop out due to lack of 
efficacy. In the group receiving the experimental treatment, assuming there is some 
beneficial effect, fewer patients will drop out. This can often lead to groups with unequal 
sizes because fewer of the patients with severe disease remain in the control group, 
biasing the end result [82].  
 
4.4.1 Description of the simulation study scenarios 
 
This simulation study examines eight different scenarios in total, categorised (i) to (viii) 
(Table 4.1). Therefore, in the following table (Table 4.1) there will be a full description of 
these eight different scenarios, considered according to the different levels of missing data 
introduced and with the different levels of the assumed patient-level correlation 
p
 taken into 
account. It should be noted that missing data have been introduced for some scenarios 
(scenarios i and ii of MCAR and scenarios v and vi of MAR) only in one outcome (outcome 
1), while for other scenarios (scenarios iii and iv of MCAR and scenarios vii and viii of MAR) 
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missingness was introduced in all outcomes. It also has to be considered that the amount of 
missing data simulated varies in the scenarios considered. 
 
Table 4.1 Missing IPD scenarios used in the simulation 
Scenario 
Assumed patient-level 
correlation: p  
Description 
 Missing completely at random (MCAR) 
i 
0  
20% MCAR in the IPD for outcome 1  
0.2  
0.5  
0.8  
RA_corr 
ii 
0  
40% MCAR in the IPD for outcome 1  
0.2  
0.5  
0.8  
RA_corr 
iii 
0  
20% MCAR in the IPD for all outcomes 
0.2  
0.5  
0.8  
RA_corr 
iv 
0  
40% MCAR in the IPD for all outcomes 
0.2  
0.5  
0.8  
RA_corr 
  Missing at Random (MAR) 
v 
0  
20% MAR in the IPD for outcome 1  
0.2 
0.5  
0.8  
RA_corr 
vi 
0  
40% MAR in the IPD for outcome 1  
0.2  
0.5  
0.8  
RA_corr 
vii 
0  
20% MAR in the IPD for all outcomes 
0.2  
0.5  
0.8  
RA_corr 
viii 
0  
40% MAR in the IPD for all outcomes 
0.2  
0.5  
0.8  
RA_corr 
RA_corr: Rheumatoid Arthritis correlations from a clinical trial previously conducted, 0.67 (Y1 & Y2), 
0.55 (Y1 & Y3), 0.38 (Y2 & Y3) 
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In this section, all the scenarios have been defined. In the next section, the aim is to 
describe how the missing data at the IPD level for each study within each simulation have 
been generated. 
 
4.5 Generating the missing outcome data at the individual participant 
data level 
 
As described in Chapter 3, the IPD complete case datasets were generated. In this section, 
the aim is to describe how the missing data in the IPD were introduced for each study in 
each simulation at the IPD level.  
 
As defined in Chapter 3, for each of the three outcomes, the treatment effect is defined as 
the mean difference between the group of patients randomised to control (C) and the group 
of treated patients (T).   
 
Firstly, the number of studies (n) within each meta-analysis and each simulation scenario 
was fixed at five studies and 10 studies respectively. Secondly, the goal was to simulate IPD 
for each study, adhering as far as possible to what had been assessed in some SRs for 
treatment of rheumatoid arthritis analysed. Thirdly, the ratio between the sample sizes of 
patients in each treatment arm was therefore set as 1:1. 
 
The true effect estimates (mean differences) were set equal to -5 for outcome one (TJC), -3 
for outcome two (SJC) and -6 for outcome three (pain). While the choice of treatment effect 
estimates may be seen as an arbitrary one in a simulation study, typically these were set 
such that they were the ‘average’ treatment effect values observed in the rheumatoid 
arthritis reviews. As an example, for TJC, an interpretation of a mean difference of -5 would 
reflect that ‘on average’ five fewer TJCs were observed in the treatment group than in the 
control group. 
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In the five study scenarios, the sample size (N) for each study ranged from 30 to 70 in each 
treatment arm, and this was from 10 to 100 in each treatment arm for meta-analyses 
containing 10 studies. Sample sizes were fixed for each study across all simulations. For 
scenarios where n = 5 studies were simulated, the first study contained 30 patients in each 
treatment arm, increasing in increments of 10 additional patients up to study 5, which had 70 
patients.  
 
The characteristics of the missing data mechanism are as follow. 
 
i. Missing data has been introduced in one outcome or in three outcomes. 
 
ii. The amount of 20% or 40% of missing data has been considered missing for each 
study. 
 
a. First, the scenario where n = 5 studies were simulated could be described as 
follows. In the scenario where each study had 20% missing data had been 
considered, the number of data deleted in each treatment group was equal to 12 
for the first study, 16 for the second study, 20 for the third study, 24 for the 
fourth study, and finally 28 for the fifth study. In the scenario where 40% of 
missing data has been considered, the number of data deleted in each 
treatment group was equal to 24 for the first study, 32 patients for the second 
study, 40 for the third study, 48 for the fifth study and finally 56 for the fifth study. 
 
b. Second, the scenario where n = 10 studies were simulated will be described as 
follows. In each study that had 20% of missing has been considered, the 
number of data deleted in each treatment group was equal to 2 for the first 
study, 4 for the second study, 6 for the third study, 8 for the fourth study, 10 for 
the fifth study, 12 for the sixth study, 14 for the seventh study, 16 for the eighth 
study, 18 for the ninth study and finally 20 for the tenth study. In the scenario 
where 40% of missing data has been considered, the number of data deleted in 
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each treatment group was equal to 4 for the first study, 8 for the second study, 
12 for the third study, 16 for the fourth study, 20 for the fifth study, 24 for the 
sixth study, 28 for the seventh study, 32 for the eighth study, 36 for the ninth 
study and finally 40 for the tenth study.  
 
For MCAR, the probability of an observation (the outcome value for TJC, SJC or pain) being 
missing does not depend on observed or unobserved measurements. Therefore, the 
participant data were excluded from each study by randomly excluding outcome data from 
patients assigned to either the treatment or control group. For scenarios with 20% missing 
data, 20% of the data values for each study were randomly removed from treatment or 
control group. For scenarios with 40% missing data, 40% of the data values for each study 
were randomly removed from treatment or control group. On average, the number of 
participants with missing data was expected to be similar for both groups. The missing data 
were considered to be MCAR as the random selection ensured that the missingness was not 
dependent on either the treatment allocation or the outcome value.        
 
For MAR, given the observed data (the outcome value for TJC, SJC or pain), the 
missingness mechanism does not depend on the unobserved data. Therefore, the 
participant data were excluded from patients assigned to either the treatment or control 
group, but the exclusion of data was not completely random. For scenarios with 20% 
missing data, all data values above the 80th percentile for each study were removed, while 
for 40% missing data, all values above the 60th percentile for each study were removed. This 
mechanism resembled the situation where patients might drop out because treatment is 
ineffective (i.e. higher values are associated with more TJC, SJC and more pain).  
 
The detailed SAS code used to generate IPD and to introduce missing data at individual 
participant level in the simulated data sets is contained in Appendix D. It should be noted 
that a MNAR missing data mechanism was not considered in this simulation in order to 
maintain equal balance in the treatment groups; this is commented on in the discussion.  
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4.6 Assessment of performance 
 
As defined in Chapter 3 in Section 3.9, some parameters to assess the performance of the 
estimates of univariate and MFMA has been calculated. Therefore as in Chapter 3 the Bias 
(Equation 3.9), standard error (SEsim), mean square error (MSEsim), coverage, power and 
BoS (Equation 3.10) were calculated.  
 
Once the data has been simulated and analysed, the interest will be in comparing the results 
obtained for the complete case scenario with the results obtained for the missing data 
scenarios. Furthermore, the interest is focused on the comparison between the results 
obtained from MFMA and the UFMAj. The comparison between the results obtained from 
MFMA and the UFMAs is also of interest, as, finally, is the comparison between the results 
obtained from the UFMAj and UFMAs models. 
 
4.7 Simulation results 
 
Here the focus is on the results obtained from the analysis of IPD under assumption of 
MCAR and MAR.  
 
When zero patient-level correlation p was considered, unrelated to the missing data 
mechanism, performance indicators for MFMA and UFMA (joint and separate UFMAj and 
UFMAs approaches) were identical for all scenarios considered (Table E.2 to Table E.9 in 
Appendix E). In the tables of the appendix E, 1 refers to the outcome 1 (TJC), 2 refers to 
the outcome 2 (SJC) and finally 3 refers to the outcome 3 (pain). 
 
 
81 
 
4.7.1 The complete case scenario 
 
For the complete case (results from Chapter 3 for comparison only and considering only 
UFMAj; Table E.1 of Appendix E), there was a small bias for all the three outcomes 
simulated and for all scenarios considered, with only a small notable benefit to be gained 
from using MFMA over UFMAj for all three outcomes when the patient-level correlation was 
high ( p = 0.8). For example, when n=5 studies were simulated the bias for outcome 1 was 
equal to 0.035, for outcome 2 it was equal to 0.020 and for outcome 3 it was equal to 0.023 
when the MFMA model was applied, while it was equal to 0.044 for outcome 1, to 0.022 for 
outcome 2 and 0.033 for outcome 3 when UFMAj was implemented. As expected, there 
were gains in precision (smaller SEs) for all scenarios when MFMA was applied over 
UFMAj; this also translated into improved MSEs for all scenarios. As the patient-level 
correlations increased, there was also an increase in the %BoS for all outcomes. As an 
example, for five studies the %BoS for the three outcomes respectively was 1.8%, 1.9% and 
1.7% when the patient-level correlation ( p ) was 0.2, compared to 2.8%, 2.9% and 2.9% 
for the three outcomes when the patient-level correlation ( p ) was 0.8. The coverages 
estimated were around the nominal range for all scenarios and methods of estimation. 
 
4.7.2 Missing completely at random  
 
When MCAR missingness was introduced in one outcome (outcome 1) and the percentage 
of missingness was at its lowest level (20%) (Table E.2), there were elevated biases in the 
pooled effect for outcome 1 with missing data, particularly when five studies were 
considered. The introduction of MCAR also caused slightly raised biases in outcomes with 
no missing data, particularly with higher patient-level correlations with five study scenarios. 
This bias appeared to be less marked when the number of studies increased to 10. For the 
outcome with missing data, there appeared to be no benefit (in terms of bias reduction) in 
the MFMA approach and the least-biased estimate appeared to be UFMAs. For example, for 
the scenario where the number of simulated studies was five and the patient-level 
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correlation ( p ) was equal to 0.5, the bias was equal to 0.082 when the MFMA model was 
applied, while it was equal to 0.013 when the UFMAs was applied. Increasing the number of 
studies to 10 and keeping the same value of patient-level correlation ( p ), the bias 
calculated was equal to 0.041 when the MFMA model was applied while it was equal to 
0.035 when UFMAs was implemented. When increasing the patient-level correlation ( p ) 
to 0.8 when n=5 studies were simulated, the bias was equal to 0.084 when the MFMA model 
was applied, while it was equal to 0.012 when the UFMAs was applied. Increasing the 
number of studies to 10 and keeping the same value of patient-level correlation ( p = 0.8), 
the bias calculated was equal to 0.039 when the MFMA model was applied, while it was 
equal to 0.035 when UFMAs was implemented. In the two outcomes with no missing data, 
there were trade-offs to be made: UFMAs often had larger biases in the estimation of 
outcome three and sometimes MFMA was preferred but there was no obvious pattern in the 
consistency of results. 
 
Nevertheless, there was a visible advantage in MFMA when observing the BoS. In outcome 
one, where there were missing data, greater percentage changes in BoS were observed, 
providing evidence of BoS when using the MFMA approach. Larger %BoS changes were 
observed between MFMA and UFMAs than MFMA and UFMAj, and, as previously 
mentioned, this was more pronounced when there were missing data (in this case outcome 
one only) and the patient-level correlation ( p ) increased. As an example, for 10 studies 
with a patient-level correlation ( p ) of 0.8, the %BoS for the three outcomes respectively 
between MFMA and UFMAs was 17.0%, 4.4% and 4.1% compared to 4.1%, 4.3% and 3.9% 
between MFMA and UFMAj. In another example, the %BoS for MFMA vs. UFMAs using a 
patient-level correlation ( p ) of 0.2 (10 studies) was 4.6%, 2.7% and 2.5% for the three 
outcomes compared to the 17.0%, 4.4% and 4.1% for a patient-level correlation ( p ) of 
0.8.  
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As expected, the precision was always better for the MFMA approach over both UFMAs and 
UFMAj. The precision increased as the patient-level correlation ( p ) increased. Notably, 
the precision for UFMAj was always at least the same (but mostly improved) over UFMAs. 
The same gains were not observed in the outcomes with no missing data. Overall, this 
provided an interesting result in terms of the MSEs. For all scenarios and outcomes, MFMA 
was shown to be improved over UFMAs and UFMAj and UFMAj was shown to be improved 
over UFMAs. 
 
Coverage was actually slightly lower than the nominal for MFMA than both the UFMA 
approaches but the difference was small and not thought to be of concern.  
 
4.7.2.1 Missing completely at random - doubling the amount of missingness 
 
When the level of missingness doubled to 40% but was still only introduced in one outcome 
(Table E.3), the results were not too dissimilar from a reduced level of missingness 
discussed in section 4.9.2. In fact, the amount of bias did not increase (and in some cases 
even decreased). This is a not an atypical finding when the missingness is MCAR, as the 
missingness is unrelated to the observed or unobserved outcome data. There was a 
marginal gain in using MFMA over the two univariate approaches when using 10 studies and 
a patient-level correlation ( p ) set to 0.8. In the outcome with the missing data (outcome 
1), there were raised SEs as a result of the inefficiency of having less data available for 
analysis but the gains remained for MFMA. For all scenarios, on average MFMA was still 
shown to be superior when considering MSEs, The increase in missing data also 
encouraged extra BoS from the MFMA approach. As an example, considering 10 studies 
with a patient-level correlation ( p ) of 0.8 (comparing to UFMAs), the %BoS for 20% 
missing data in outcome one was 17% compared to 30.6% with 40% missingness. There 
were no new notable concerns with coverage.             
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4.7.2.2 Missing completely at random – missingness in all outcomes 
 
Tables E.4 and E.5 show the results for 20% missingness and 40% missingness 
respectively when missingness was introduced in all three outcomes. The results were 
mainly similar for missingness in one outcome but the general trend could be applied to all 
three outcomes. For example, there was now an increase in SEs for all three outcomes as a 
result of introducing missingness in each outcome. The %BoS was also consistent for all 
outcomes. As an example, for 40% missingness in all outcomes, for 10 studies with a 
patient-level correlation ( p ) set to 0.8, the %BoS for each outcome was 33.4%, 34.9% 
and 33.0% respectively. The same level of borrowed strength was only observed in outcome 
one when missingness was introduced only in this outcome. For both levels of missingness, 
in terms of MSEs, MFMA was still preferred over the two univariate approaches for all 
scenarios and the percentage gains were larger when there were more missing data and the 
patient-level correlations were higher. One notable concern was the MFMA coverage when 
there was 40% missing data in all outcomes when 10 studies were considered. This is likely 
caused by the trade-off between a slightly increased bias (as a result of the missingness) in 
the estimation of the parameter estimates and the increased precision in the estimation of 
standard errors. This issue was not evident when there were lower levels of missingness 
(20%).  
 
4.7.3 Missing at random  
 
When a MAR missing data mechanism was introduced in one outcome (outcome 1) and the 
percentage of missingness was at its lowest level (20%) (Table E.6), there were much larger 
biases observed in the outcome with missing data than the MCAR scenarios. In the majority 
of cases when there were missing MAR data, MFMA outperformed both UFMAs and UFMAj 
in terms of bias reduction. There was just one example when this was not the case, but this 
was negligible (a difference in bias of 0.01).   
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There was evidence that the bias in UFMAj and MFMA reduces as the patient-level 
correlation ( p ) increases, but no such reductions were observed for UFMAs. As an 
example, for 10 studies, when the correlation was set to 0.2, the average bias in the MFMA 
estimate was 0.341 compared to 0.277 for a correlation of 0.8, nearly a 20% reduction. 
There were no obvious benefits of using MFMA in terms of bias reduction in the two 
outcomes where there were no missing data.   
 
There were benefits of increased precision (lower average SEs) for all scenarios using 
MFMA over the two univariate approaches and, as before, this translated into improved 
MSEs. Again, larger BoS was observed when comparing MFMA with UFMAs than with 
UFMAj, although the amount of BoS was not as pronounced as for MCAR. The improvement 
in increasing the patient-level correlation ( p ) was not observed as before, with the BoS 
remaining consistently around 4-5% when comparing MFMA with UFMAs (10 studies). 
There was a slight drop in coverage for the outcome with missing data, which is to be 
expected, but this largely affected all three methods of estimation in the same way. 
 
4.7.3.1 Missing at random – doubling the amount of missingness 
 
As the amount of missingness increased to 40%, larger biases were observed in the 
outcome with missing data and again MFMA appeared to outperform UFMAs and UFMAj in 
all but one case in terms of bias reduction (Table E.7). Again, with the one case, the bias 
change was only 0.02 (with a marginal benefit of UFMAj only) and was not considered 
problematic. As the patient-level correlation ( p ) increased, the difference in the bias 
between MFMA and UFMAs in particular was now quite dramatic. As an example, for five 
studies with a patient-level correlation ( p ) set to 0.8, the MFMA bias estimate was 0.288 
compared to 0.592 for UFMAs, a 51% reduction in bias. As previously mentioned, the 
UFMAs approach does not improve as the patient-level correlation ( p ) increases. 
Benefits in reduced SEs and MSEs in favour of MFMA were seen throughout. A similar 
pattern in the consistency of lower BoS was again observed when compared to MCAR with 
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the same levels of missingness. Increasing the patient-level correlations also did not appear 
to consistently increase the level of BoS as with MCAR, but larger BoS was observed than 
MAR with only 20% missingness. Coverages were affected more by having an increased 
level of MAR data in outcome 1, with no benefit for any of the estimation methods when 
considering this performance parameter, although there is an argument that UFMAj did 
perhaps perform slightly better.            
 
4.7.3.2 Missing at random – missingness in all outcomes 
 
Tables E.8 and E.9 show the results for 20% missingness and 40% missingness 
respectively when missingness was introduced in all three outcomes. More often than not, 
MFMA outperformed UFMAs and UFMAj in terms of bias reduction and again SEs and 
MSEs always benefitted MFMA. Again, there was consistency in the amount of BoS across 
all three outcomes for the same scenario with higher levels of BoS as the amount of 
missingness increased from 20% to 40%. Coverage was lowered for all outcomes for all 
scenarios based on the level of missingness and the MAR mechanism. There was some 
suggestion that UFMAj was the better of the estimation methods when considering 
coverage, although the benefit was not considerable.    
 
4.8 Discussion  
 
Various forms of missing data plague the validity of conclusions to many meta-analyses. 
Adjustment approaches are available to systematic reviewers to adjust for missing data at 
the study level, whether this be for outcome reporting bias or publication bias. As an 
example, the MVMA approach proposed in Chapter 3 (alongside other methods, [88], for 
example the Bias bound estimate) has been proposed as an adjustment method for 
outcome reporting bias and, for example, Egger, trim and fill [89] are available methods for 
adjusting for publication bias. However, little is known about the impact of missing data 
within the IPD in a trial on the conclusions when reviewing meta-analyses, or how reviewers 
might adjust for this form of missingness, particularly if the amount of missing participant 
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data is unknown, because it is not reported in the trial publication and the IPD are not 
available. In some cases, trial authors may adjust for this form of missing data in their 
primary analyses, and therefore reviewers may be able to look at the sensitivity on the 
pooled results using reported, unadjusted and adjusted analyses. However, the literature 
suggests that trialists often do not impute missing data [85] and, even when they do, in a 
large majority of cases, an inappropriate method was used. Most reviewers will only assess 
this form of missingness in the risk of bias assessment, but often the lack of quality of 
available evidence is not accounted for in the overall review conclusions.       
 
Assuming the IPD are available, reviewers could apply an appropriate imputation method to 
the data before synthesising the data, and similarly could look at the sensitivity of the pooled 
results from the imputed data to the complete case data. However, IPD are rarely available 
for all studies and applying some of the advanced imputation methods may be beyond the 
skill set of some reviewers. Moreover, determining the missing data mechanism, and hence 
selecting an appropriate imputation strategy, can be difficult to determine, especially without 
any first-hand knowledge of the way the trial was conducted.   
 
In a similar way that MVMA offers advantages in the presence of missing study data, the 
concept that the method may also improve pooled estimates in the presence of missing 
participant data has been explored in this chapter. In a similar set-up to the previous 
chapter, a two-stage IPD-MA simulation study was employed such that missing participant 
data could be incorporated into the trial data under both a MCAR and a MAR missing data 
mechanism. The two-stage approach was particularly advantageous here, as insight into the 
benefit of the MVMA approach over the two univariate specifications in the second stage 
under this type of missingness could also be observed, if reviewers were only presented with 
AD from the trial reports (recalling the two-stage approach essentially reduces the IPD to AD 
for the second stage). 
 
The results from the simulation study were encouraging and, considering the mean square 
error (MSE) as a trade-off between preferred bias and improved precision, then the MVMA 
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approach was preferred over the two different univariate specifications irrespective of an 
MCAR or MAR missing data mechanism and two different levels of missing data (20% and 
40%). The benefit in MFMA when looking at %BoS was also clear to see, particularly as the 
amount of missing data and the patient-level correlation ( p ) between outcomes increase. 
More BoS occurred in outcomes when the missingness was MCAR than MAR. Whilst some 
very minor advantages were seen in some performance indicators from the univariate 
approaches (coverage and bias in some cases), the differences in most cases were small 
and simulation error could not be ruled out. As a consequence, the general recommendation 
would be that the multivariate approach would still be preferred. 
 
A limitation of this simulation study is that a MNAR missing data mechanism within the IPD 
was not generated. This was omitted by design to prevent an imbalance in the number of 
participants within each treatment arm when the missingness had been introduced. 
Nevertheless, outcome reporting bias that was investigated in Chapter 3 is an MNAR 
missing data mechanism, and therefore it is anticipated (as shown in Chapter 3) that a 
MVMA would still show the same benefits if MNAR was introduced in the IPD. 
 
Overall, the MVMA approach offers an improved estimate of pooled-effects estimate for a 
range of different missing data mechanisms of varying degrees of missingness in the IPD. 
This is particularly beneficial when the true missing data mechanism and the amount of 
missingness is unknown. The method also offers the advantage that it could be simpler for 
reviewers to implement over imputation methods, if the IPD are available.  
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Chapter 5 – Assessing the impact of multivariate 
meta-analysis using Systematic Reviews of 
Rheumatoid Arthritis 
 
5.1 Introduction 
 
In Chapter 2, an assessment of ORB was carried out through a set of SRs for the 
pharmacological treatment of RA. The process identified high and low risk of bias for trials 
where selective non-reporting was suspected.   
 
In Chapter 3, a simulation study was presented where both UFMA and MFMA models were 
applied to IPD for a number of different scenarios. The results from Chapter 3 demonstrated 
that there were benefits in terms of improvements in the performance indicators when 
applying the MVMA approach, particularly in the presence of suspected ORB. 
 
In this current chapter, the aim is to consider a selection of these SRs presented in detail in 
Chapter 2 and to determine the statistical impact (and where possible the potential clinical 
impact) on the conclusions to the pooled effect estimates when a MVMA approach is applied 
over standard UVMA, when ORB is suspected.   
 
In this chapter, the multivariate random-effects meta-analysis (MRMA) model is also 
introduced for the first time as for some of the examples, a REMA may be more appropriate. 
The results of each application are presented using both fixed and random effects 
approaches for comparison. To assist with the interpretation, a multivariate measure of 
heterogeneity is introduced and also a multivariate forest plot is presented.    
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5.2 Review eligibility criteria for assessment 
 
The 21 reviews containing 172 trials that were considered for ORB assessment in Chapter 2 
were also considered here for further analysis.  
 
There were three eligibility criteria according to which the SRs were considered and 
analysed in this chapter: 
 
 The SR had to contain at least three clinical trials. The reason for this choice is that 
it would be difficult to fit the MVMA model if there were fewer studies. This is due to 
the fact that in the SRs that have been assessed the MA is conducted with AD.   
 
 The SR had to have considered the individual core outcomes as review outcomes of 
interest, rather than a composite measure of all the core outcomes. 
 
 The SR had to consider only one MA for each of the core outcomes taken in 
account. 
 
On the basis of these eligibility criteria, among the 21 reviews considered only seven could 
be taken further and analysed. Among the 14 SRs that were not analysed: 
 
 Four SRs (Azathioprine [47], Cyclophosphamide [49], Cyclosporine [50], and 
Injectable gold [51]) were not considered because they analysed a limited number of 
clinical studies. 
 
 Ten SRs (Methotrexate monotherapy versus methotrexate combination therapy with 
non-biologic disease modifying antirheumatic drugs for rheumatoid arthritis [41], 
Penicillamine [53], Folic acid and folinic acid for reducing side effects in patients 
receiving methotrexate [56], Anakinra [59], Certolizumab Pegol [60], Etanercept [61], 
Infliximab [62], Golimumab [63], Tocilizumab [64], Glucocorticoids [65]) were 
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excluded because even if they were presenting more than one study for each of the 
core outcome, each study was measuring and analysing the outcomes at different 
time-points.  
 
Seven SRs (Antimalarials [46], Auranofin [48], Methotrexate [52], Sulfasalazine [54], 
Leflunomide [55], Adalimumab [57] and Abatacept [58]) met the eligibility criteria and are 
considered in this chapter. These were the straightforward reviews where UVMA and MVMA 
could easily be applied. Given these reasons, it is essential to recall that in the following 
examples only the results in terms of MD have been considered, extracted from the SRs that 
were comparable with each other. The included SRs have been considered to have 
homogeneous measures in terms of treatment/placebo dose administered to two groups of 
patients. 
 
The outcome RD was not considered in the analysis for two reasons, firstly this outcome 
was not meta-analysed in any of the SRs considered in this analysis, secondly RD is 
analysed only in RCT that have a duration greater than or equal to 48 weeks, meaning that 
there was no OMERACT recommendation to measure this outcome in most RCTs (89%) 
included in the SRs reported in this chapter. Therefore, only the remaining seven outcomes 
have been considered for each SR analysed. In the following section, the ORB tables will be 
presented for each SR analysed with the UVMA and MVMA and presented in this chapter 
[35].  
 
In some SRs included in the analysis for this chapter, some outcomes were classified as FR. 
This happened because these outcomes were fully assessed in the original studies included 
in each SR but the SR itself was not considering the measurement instrument used. 
Therefore, although this missing data could not be classified as a suspected case of ORB, it 
could not be included in the MA. All these cases have been considered as missing data 
when the meta-analysis models were fitted even if they were not suspected of ORB. 
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5.3 Models applied to the systematic reviews analysed 
 
To illustrate the impact that ORB may have in an SR containing multiple outcomes, a MVMA 
approach was applied to a review comparing each treatment of interest (T) with a control (C) 
for rheumatoid arthritis. The aim was to examine whether the summary results and 
conclusions from the MVMA differed to those from the original MAs performed by the review 
authors. The impact was assessed in terms of the change in the treatment effect estimates, 
change in the statistical significance of the treatment effect estimates, and change in the 
precision of the treatment effect estimates, for each of the outcomes of interest. All 
examples that will be considered in this chapter have been analysed using FEMA and 
REMA. The rationale for this is that in a univariate analysis, authors may select a different 
method for each outcome depending on levels of heterogeneity [17].  
 
Furthermore, it is important to say that the analysis performed in this chapter is an AD-MA, 
as this was the approach the original authors used in the practical examples and it was 
impossible to obtain the IPD from the researchers for all studies. In the IPD simulations that 
were presented in Chapter 3 and Chapter 4, a 2-stage IPD-MA approach was used. It could 
be demonstrated that the AD-MA models applied in this chapter are the same models that 
were fitted at the second stage of the IPD-MA. In this chapter, for all examples analysed, the 
estimate of the MD and the estimate of the SE for each study have been used to run the 
models. These data are extracted from the original SRs conducted by the authors. 
 
Firstly, UFMA and MFMA models were fitted. Secondly, URMA and MRMA models were 
then fitted for comparison, on the basis that the review commented that in some cases 
heterogeneity existed, as assessed using )(
2I .  
 
5.3.1 Univariate fixed-effects meta-analysis  
 
In FEMA it is assumed that that all studies are estimating the same true effect. It is also 
assumed that the variability between study results is due solely to the sample of patients 
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within each study. Another important assumption is that precision depends mainly on study 
size. The UFMA was presented in Chapter 3 in Equation 3.1 and in Equation 3.2.  
 
As defined in Chapter 3, the assumption for the UFMA model is that there are m outcomes 
for each study i. Each study i supplies a set of m estimates of the MD, ),......,( 21 imii yyy  
and associated variances ),......,(
22
2
2
1 imii sss , for each outcome [16]. 
 
However, in Chapter 3, the UFMA model was applied at the second stage of the IPD-MA, 
while in this part of the study the UFMA is applied directly to the AD provided for each study 
of the SRs analysed.   
 
5.3.2 Univariate random-effects meta-analysis  
 
In REMA the treatment effects for the individual studies are assumed to vary around some 
overall average treatment effect μ.  
 
Suppose that there are m outcomes for each study i. Each study i supplies a set of m 
estimates ),......,( 21 imii yyy  for all the outcomes. Each summary statistic is assumed to be 
an estimate of a true value 
i in each study i, and in a hierarchical structure each i is 
assumed to be drawn from a normal distribution with mean value   and between study 
variance
2
i . Then the URMA can be specified as [73]: 
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where ),......,(
22
2
2
1 imii sss are the w/s variances and ),......,(
22
2
2
1 imii
 between-study 
variances. All outcomes are considered independent in the equation. To estimate the 
parameters of each model we used the REML method.  
 
5.3.3 Multivariate fixed-effects meta-analysis  
 
For MFMA, all outcomes are analysed simultaneously [73]. In addition to the two quantities 
required for a UFMA from each study (treatment effect estimate and the w/s variance), the 
w/s correlation is also required. The MFMA model was presented in Chapter 3 in Equation 
3.3 and in Equation 3.4.  
 
As defined in Chapter 3, the vector for the m treatment effect estimates iY  
),........,,( 21 imii yyy , the vector μ ),........,,( 21 m of the fixed true treatment effects for 
the outcomes and the w/s variance-covariance matrix  iS of the effects’ estimates need to 
be known.  
 
However, in Chapter 3, the MFMA model was applied at the second stage of the IPD-MA, 
while in this part of the study the MFMA is applied directly to the AD provided for each study 
of the SR analysed.   
 
5.3.4 Multivariate random-effects meta-analysis  
 
In addition, for MRMA, all outcomes are analysed simultaneously [78]. The MRMA model is 
based on treatment effect estimates and has a hierarchical structure with multivariate normal 
distributions at each of two levels, corresponding to w/s and between-study components. 
Therefore, the multivariate random-effects model is presented in Equation 5.2. 
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Where iS and   are the w/s and the between-study variance-covariance matrices 
respectively. 
 
The objective of a MRMA is to estimate the mean treatment effects across 
studies, ),........,,( 21 imii  , and the between-study covariance matrix,  . The model 
parameters were estimated using the ‘‘mvmeta’’ module [78] in Stata using the method of 
ML for FEMA models and REML method for REMA models. 
 
In Section 5.3.5 the method proposed by Wei and Higgins [74] to derive and calculate the 
w/s covariance will be described. 
 
5.3.5 Estimating the within-study covariance 
 
The methods described in Section 5.3.3 and 5.3.4 assume that the w/s variance-covariance 
matrix is known. The entries of the w/s variance-covariance matrix could be derived 
straightforwardly in the simulations studies described in Chapter 3 and in Chapter 4 as IPD 
has been generated. In the examples described and analysed in this chapter for each SR 
only the AD were known. And in a situation of AD MA it is not straightforward to obtain the 
quantities needed for the variance-covariance matrix. 
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Previous studies have stated that these quantities are rarely reported or even calculated for 
each study. Kirkham et al. [15] describes three possible methods of obtaining the correlation 
between these estimates. First, the availability of IPD would allow us to calculate the w/s 
correlation between the estimators directly in each study (mentioned above) [73]. Second, if 
no IPD data are available, it may still be possible to approximate the w/s correlation using 
biological reasoning or expert opinion [73]. Third, Pearson correlation method can be used 
when it is impossible to obtain w/s correlation from IPD or from expert opinion [73]. 
 
In the examples in this chapter, the first method was followed. The patient-level Pearson 
correlations p between outcomes were provided in a previous study conducted by 
Professor Dr. George Wells (unpublished data). In this study, the researchers performed an 
individual patient data (IPD) analysis for two rheumatoid arthritis trials which recorded data 
on all core outcomes. These individual-level correlations from the two separate trials 
analysed were averaged and these estimates were used to approximate the likely patient-
level correlation p estimates in other studies that did not provide them. 
 
Therefore, the patient-level Pearson correlations needed to be taken in account and 
converted to obtain the w/s covariances needed to fit the MVMA model; the appropriate 
approximation was applied using Wei and Higgins’ method [74].   
 
Given a known patient-level correlation coefficient p  between the two outcomes 
themselves, and assuming it is the same in both treatment groups, the following equation 
gives the analytical form for the covariance between MDs (MD1, MD2): 
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In Equation 5.3, tn1 is defined as the number of participants reporting outcome 1 in the 
treatment group; tn2 as the number of participants reporting outcome 2 in the treatment 
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group; tn12 the number of participants reporting both outcome 1 and outcome 2 in the 
treatment group; and cn12 , cn1 and cn2 are defined in the similar way for the control group. 
Furthermore, in Equation 5.5, ts1 is defined as the standard error in outcome 1 for the 
treatment group, while ts2  is the standard error in outcome 2 for the treatment group; cs1  
and cs2  are defined in the similar way for the control group. Once the w/s covariance has 
been obtained and the standard errors are known, it is possible to obtain the w/s correlation 
for outcomes 1 and 2, applying the following formula: 
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5.3.6 Methods to assess heterogeneity in a meta-analysis  
 
In the previous sections, different techniques for meta-analysis have been described.  
 
One of the main concepts of the REMA is related to the between-study variance. Therefore, 
if the between-study variance is assumed to be zero, then the model described in Equation 
5.5 is referred to as the FEMA model. It could be said that FEMA models are sometimes 
preferable because they simplify the interpretation of the estimates and make the 
computation of the estimates easier. Nevertheless, the assumption of no between-study 
variation seems generally unlikely, unless it is known that the studies are performed in the 
same way and involve individuals sampled from the same population [90]. 
 
In order to understand if it is feasible to fit a FEMA model and to help choose the most 
appropriate model (fixed or random), it is useful to observe and calculate the level of 
heterogeneity. If the heterogeneity is calculated to be high across the studies, then it is more 
advisable to apply a REMA model that to apply a FEMA model. Therefore, a test for the 
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presence of heterogeneity needs to be defined and calculated and presented with the results 
of a meta-analysis. 
 
5.3.6.1 Univariate meta-analysis scenario 
 
A test for heterogeneity examines the null hypothesis that all studies are evaluating the 
same effect. The usual test statistic (Cochran's Q) is computed by summing the squared 
deviations of each study's estimate from the overall meta-analytic estimate, weighting each 
study's contribution in the same manner as in the meta-analysis [11]. The weights are 
defined with   for the ith study. Therefore, the Cochran’s equation for testing the 
heterogeneity is: 
 
)5.5()ˆ( 2  iiwQ  
 
Given this result, Higgins and Thompson defined [11] the index 
2H obtained with the 
following equation:   
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Using this result, Higgins and Thompson calculated the 
2I index to test the heterogeneity in 
the UVMA models [11].  
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In the univariate case, this index describes the heterogeneity due to the variation across the 
studies considered in the meta-analysis. Therefore, the index 
2I provides an estimate of the 
percentage of variability in the meta-analysis due to the difference between each study. 
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Higgins and Thompson also suggested a simple categorisation of 
2I values, tentatively 
assigning adjectives of low, moderate, and high to 
2I values of 25%, 50%, and 75%. 
Nevertheless, one of the limits of this index in defining heterogeneity is the over-
interpretation caused by the overlapping of the intervals for 
2I [11]. To avoid this 
misinterpretation, Higgins and Thompson defined another index, called R , and which is 
calculated by the following formula: 
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F
R
V
V
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In Equation 5.8, 
R
V  and 
F
V are defined as the length of the confidence intervals for the 
treatment effect that come from the REMA and the FEMA model, respectively.  
 
In this section, the univariate index 
2I  proposed by Higgins and Thompson has been 
described, but they also generalised its application to the MVMA scenarios. In the next 
section, the extension to the MVMA model will be described and discussed. 
 
5.3.6.2 Multivariate meta-analysis scenario 
 
In this section, MVMA heterogeneity will be considered. In the MVMA scenario there are 
multiple outcomes denoted with the letter m. In the examples analysed and reported in this 
chapter the core outcomes considered are m=7.  
 
Therefore, the R calculated before for the UVMA case is applied to the MVMA scenarios as 
follows: 
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Higgins and Thompson [11] also provided and calculated
2
RI , taking into account this new 
index calculated for the multivariate case. The following formula will provide the desired 
index: 
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This index is the multivariate counterpart of the 
2I  index calculated to estimate the 
heterogeneity of a meta-analysis. The index
2
RI  provides the percentage of variability in the 
meta-analysis due to the between-study variability across the studies considered. Therefore, 
it is also possible to consider for index 
2
RI  a simple categorisation of its values, assigning 
low, moderate, and high to values of 25%, 50%, and 75% respectively [90]. 
 
5.3.7 Univariate and multivariate meta-analysis: forest plot 
 
In this section, forest plots for univariate and MVMA will be presented alongside the tables 
with the estimates and the results obtained from the models fitted to each single example 
examined. The forest plot has the following common characteristics that make it a useful tool 
to give a graphic view of the results of a meta-analysis:  
 
 Each individual study is represented on a common scale.  
 
 Each study’s effect and respective confidence interval are plotted on one set of 
axes.  
 
 The effect estimate (in this example the MD) is represented by a square and the 
size of the square is related to the weight that the study has in the meta-analysis. 
Therefore, it could be stated that a small and slightly informative clinical trial will 
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have a large confidence interval, indicating that the estimate of the treatment effect 
is not precise.  
 
 The pooled MD estimate is plotted at the bottom of the graph and is usually 
represented as a diamond.  
 
 The pooled estimates obtained from the UVMA model and from the MVMA model 
fitted with the data from each single study are represented in the forest plots. This 
happens both for FEMA and REMA approaches. The centre of the diamond 
represents the pooled estimate and the width of the diamond shows the confidence 
interval. 
 
 The forest plot also allows a graphical examination of the degree of heterogeneity 
between studies. The more confidence intervals are overlapping, the less 
heterogeneity could be detected by the meta-analysis of the SR.  
 
 The forest plots present for each outcome considered both UVMA and MVMA 
estimate (diamond). While the global UVMA estimate is obtained averaging all the 
results from each single study for each single outcome, the global MVMA estimate is 
obtained considering simultaneously all the outcomes considered in the MA. 
 
To obtain the forest plots presented, the STATA command mvmeta_forest ‘version 10.1’ was 
used. 
 
5.3.8 Parameters used to assess the difference between univariate meta-analysis and 
multivariate meta-analysis 
 
In analysing the results, which are presented in section 5.4 of this chapter, the aim was to 
assess the difference between the univariate model (UFMA or URMA) and the multivariate 
model (MFMA or MRMA). 
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To assess the difference between the models fitted in this analysis the attention was focused 
on discussing: 
 
 the change in the estimates of the pooled MD obtained from fitting the univariate 
model (UFMA or URMA) and the estimates of the pooled MD obtained fitting the 
multivariate model (MFMA or MRMA); 
 
 the change in the estimates of the Standard Error (SE) obtained from fitting the 
univariate model (UFMA or URMA) and the estimates of the MD obtained fitting the 
multivariate model (MFMA or MRMA); 
 
 the change in the P-values obtained from fitting the univariate model (UFMA or 
URMA) and the estimates of the MD obtained from fitting the multivariate model 
(MFMA or MRMA); 
 
 the result of the heterogeneity index (
2I  UVMA) provided from the original SR; 
 
 the heterogeneity index (
2
RI  MVMA). 
 
In the following section, the main results for each SR and for each outcome considered will 
be presented, focusing attention on the comparison between UVMA and the MVMA model. 
The interest will be addressed also to the comparison between REMA and the FEMA 
approach.  
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5.4 Results  
 
For each SR, a summary of the ORB assessment will be reported, a summary of the 
conclusions from the actual review will be presented, and finally a description of the main 
difference in results between univariate and multivariate will be explained. 
 
5.4.1 Antimalarials for treating rheumatoid arthritis  
 
5.4.1.1 Summary of the outcome reporting bias assessment 
 
The SR ‘Antimalarials for treating rheumatoid arthritis’ was conducted by Suarez-Almazor et 
al. [46]. This SR presents the results of UFMA. 
 
The objective of this SR was to compare the short-term efficacy and toxicity of Antimalarials 
for the treatment of RA by comparing hydroxychloroquine with placebo. The review aimed to 
synthesise data on all of the RA core outcomes, amongst a selection of other outcomes. 
This SR identified four eligible studies, with a combined total of 300 randomised to 
hydroxychloroquine and 292 to placebo. No studies were excluded due to ‘no relevant 
outcome data’.  
 
The results for the ORB assessment for the core outcomes (undertaken for this review in 
Chapter 2) are summarised in Table 5.1.   
 
Table 5.1 ORB matrix for Antimalarials systematic review 
Study TJC SJC Pain 
Phy. 
Global 
Pat. 
Global 
Function APR 
Davis  
‘91 
  (D) (H) (H) (FR)  
Clark  
‘93 
   (C) (C) (FR)  
Blackburn  
‘95 
     (D)  
HERA             
‘95 
       
TJC: Tender Joint Count; SJC: Swollen Joint Count; Phy.: Physician; Pat.: Patient; APR: Acute Phase Reactant; 
FR: Fully reported 
ORB Classification [9] A: Partial reporting, High Risk ORB; B: Partial reporting, No Risk ORB; C: Partial reporting, 
Low Risk ORB; D: None, High Risk ORB; E: None, High Risk ORB; F: None, Low Risk ORB; G: None, High Risk 
ORB; H: None, Low Risk ORB; I: NA, No Risk ORB. 
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Only the study HERA '95 reported on all of the core outcomes, while the core outcomes 
TJC, SJC and APR were reported in all four studies. Amongst the other outcomes, there 
was a mixture of high and low ORB classifications (justifications for these classifications can 
be found in Appendix A (from Chapter 2)). Function was classified as FR in two studies 
(Davis ‘91 and Clark ‘93) because they reported on a measure of function in the trial report, 
but not using an acceptable measurement instrument for inclusion in the review.      
 
5.4.1.2 Summary of the results from the original systematic review  
 
In this particular SR, the original study authors applied a FEMA to all seven core outcomes 
being considered. For TJC (0%), SJC (0%), Phy.Global (0%) and APR (0%) the value of the 
heterogeneity index 
2I was low. For other outcomes as pain (88%) and function (100%) the 
value of heterogeneity index was high. For the outcome Pat.Global the heterogeneity index 
was moderate and equal to 51%. The pooled results for each outcome, as reported in the 
original review, can be found in Table 5.2 (UFMA). The use of hydroxychloroquine appears 
to be efficacious (the pooled estimates for the MD is negative) for the treatment of RA when 
considering all other core outcomes.  For the outcome function the pooled MD estimate is 
equal to -0.06. All the estimates of the MD are statistically significant, with the exception of 
the outcome function (p-value = 0.609). 
105 
 
 
Table 5.2 Meta-analysis results for the Antimalarials data set 
Outcome 
Univariate meta-analysis Multivariate meta-analysis 
Mean 
difference 
SE P-value 95% CI 
Mean 
difference 
SE P-value 95% CI 
UFMA MFMA 
TJC -2.57† 0.62 <0.001*** -3.78; -1.36† -1.44 0.54 0.007** -2.50; -0.39 
SJC -3.71† 0.59 <0.001*** -4.86; -2.57† -2.84 0.53 <0.001*** -3.87; -1.80 
Pain -0.45† 0.14 0.001** -0.72; -0.18† -0.12 0.06 0.049 -0.23; -0.001 
Phy.Global -0.39† 0.09 <0.001*** -0.57; -0.21† -0.23 0.06 <0.001*** -0.34; -0.12 
Pat.Global -0.34† 0.10 0.001** -0.53; -0.15† -0.08 0.05 0.080 -0.17; 0.01 
Function -0.06† 0.12 0.609 -0.29;  0.17† 0.10 0.09 0.256 -0.07; 0.28 
APR -6.38† 1.09 <0.001*** -8.51; -4.24† -5.45 1.07 <0.001*** -7.54; -3.36 
 URMA MRMA 
TJC -2.68 0.74 <0.001*** -4.12; -1.23 -2.56 0.71 <0.001*** -3.96; -1.17 
SJC -3.70 0.60 <0.001*** -4.87; -2.53 -3.50 0.57 <0.001*** -4.63; -2.38 
Pain -3.67 3.56 0.303 -10.63; 3.30 -3.45 3.62 0.341 -10.54; 3.65 
Phy.Global -0.33 0.27 0.233 -0.87; 0.21 -0.30 0.25 0.227 -0.79; 0.19 
Pat.Global -0.22 0.48 0.642 -1.15; 0.71 -0.24 0.41 0.567 -1.04; 0.57 
Function -0.05 2.97 0.988 -5.87; 5.78 -0.01 2.78 0.996 -5.47; 5.44 
APR -5.84 1.62 <0.001*** -9.03; -2.66 -5.57 1.69 0.001** -8.89; -2.25 
† Result from the original meta-analysis performed in the original systematic review 
 
 
5.4.1.3 Summary of the differences between univariate and multivariate meta-analysis 
 
In Figure 5.1, the forest plot for each outcome is reported. Each forest plot show for each 
study the MD and the pooled effect estimate obtained by applying UFMA and the MFMA 
models. In this figure, the pooled estimates obtained from the UFMA and MFMA models are 
considered. From Figure 5.1, it can be seen that for all the outcomes considered there is a 
benefit to be gained from treatment with Antimalarials. It is possible to see this benefit 
especially for the TJC, SJC and APR. Nevertheless, the 95% confidence interval associated 
with this estimate for the outcome function contains 0 and therefore it is not possible to reject 
with certainty the null hypothesis of no difference between the treatment with Antimalarials 
and the treatment with placebo (Table 5.2). When considering the MFMA approach, all 
outcomes had smaller SEs (increased precision) but appeared to be less efficacious than 
the equivalent UFMA. The highest difference in the estimates was for Pat.Global – from an 
estimate of the MD of -0.34 for UFMA to an estimate of the MD of -0.08 for MFMA. The 
statistical significance of the outcome Pat.Global was also overturned and was no longer 
significant, while the outcome pain was now only bordering on statistical significance. 
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Applying MFMA, the MD estimate for function appeared to be (MFMA) also positive, 
denoting a favourable result (but not statistically significant) for the placebo treatment. It was 
interesting to note that these differences occurred in the outcomes where ORB was 
suspected, and the direction of the adjustment in applying the MVMA approach was 
consistent with the direction expected when ORB is present.   
 
 
 
In Figure 5.2 each forest plot reports for each study the MD and the pooled effect estimate 
obtained with the URMA and with the MRMA. As was seen also in Figure 5.1, in Figure 5.2 it 
is possible to observe that, for all the outcomes considered, the pooled estimates of the MD 
are lower than zero, indicating that there is a benefit in favour of the treatment with 
Antimalarials. It is possible to see this benefit especially for the APR. Nevertheless, the 95% 
confidence interval associated with the estimate of the MD for four outcomes – pain, the 
global outcomes (patient and physician) and function – contains 0 and therefore it is not 
possible to rule out the null hypothesis that the two treatments are not different. 
Figure 5.1 Antimalarials Forest Plots Fixed-Effects 
107 
 
.  
 
 
 
When the MRMA model was fitted, the 
2
RI  value was 97%, indicating that, across all 
outcomes, the total variation in the meta-analysis is mainly due to between-study 
heterogeneity; this suggests that the REMA model might be the appropriate model to fit to 
these data. With the exception of the outcome pain, when comparing the MRMA approach 
and the URMA, all outcomes had smaller standard errors, meaning increased precision, but 
appeared to be less efficacious than the equivalent univariate analysis. The outcomes TJC, 
SJC count and APR were significant for URMA and are still significant for the MRMA 
approach.  
Figure 5.2 Antimalarials Forest Plots Random-Effects 
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5.4.2 Auranofin for treating rheumatoid arthritis  
 
5.4.2.1 Summary of the outcome reporting bias assessment 
 
The SR ‘Auranofin for treating rheumatoid arthritis’ conducted by Suarez-Almazor et al. [48] 
presents the results of UFMA.  
 
The objective of this SR was to compare the short-term efficacy and toxicity of Auranofin for 
the treatment of RA by comparing auranofin with placebo. The SR aimed to synthesise data 
on all of the RA core outcomes, amongst a selection of other outcomes. This SR identified 
nine eligible studies, with a combined total of 539 randomised to auranofin and 510 to 
placebo. Two studies were excluded due to ‘no OMERACT outcomes reported in this 
article’. Four studies were excluded because there was ‘no placebo group’.  
 
The results for the ORB assessment for the core outcomes are summarised in Table 5.3.   
 
Table 5.3 ORB matrix for Auranofin systematic review 
Study TJC SJC Pain 
Phy. 
Global 
Pat. 
Global 
Function APR 
Davies  
‘82 
 (H)  (H) (H)  (C) (A) 
Palmer  
‘82 
  (C) (H)    
Prouse  
‘82 
 (H)  (H) (H) (C)  
Lewis  
‘84 
(F) (H) (E) (H) (H) (F)  
Johnsen  
‘89 
   (D)  (FR)  
Ward  
‘83 
     (FR)  
Wenger  
‘83 
    (H) (C)  
Bombardier  
‘86 
       
Glennas  
‘97 
(G)   (H) (H)  (H) 
TJC: Tender Joint Count; SJC: Swollen Joint Count; Phy.: Physician; Pat.: Patient; APR: Acute Phase Reactant; 
FR: Fully reported  
ORB Classification [9] A: Partial reporting, High Risk ORB; B: Partial reporting, No Risk ORB; C: Partial reporting, 
Low Risk ORB; D: None, High Risk ORB; E: None, High Risk ORB; F: None, Low Risk ORB; G: None, High Risk 
ORB; H: None, Low Risk ORB; I: NA, No Risk ORB. 
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Four studies were found to have low risk of ORB in one or more of the core outcomes 
according to the ORBIT classification system [28] (Palmer ’82; Prouse ’82; Ward ’83; 
Wenger ’83). The remaining four studies present a high risk of ORB for only one outcome 
(Davies ’82, APR; Lewis ’84, Pain; Johnsen ’89, Phy.Global; Glennnas ’97, TJC) and low 
risk of ORB classification for other outcomes. 
 
5.4.2.2 Summary of the results from the original systematic review 
 
In this particular review, the original study authors applied a FEMA to all seven core 
outcomes being considered. For pain (0%) and function (0%). Pat.Global (8%) and TJC 
(33%) the value of the heterogeneity index 
2I was low. While for remaining outcomes as 
SJC (68%), APR (68%) and Phy.Global (83%) the value of 
2I  was high. For the outcome 
Pat.Global (51%) the value of the heterogeneity index was moderate. The pooled results for 
each outcome, as reported in the original review, can be found in Table 5.4 (UFMA). The 
use of Auranofin appears to be efficacious (the pooled estimates for the MD is negative) for 
the treatment of RA when considering all the core outcomes meta-analysed. The most 
efficacious effect of the treatment was calculated for the outcome APR (MD equal to -9.04) 
while the least efficacious effect of the treatment was estimated for the outcome function 
(MD equal to -0.13).  Some estimates of the MD are statistically significant, this happened 
for TJC, pain, Pat.Global and Phy.Global and for APR. The remaining outcomes were 
characterised by non-significant estimates of the MD. 
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Table 5.4 Meta-analysis results for the Auranofin data set  
Outcome 
Univariate meta-analysis Multivariate meta-analysis 
Mean  
difference 
SE P-value 95% CI 
Mean 
difference 
SE P-value 95% CI 
UFMA MFMA 
TJC -3.76† 0.67 <0.001*** -5.06; -2.45† -3.23 0.56 <0.001*** -4.32; -2.12 
SJC -0.29† 0.61 0.634 -1.49; 0.90† -0.05 0.56 0.933 -1.14; 1.05 
Pain -4.68† 0.97 <0.001*** -6.59; -2.77† -5.00 0.57 <0.001*** -6.11; -3.89 
Phy.Global -0.36† 0.08 <0.001*** -0.52; -0.21† -0.28 0.06 <0.001*** -0.40; -0.15 
Pat.Global -0.41† 0.12 0.001** -0.65; -0.17† -0.24 0.06 <0.001*** -0.36; -0.13 
Function -0.13† 0.07 0.066 -0.27; 0.01† -0.16 0.06 0.004** -0.27; -0.05 
APR -9.04† 1.59 <0.001*** -12.16; -5.92† -8.72 1.54 <0.001*** -11.74; -5.71 
 URMA MRMA 
TJC -3.82 0.92 <0.001*** -5.63; -2.02 -3.62 0.97 <0.001*** -5.52; -1.73 
SJC 0.15 1.18 0.900 -2.17; 2.46 0.41 1.17 0.726 -1.88; 2.69 
Pain -4.68 0.97 <0.001*** -6.59; -2.77 -4.44 1.07 <0.001*** -6.53; -2.35 
Phy.Global      -0.39 0.21 0.058 -0.80; 0.01 -0.39 0.25 0.120 -0.89; 0.10 
Pat.Global -0.41 0.12 0.001** -0.65; -0.17 -0.43 0.28 0.124 -0.98; 0.12 
Function -0.13 0.07 0.066 -0.27; 0.01 -0.21 0.11 0.054 -0.42; 0.00 
APR -9.79 3.25 0.003** -16.16; -3.41 -10.26 3.22 0.001** -16.57; -3.95 
† Result from the original meta-analysis performed in the original systematic review 
 
5.4.2.3 Summary of the differences between univariate and multivariate meta-analysis 
 
In Figure 5.3, the forest plots for the FEMA models applied are reported. When considering 
the MFMA approach, all outcomes had smaller standard errors (increased precision). With 
the exception of pain and function, all the other outcomes appeared to be less efficacious 
than the equivalent UFMA. The statistical significance of the outcome function was 
significant (0.004**) with the MFMA approach, while it was not significant (0.066) with the 
UFMA approach. This could be explained with the slight shift in the estimate of the MD away 
from the null from a value of -0.13 for UFMA to a result of -0.16 for MFMA. With the 
exception of the outcome pain, it is interesting to note that these differences occurred in the 
outcomes where ORB was suspected, and the direction of the adjustment in applying the 
MVMA approach was consistent with the direction expected when ORB is present.   
 
 
 
111 
 
 
 
 
 
In Figure 5.4, the forest plots for the REMA models applied are reported. When the MRMA 
model was fitted, the 
2
RI  value was 83%, indicating that, across all outcomes, the total 
variation in the meta-analysis is mainly due to between-study heterogeneity; this suggests 
that the REMA model might be the appropriate model to fit to these data. The global 
estimate of the MD calculated suggested a benefit in the direction of the treatment with 
Auranofin for TJC, pain, Phy.Global, Pat.Global, function and APR, as for both URMA and 
MRMA it was less than zero. However, for TJC and pain, the estimates calculated with the 
MRMA model show that the treatment with Auranofin is less effective, while for Pat.Global, 
function and APR the MD estimates obtained with the MRMA model indicate that the 
treatment with Auranofin is more effective. The global MD for SJC was positive, indicating no 
effect of the treatment with Auranofin. When comparing the MRMA approach and the 
URMA, the outcomes TJC, pain, Phy.Global, Pat.Global and function had higher standard 
error applying the MRMA approach than the URMA model. On the other side, the outcomes 
SJC and APR had smaller standard error using the MRMA approach than the URMA 
approach. Pat.Global was significant for the URMA model (p-value equal to 0.001**) and 
switched to be not significant for the MRMA (p-value equal to 0.124) approach. 
 
 
 
 
Figure 5.3 Auranofin Forest Plots Fixed-Effects 
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5.4.3 Leflunomide for the treatment of rheumatoid arthritis  
 
5.4.3.1 Summary of the outcome reporting bias assessment 
 
The SR ‘Leflunomide for treating rheumatoid arthritis was conducted by Osiri et al. [55]. This 
SR presents the results of UFMA.  
 
The objective of this SR was to assess the efficacy and toxicity of Leflunomide 
(monotherapy or combined with another DMARD) compared to placebo or other DMARDs in 
the treatment of RA. The SR aimed to synthesise data on all of the RA core outcomes, 
amongst a selection of other outcomes. This SR identified 33 eligible studies, while 24 
studies were excluded. The five RCTs considered are all trials that test the same difference 
in the effectiveness of treatment with leflunomide against the treatment methotrexate. Al 
these trials considered measured and analysed the difference between these two treatments 
after 6 months of follow-up. 
 
For the application of the UVMA and MVMA five studies were extracted from the 33 eligible 
RCT considered for the assessment of ORB and presented in Chapter 2. For the five studies 
considered (Strand ’99, Bao ’00, Lao ’01, Shuai ’02, Wislowska ’07) when TJC, SJC, pain 
and APR were analysed, 390 subjects were randomised to the treatment with Leflunomide 
Figure 5.4 Auranofin Forest Plots Random-Effects 
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and 373 were randomised to the alternative treatment with MTX. When Phy.Global and 
Pat.Global were analysed 360 subjects were randomised to the treatment with Leflunomide 
and 343 were randomised to the alternative treatment with MTX. Finally for the outcome 
function 104 subjects were randomised to the treatment with Leflunomide and 104 were 
randomised to the alternative treatment with MTX. 
 
Three of the studies considered measures and reported on the seven core outcomes set 
(COS) (Strand ’99, Lao ’01, Shuai ‘02). Two studies were found to have high risk of ORB in 
one or more of the core outcomes according to the ORBIT classification system [28] (Bao 
’00 – see Function; Wislowska ’07 – see the global measurements patient and Phy.Global) 
and no risk of ORB classification for the other outcomes. 
 
Table 5.5 ORB matrix for Leflunomide systematic review 
Study TJC SJC Pain 
Phy. 
Global 
Pat. Global Function APR 
Strand  
‘99 
     (FR)  
Bao  
‘00 
     (E)  
Lao  
‘01 
       
Shuai  
‘02 
       
Wislowska  
‘07 
   (G) (E)   
TJC: Tender Joint Count; SJC: Swollen Joint Count; Phy.: Physician; Pat.: Patient; APR: Acute Phase 
Reactant; FR: Fully reported  
ORB Classification [9] A: Partial reporting, High Risk ORB; B: Partial reporting, No Risk ORB; C: Partial 
reporting, Low Risk ORB; D: None, High Risk ORB; E: None, High Risk ORB; F: None, Low Risk ORB; G: 
None, High Risk ORB; H: None, Low Risk ORB; I: NA, No Risk ORB. 
 
Observing the table reported (Table 5.5) in this section, it is possible to notice that TJC, SJC, 
pain and APR were FR in all studies of this SR.  
 
5.4.3.2 Summary of the results from the original systematic review 
 
In this review, the original study authors applied a FEMA to all seven core outcomes being 
considered. For TJC (0%), SJC (0%), Phy.Global (0%), Pat.Global (0%) and APR (20%) the 
value of the heterogeneity index 
2I was low. For the outcome function (53%) the value of 
2I was moderate. The pooled results for each outcome, as reported in the original review, 
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can be found in Table 5.6 (UFMA). The use of Leflunomide appears to be efficacious for the 
treatment for RA when considering TJC, pain, Phy.Global, Pat.Global and function (slightly -
0.01), while the use of alternative treatment appears to be efficacious when examining SJC 
(0.14) and APR (1.54). For Phy.Global and Pat.Global, the estimates of the MD are 
statistically significant, with a p-value equal to 0.005 (Phy.Global) and 0.001 (Pat.Global), 
while for all the other outcomes the MDs are not significant. 
 
Table 5.6 Meta-analysis results for the Leflunomide data set 
Outcome 
Univariate meta-analysis Multivariate meta-analysis 
Mean 
difference 
SE P-value 95% CI 
Mean 
difference 
SE P-value 95% CI 
UFMA MFMA 
TJC -0.64† 0.41 0.112 -1.44; 0.15† -0.13 0.35 0.715   -0.82; 0.56 
SJC 0.14† 0.31 0.654 -0.47; 0.75† 0.42 0.29 0.148 -0.15; 1.00 
Pain -0.32† 0.24 0.180 -0.78; 0.15† -0.08 0.14 0.565 -0.35; 0.19 
Phy.Global -0.48† 0.17 0.005** -0.82; -0.15† -0.30 0.13 0.002** -0.56; -0.05 
Pat.Global -0.60† 0.18 0.001** -0.95; -0.26† -0.33 0.11 0.021* -0.54; -0.12 
Function -0.01† 0.05 0.889 -0.11; 0.09† 0.04 0.04 0.275 -0.03; 0.11 
APR 1.54† 1.50 0.647 -1.41; 4.48† 1.59 1.45 0.270 -1.25; 4.44 
 URMA MRMA 
TJC -0.64 0.41 0.116 -1.44; 0.16 -0.10 0.37 0.788 -0.83; 0.63 
SJC 0.11 0.34 0.735 -0.55; 0.78 0.40 0.32 0.202 -0.22; 1.02 
Pain -0.34 0.25 0.181 -0.83; 0.16 -0.05 0.16 0.759 -0.37; 0.27 
Phy.Global -0.49 0.18 0.001** -0.83; -0.14 -0.31 0.14 0.005** -0.57; -0.04 
Pat.Global -0.62 0.19 0.006** -1.00; -0.24 -0.33 0.12 0.024* -0.55; -0.10 
Function -0.01 0.07 0.925 -0.15; 0.14 0.03 0.06 0.587 -0.09; 0.15 
APR 0.52 2.53 0.838 -4.45; 5.49 1.35 2.53 0.594 -3.62; 6.32 
† Result from the original meta-analysis performed in the original systematic review 
 
5.4.3.3 Summary of the differences between univariate and multivariate meta-analysis 
 
In Figure 5.5, the forest plots for the FEMA models applied are reported. When considering 
the MFMA approach, for TJC, pain, Phy.Global and Pat.Global the efficacy of the treatment 
with Leflunomide decreases. For SJC and for APR, where the benefit is in favour of 
alternative treatment with MTX, this result is more noticeable with the MFMA approach than 
with the UFMA. For the outcome function, there is a change in the direction of effectiveness, 
which is in favour of the treatment with Leflunomide (-0.01) for the UFMA approach while it is 
in favour for the treatment with MTX (0.04) for the MFMA approach. For all outcomes 
considered in the analysis, a reduction in the standard error (higher precision) may be 
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noticed when comparing from the MFMA to the UFMA model approach. The outcomes 
Phy.Global and Pat.Global are the only two that have significant estimates for both the 
studied models. 
 
 
 
 
In Figure 5.6, the forest plots for the REMA models applied are reported. When the MRMA 
model was fitted, the 
2
RI  value was 34%, indicating that, across all outcomes, the total 
variation in the meta-analysis is mainly due to between-study heterogeneity; this suggests 
that the REMA model might be the appropriate model to fit to these data. As was described 
before, also for the comparison between MRMA and URMA, for TJC, pain, Phy.Global and 
Pat.Global the treatment with Leflunomide appears to be less efficacious. For SJC and APR, 
where the efficacy was in the opposite direction in favour of the alternative treatment, the 
alternative treatment seems to be more efficacious with the MRMA approach than with the 
URMA approach. For function, the estimate of the MD was negative for the URMA (-0.01) 
while it was positive for the MRMA (0.03). With the exception of APR, all the estimates 
appear to be more precise (as the Standard Errors decrease) using the MRMA approach 
rather than the URMA approach. The MD for the outcomes Phy.Global and Pat.Global are 
statistically significant for both the URMA and MRMA approaches.  
 
 
 
Figure 5.5 Leflunomide Forest Plots Fixed-Effects 
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5.4.4 Methotrexate for treating rheumatoid arthritis  
 
5.4.4.1 Summary of the outcome reporting bias assessment 
 
The SR ‘Methotrexate for treating rheumatoid arthritis’ was conducted by Suarez-Almazor et 
al [52]. This SR presents the results of UFMA.  
 
The objective of this SR was to evaluate the short term efficacy and toxicity of MTX for the 
treatment of RA. This SR identified five eligible studies with a combined total of 113 
randomised to MTX and 106 to placebo. 
 
Observing the table reported (Table 5.7) in this section, it can be seen that TJC and function 
were FR in all (100%) studies of this SR. In addition, the other outcomes considered showed 
a high percentage of fully reporting, as 80% of the studies of this SR were reporting these 
outcomes.  
Figure 5.6 Leflunomide Forest Plots Random-Effects 
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Table 5.7 ORB matrix for Methotrexate systematic review 
Study TJC SJC Pain 
Phy. 
Global 
Pat. 
Global 
Function APR 
Andersen  
‘85 
       
Weinblatt  
‘85 
  (H)     
Williams  
‘85 
      (C) 
Furst  
‘90 
       
Pinheiro  
‘93 
 (G)  (H) (H)   
TJC: Tender Joint Count; SJC: Swollen Joint Count; Phy.: Physician; Pat.: Patient; APR: Acute Phase 
Reactant; FR: Fully reported  
ORB Classification [9] A: Partial reporting, High Risk ORB; B: Partial reporting, No Risk ORB; C: Partial 
reporting, Low Risk ORB; D: None, High Risk ORB; E: None, High Risk ORB; F: None, Low Risk ORB; G: 
None, High Risk ORB; H: None, Low Risk ORB; I: NA, No Risk ORB. 
 
Two of the studies considered measured and reported on the seven core outcomes set 
(Andersen ’85 and Furst ‘90). Two studies were found to have low risk of ORB in one of the 
core outcomes according to the ORBIT classification system [28] (Weinblatt ’85 see Pain; 
Williams ’85 see APR) and no risk of ORB classification for the other outcomes. One study 
(Pinheiro ’93) was found to have high risk of ORB in one of the core outcomes according to 
the ORBIT classification system [28] (SJC) and low risk of ORB classification for two 
outcomes (patient and physician’s global) and no risk for the other outcomes. 
 
5.4.4.2 Summary of the results from the original systematic review 
 
In this review, the original study authors applied a FEMA to all seven core outcomes being 
considered. For the outcomes Function (95%), Pat.Global (94%), Phy.Global (93%), pain 
(915) and TJC (68%) the heterogeneity index 
2I was high. For the outcome APR (56%) the 
index 
2I was moderate and finally for the outcome SJC (31%), the value of 2I was low. The 
pooled results for each outcome, as reported in the original review, can be found in Table 
5.8 (UFMA). The use of methotrexate appears efficacious for all the outcomes considered in 
this systematic review. Some outcomes have a substantial value for the MD, such as TJC (-
17.85), APR (-8.95) and pain (-3.0). With the exception of ‘APR’, the estimates of the MD are 
statistically significant (p-value is < 0.001***).  
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Table 5.8 Meta-analysis results for the Methotrexate data set 
Outcome 
Univariate meta-analysis Multivariate meta-analysis 
Mean 
difference 
SE P-value 95% CI 
Mean 
difference 
SE P-value 95% CI 
UFMA MFMA 
TJC -17.85† 3.12 <0.001*** -23.97; -11.73† -5.33 2.70 0.048* -10.62; -0.05 
SJC -7.31† 1.60 <0.001*** -10.44; -4.18† -1.38 1.35 0.310 -4.03; 1.28 
Pain -3.00† 0.54 <0.001*** -4.07; -1.93† -1.25 0.37 0.001** -1.97; -0.53 
Phy.Global -1.05† 0.13 <0.001*** -1.31; -0.80† -0.39 0.10 0.040* -0.60; -0.20 
Pat.Global -0.92† 0.15 <0.001*** -1.20; -0.63† -0.16 0.08 <0.001*** -0.30; -0.01 
Function -0.48† 0.05 <0.001*** -0.58; -0.38† -0.39 0.04 <0.001*** -0.47; -0.31 
APR -8.95† 4.70 0.057 -18.17; 0.27† 1.80 4.51 0.690 -7.03; 10.63 
 URMA MRMA 
TJC -22.63 7.00 0.001** -36.35; -8.90 -19.19 6.21 0.002** -31.36; -7.01 
SJC -8.74 2.37 <0.001*** -13.38; -4.09 -6.88 2.07 0.001** -10.94; -2.82 
Pain -15.20 6.22 0.015* -27.40; -3.00 -15.46 6.90 0.025* -28.99; -1.94 
Phy.Global -5.01 5.73 0.374 -17.07; 5.37 -5.85 5.91 0.310 -16.59; 6.57 
Pat.Global -6.53 7.35 0.397 -20.93; 7.86 -7.59 7.47 0.307 -22.24; 7.06 
Function -12.61 10.35 0.223 -32.89; 7.66 -9.52 10.17 0.349 -29.45; 10.41 
APR -7.41 7.27 0.308 -21.65; 6.83 -6.72 6.75 0.320 -19.95; 6.52 
† Result from the original meta-analysis performed in the original systematic review 
 
 
5.4.4.3 Summary of the differences between univariate and multivariate meta-analysis 
 
In Figure 5.7, the forest plots for the FEMA models applied are reported. When considering 
the MFMA approach, it is possible to notice how for TJC, SJC, pain, Pat.Global, Phy.Global 
and function there is a change in the estimates of the MD and the effectiveness of treatment 
with methotrexate decreases. The outcome APR showed an estimate of the MD (-8.95) that 
suggested efficacy of the treatment with Methotrexate with the UFMA approach, while it 
showed an estimate of the MD (1.80) that suggested efficacy of the alternative treatment 
with the MFMA approach. For all the outcomes, the estimate of the standard error calculated 
with the MFMA approach is lower than the standard error calculated with the UFMA, and 
therefore the estimates of the MD calculated for the MFMA approach are more precise than 
the estimates of the MD calculated with UFMA. With the exception of SJC, all the estimates 
that were statistically significant with the UFMA approach are also significant with the MFMA 
approach. The estimates of the MDs calculated for the outcome APR are not significant, 
neither with the UFMA nor with the MFMA. 
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In Figure 5.8, the forest plots for the REMA models applied are reported. When we fitted the 
MRMA, the value of 
2
RI was equal to 99.5%, indicating that, across all outcomes, the total 
variation in the meta-analysis is mainly due to between-study heterogeneity; this suggests 
that the REMA model might be appropriate to fit to these data. From the comparison 
between the MRMA and URMA models, the treatment with MTX appears to be less 
efficacious with the MRMA model than with the URMA for the outcomes TJC, SJC, function 
and APR, while the treatment with Methotrexate seems to be more efficacious with the 
MRMA model than with URMA for the outcomes pain, Phy.Global and Pat.Global. The 
outcomes TJC, SCJ, function and APR have more precise estimates of the MD with the 
MRMA than with the URMA model, while the outcomes pain, Phy.Global and Pat.Global 
have more precise estimates of the MD with the URMA than with the MRMA. The outcomes 
TJC, SJC and pain appear to have significant estimates of the MD for both the models 
considered, URMA and MRMA. 
 
Figure 5.7 Methotrexate Forest Plots Fixed-Effects 
120 
 
 
 
5.4.5 Sulfasalazine for treating rheumatoid arthritis  
 
5.4.5.1 Summary of the outcome reporting bias assessment 
 
The SR ‘Sulfasalazine for treating rheumatoid arthritis’ was conducted by Suarez-Almazor et 
al [54]. This SR presents the results of UFMA.  
 
The aim of this SR was to estimate the short-term efficacy and toxicity of Sulfasalazine for 
the treatment of RA. For the analysis to obtain the results included in this section, attention 
was focused on the comparison Sulfasalazine vs. Placebo. This SR considered six eligible 
trials, including 468 patients. These patients were randomised to Sulfasalazine (243) and to 
Placebo (225). 
 
As can be seen in the following table, this SR considered six studies. Six outcomes were 
considered and analysed as none of the studies examined functional outcomes with 
comprehensive functional scales, and therefore this outcome could not be adequately 
assessed in the meta-analysis. Observing the table reported in this section (Table 5.9), it is 
possible to notice that TJC was FR in 67% of the studies in this SR, while SJC, pain, and 
APR were FR in half of the included studies (50%). Pat.Global and Phy.Global were FR in 
33% of the studies. All the studies considered had at least one of the six core outcomes set 
at risk of ORB according to the ORBIT classification system [28]. All the studies considered 
Figure 5.8 Methotrexate Forest Plots Fixed-Effects 
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in this SR were found to have at least one study with a high risk of ORB classification. For 
one study (Pullar ’83) considered, all the COS were found to have a high risk of ORB 
classification. For another study (Skosey ’88) considered, two of the COS were found to 
have a high risk of ORB classification (TJC and SJC), and the remaining outcomes were 
found to have a low risk of ORB. Farr ’95 was found to have three outcomes (SJC, 
Pat.Global and Phy.Global) with a high risk of ORB classification. Ebringer ’92, the global 
measurements (Pat.Global and Phy.Global) were found to have a high risk of ORB 
classification. Two studies (Williams ’88 and Hannonen ’93) were found to have a high risk 
of ORB only for one outcome each, respectively Pain and APR.  
 
Table 5.9 ORB matrix for Sulfasalazine systematic review 
Study TJC SJC Pain 
Phy. 
Global 
Pat. 
Global 
APR 
Williams  
‘88 
  (G)    
Ebringer  
‘92 
   (D) (D)  
Hannonen  
‘93 
     (D) 
Farr  
‘95 
 (G)  (D) (D)  
Pullar  
‘83 
(E) (G) (E) (G) (G) (E) 
Skosey  
‘88 
(A) (A) (C) (C) (C) (C) 
TJC: Tender Joint Count; SJC: Swollen Joint Count; Phy.: Physician; Pat.: Patient; APR: Acute Phase Reactant; FR: 
Fully reported  
ORB Classification A: Partial reporting, High Risk ORB; B: Partial reporting, No Risk ORB; C: Partial reporting, Low 
Risk ORB; D: None, High Risk ORB; E: None, High Risk ORB; F: None, Low Risk ORB; G: None, High Risk ORB; H: 
None, Low Risk ORB; I: NA, No Risk ORB. 
 
 
5.4.5.2 Summary of the results from the original systematic review 
 
In this review, the original study authors applied a FEMA to all seven core outcomes being 
considered. For the outcomes Pat.Global (78%), TJC (66%) and APR (62%) the value 
heterogeneity index 
2I was high. For the outcome Phy.Global (46%) the value of the index 
2I was moderate and finally for the outcomes SJC (18%) and pain (0%), the value of 
2I was low. The pooled results for each outcome, as reported in the original review, can be 
found in Table 5.10 (UFMA). All the outcomes considered and analysed in this systematic 
review show an efficacious result for the treatment with Sulfasalazine as the estimated MDs 
are all lower than zero. In particular, this efficacy is noticeable for APR (-17.58) and pain (-
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8.71). Treatment with Sulfasalazine has moderate efficacy for TJC (-2.45) and SJC (-2.38), 
and finally the efficacy of the treatment with Sulfasalazine appears to be slight for the 
outcomes Phy.Global (-0.16), and Pat.Global (-0.23). With the exception of Phy.Global and 
Pat.Global, the other outcomes present estimates of the MD that are statistically significant. 
 
Table 5.10 Meta-analysis results for the Sulfasalazine data set 
Outcome 
Univariate meta-analysis Multivariate meta-analysis 
Mean 
difference 
SE P-value 95% CI 
Mean 
difference 
SE P-value 95% CI 
UFMA MFMA 
TJC -2.45† 0.87     0.005** -4.15; -0.74† -0.95 0.78 0.223 -2.48; 0.58 
SJC -2.38† 0.69     0.001** -3.73; -1.03† -1.45 0.62 0.019* -2.67; -0.24 
Pain -8.71† 3.11 0.005** -14.80; -2.62† -1.52 2.56 0.552 -6.53; 3.49 
Phy.Global -0.16† 0.11 0.140 -0.37; 0.05† -0.03 0.09 0.747 -0.20; 0.15 
Pat.Global -0.23† 0.12 0.052 -0.46; 0.00† -0.15 0.10 0.117 -0.35; 0.04 
APR -17.58† 2.22 <0.001*** -21.93; -13.23† -15.03 2.04 <0.001*** -19.04; -11.03 
 URMA MRMA 
TJC -4.29 2.41 0.075 -9.01; 0.43 -4.40 2.76 0.111 -9.81; 1.02 
SJC -2.72 0.96 0.004** -4.59; -0.85 -2.20 0.79 0.006** -3.76; -0.64 
Pain -8.84 3.88 0.023* -16.44; -1.24 -14.20 10.31 0.169 -34.41; 6.01 
Phy.Global -0.19 0.14 0.169 -0.46; 0.08 -0.20 0.17 0.219 -0.53; 0.12 
Pat.Global -0.31 0.18 0.089 -0.67; 0.05 -0.33 0.20 0.098 -0.73; 0.06 
APR -15.07 5.74 0.009** -26.32; -3.83 -17.10 2.69 <0.001*** -22.37; -11.83 
† Result from the original meta-analysis performed in the original systematic review 
 
 
5.4.5.3 Summary of the differences between univariate and multivariate meta-analysis  
 
In Figure 5.9, the forest plots for the FEMA models applied are reported. When considering 
the MFMA approach, it is possible to notice how for all the outcomes considered in this 
meta-analysis the estimates of the MD decrease, suggesting that the treatment with 
Sulfasalazine appears to be less efficacious with an MFMA approach than with a UFMA 
approach. All the outcomes taken into account in this meta-analysis show how the estimate 
of the MD appears to be more precise with an MFMA approach than with a UFMA one, as 
the Standard Errors calculated by the MFMA model are lower than the Standard Errors 
calculated by the UFMA. For two outcomes, TJC and pain, the estimates of the MD were 
significant for the UFMA approach as they were presenting a p-value equal to 0.005. For the 
other outcomes considered there were no changes, and therefore the estimates of the MDs 
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were significant for both UFMA and MFMA for SJC and APR, while they were not significant 
for both UFMA and MFMA for Phy.Global and Pat.Global. 
 
 
 
In Figure 5.10, the forest plots for the REMA models applied are reported. When the MRMA 
was fitted, the value was 49.1%, indicating that, across all outcomes, 49.1% of the total 
variation in the meta-analysis is due to between-study heterogeneity. The observation of 
estimates calculated by the MRMA model suggests that, with the exception of the outcome 
SJC, there is an increase in the estimated efficacy of the treatment with Sulfasalazine. The 
estimates of the MD, switching from URMA to MRMA model, become more precise for SJC 
and APR, while for the other outcomes they become less precise as the Standard Errors 
calculated increase. In particular, for outcome pain, which was seen to be characterised by 
high suspicion of ORB, the Standard Error calculated increases by 62% from an SE equal to 
3.88 calculated by URMA to an SE equal to 10.31 calculated by the MRMA model. 
Observing the results for the outcome pain is interesting also regarding the significance of 
the estimates, as it is possible to notice how the MD estimated by the URMA model was 
significant (p-value equal to 0.023) while it was not significant when the MRMA model was 
applied (p-value equal to 0.169). For other outcomes considered, the statistical significance 
of the estimates does not change, and therefore the MDs calculated are still significant for 
the outcomes SJC and APR, while they are still not significant for the outcomes TJC, 
Phy.Global and Pat.Global. 
 
Figure 5.9 Sulfasalazine Forest Plots Fixed-Effects 
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5.4.6 Adalimumab for treating rheumatoid arthritis  
 
5.4.6.1 Summary of the outcome reporting bias assessment 
 
The SR ‘Adalimumab for treating rheumatoid arthritis’ was conducted by Navarro-Sarabia et 
al [57]. This SR presented the results of URMA.  
 
The aim of this review was to assess the efficacy and safety of adalimumab in the treatment 
of RA. Therefore six studies with 2381 patients were included in this review. Two 
comparisons were done: A. adalimumab subcutaneously (sc) + methotrexate (or DMARDs) 
versus placebo sc + MTX (or DMARDs). B. Adalimumab sc in monotherapy versus placebo 
sc.  
 
To run the model UVMA and MVMA for this example, attention was focused on the 
comparison between treatment with Adalimumab sc + MTX (or DMARDs) and Placebo sc + 
MTX (or DMARDs) and the results reported in the original SR have been considered for the 
comparison between Adalimumab sc in monotherapy and placebo. Therefore, Van De Putte 
’03 (all seven COS) and Van De Putte ’04 (six outcomes: TJC, SJC, pain, Pat.Global, 
Phy.Global and Function) were considered FR. for the application of univariate and MVMA 
models. As can be seen in the following table (Table 5.11), this SR considered six studies. 
 
Figure 5.10 Sulfasalazine Forest Plots Random-Effects 
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Observing the table reported in this section, it is possible to notice that among the outcome 
that were considered six of them (TJ, SJ, pain, Pat.Global, Phy.Global and function) were 
characterised by a 67% percentage of fully reporting. The fully reporting percentage for the 
APR outcome was 50%. Two studies (Weinblatt ’03 and Keystone ’04) measured and 
reported on the seven COS. All the remaining studies considered in this SR were found to 
have outcomes with a low risk of ORB classification. We discussed previously Van de Putte 
’03 and Van de Putte ’04. Furthermore, Furst ’03 (for all outcomes ‘F’ classification) and Rau 
’04 (for all outcomes ‘C’ classification) have to be considered. 
 
Table 5.11 ORB matrix for Adalimumab systematic review 
Study TJC SJC Pain 
Phy. 
Global 
Pat. 
Global 
Function APR 
Weinblatt  
‘03 
       
Keystone  
‘04 
       
Furst  
‘03 
(F) (F) (F) (F) (F) (F) (F) 
Van de Putte  
‘03 
(F.R) (F.R) (F.R) (F.R) (F.R) (F.R) (F.R) 
Van de Putte  
‘04 
(F.R) (F.R) (F.R) (F.R) (F.R) (F.R) (C) 
Rau  
‘04 
(C) (C) (C) (C) (C) (C) (C) 
TJC: Tender Joint Count; SJC: Swollen Joint Count; Phy.: Physician; Pat.: Patient; APR: Acute Phase Reactant; FR: 
Fully reported 
ORB Classification [9] A: Partial reporting, High Risk ORB; B: Partial reporting, No Risk ORB; C: Partial reporting, Low 
Risk ORB; D: None, High Risk ORB; E: None, High Risk ORB; F: None, Low Risk ORB; G: None, High Risk ORB; H: 
None, Low Risk ORB; I: NA, No Risk ORB. 
 
5.4.6.2 Summary of the results from the original systematic review 
 
In this review, the original study authors applied a FEMA to all seven core outcomes being 
considered. For the outcomes APR (77%) and Phy.Global (63%) the value of heterogeneity 
index 
2I was high. For the remaining outcomes SJC (19%), TJC (0%), pain (0%), 
Pat.Global (0%) and function (0%), the value of the index 
2I was low. The pooled results for 
each outcome, as reported in the original review, can be found in Table 5.12 (URMA).  
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Table 5.12 Meta-analysis results for the Adalimumab data set 
Outcome 
Univariate meta-analysis Multivariate meta-analysis 
Mean 
difference 
SE P-value 95% CI 
Mean 
difference 
SE P-value 95% CI 
UFMA MFMA 
TJC -7.50 2.06 <0.001*** -11.53; -3.47 -7.51 2.05 <0.001*** -11.52; -3.50 
SJC -6.28 1.49 <0.001*** -9.21; -3.36 -6.28 1.49 <0.001*** -9.20; -3.37 
Pain -16.02 2.77 <0.001*** -21.44; -10.60 -16.05 2.76 <0.001*** -21.46; -10.64 
Phy.Global -20.00 4.54 <0.001*** -28.91; -11.10 -20.01 4.53 <0.001*** -28.89; -11.14 
Pat.Global -18.29 3.77 <0.001*** -25.68; -10.90 -18.31 3.76 <0.001*** -25.68; -10.95 
Function -0.33 0.06 <0.001*** -0.45; -0.22 -0.33 0.06 <0.001*** -0.45; -0.22 
APR -1.23 0.48 0.010* -2.17; -0.29 -1.23 0.48 0.010* -2.16; -0.29 
 URMA MRMA 
TJC -6.68    1.20     <0.001*** -9.02; -4.33     -6.84 1.19 <0.001*** -9.18; -4.50 
SJC -5.75    0.88   <0.001*** -7.475; -4.020 -5.78 0.88 <0.001*** -7.51; -4.06 
Pain -15.79 2.28 <0.001*** -20.26; -11.32  -16.19 2.28 <0.001*** -20.65; -11.73 
Phy.Global -19.42    2.40 <0.001*** -27.19; -11.65 -18.21 2.06 <0.001*** -22.24; -14.19 
Pat.Global -17.01    2.40 <0.001*** -22.05; -13.98 -17.35 2.39 <0.001*** -22.04; -12.66 
Function -0.33 0.05 <0.001*** -0.42; -0.23 -0.33 0.05 <0.001*** -0.42; -0.24 
APR -1.21 0.20 <0.001*** -2.09; -0.33 -1.07 0.20 <0.001*** -1.46; -0.68 
† Result from the original meta-analysis performed in the original systematic review 
 
All the outcomes considered were showing a benefit from the combination treatment of 
Adalimumab and MTX (or DMARDs) as the estimate of the MD was lower than zero. In 
particular, the combination therapy of Adalimumab and MTX (or DMARDs) is highly effective 
with regard to pain, Phy.Global and Pat.Global. The therapy assessed is mildly effective with 
regard to TJC and SJC, and finally it is slightly effective with regard to APR and function. 
 
5.4.6.3 Summary of the differences between univariate and multivariate meta-analysis 
 
Figure 5.11 shows the forest plots for this systematic review considering all the outcomes 
assessed and only the two studies for which all the outcomes were FR (Weinblatt ’03 and 
Keystone ‘04). Therefore, Furst ’03, Van de Putte ’03, Van de Putte ’04 and Rau ’04 are not 
reported and not considered as they present missing values for all the outcomes. When the 
MFMA model was applied, the estimates of the MD slightly increased for the outcomes TJC, 
pain, Phy.Global and Pat.Global, suggesting higher efficacy for the combination therapy of 
Adalimumab and MTX (or DMARDs). For all the remaining outcomes, there was no change 
in the estimates of the MD comparing UFMA and MFMA. The estimates of the MD for the 
outcomes TJC, pain, Phy.Global and Pat.Global are also characterised by an increase in 
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precision as the Standard Errors calculated for the estimates of these outcomes slightly 
decreased. All the estimates of the MD were extremely significant, indicating clear support 
for combination therapy with Adalimumab and MTX (or DMARDs). This happened for both 
the UFMA and MFMA approaches. 
 
 
 
Additionally, Figure 5.12 shows the forest plots for this systematic review considering all the 
outcomes assessed and only the two studies for which all the outcomes were FR. The 
observation of estimates calculated by the MRMA model suggests that the combination 
treatment of Adalimumab and MTX (or DMARDs) appears to be more efficacious for the 
outcomes TJC, SJC, pain and Pat.Global, while the studied treatment appears to be less 
efficacious for the outcomes Phy.Global and APR. There is no change in the estimate of the 
MD comparing URMA and MRMA for the outcome function. Comparing URMA and MRMA, 
the estimates of the MD appear to be more precise for TJC, Phy.Global and Pat.Global as 
the Standard Errors calculated for these outcomes decrease. For all the other outcomes 
considered, there is no change in the estimates of the precision as the Standard Errors are 
equal across the URMA and MRMA models fitted. All the estimates of the MD were 
extremely significant, indicating clear support for combination therapy with Adalimumab and 
MTX (or DMARDs). This happened for both the URMA and MRMA approaches. 
 
Figure 5.11 Adalimumab Forest Plots Fixed-Effects 
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5.4.7 Abatacept for treating rheumatoid arthritis  
 
5.4.7.1 Summary of the outcome reporting bias assessment 
 
The SR ‘Abatacept for treating rheumatoid arthritis’ was conducted by Maxwell and Singh 
[58]. This SR presented the results of UFMA.  
 
The aim of this SR was to assess the efficacy and safety of Abatacept in reducing disease 
activity, pain, and improving function in people with RA. In this SR seven trials with 2908 
patients were included. The patients were randomised to treatment with Abatacept (2 mg/kg 
and 10 mg/kg) + DMARDs/biologic (1444) and to the treatment with placebo + 
DMARDs/biologic (757). Some outcomes were originally reported by the reviewers as 
Pat.Global (Weinblatt ’07) and Function (Genovese ’05, Weinblatt ’07 and Schiff ’08); the 
comparison was not of interest.  
 
Therefore, for these cases the notation in the table will be (FR), which means that the 
outcome was measured and reported but in this analysis it has not been considered (no risk 
of ORB). As can be observed in the following table (Table 5.13), this SR considered seven 
studies.  
Figure 5.12 Adalimumab Forest Plots Random-Effects 
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Table 5.13 ORB matrix for Abatacept systematic review 
Study TJC SJC Pain 
Phy.  
Global 
Pat. 
Global 
Function 
Weinblatt  
‘06 
(E) (E)     
Kremer  
‘03 
      
Kremer  
‘06 
      
Moreland  
‘02 
(C) (C) (C) (C) (C) (C) 
Genovese  
‘05 
(E) (E) (E) (E) (E) (FR) 
Weinblatt  
‘07 
(FR) (FR) (FR) (FR) (FR) (FR) 
Schiff  
‘08 
 (E)  (E) (E) (E) (E) (FR) 
TJC: Tender Joint Count; SJC: Swollen Joint Count; Phy.: Physician; Pat.: Patient; APR: Acute Phase Reactant; FR: 
Fully reported  
ORB Classification [9] A: Partial reporting, High Risk ORB; B: Partial reporting, No Risk ORB; C: Partial reporting, Low 
Risk ORB; D: None, High Risk ORB; E: None, High Risk ORB; F: None, Low Risk ORB; G: None, High Risk ORB; H: 
None, Low Risk ORB; I: NA, No Risk ORB.  
 
Six outcomes were considered and analysed as none of the studies examined APR and 
therefore this outcome could not be adequately assessed in the meta-analysis. Focusing 
attention on the percentage of reporting, it can be seen that Pat.Global and Phy.Global were 
FR in less than half (43%) of the studies included in this systematic review. In addition, TJ 
and SJ were FR in few (29%) of the included studies, while pain was FR in 57% of them, 
and finally function was FR in 86%. Observing the following table, it can be seen that two of 
the seven studies included in this analysis measured and reported on the seven COS 
(Kremer ’03 and Kremer ’06). Three studies were found to have high risk of ORB in one or 
more of the core outcomes according to the ORBIT classification [28]. For Genovese ’05 and 
Schiff ’08, five outcomes had high risk of ORB (83%) (TJC, SJC, Pain, Pat.Global, 
Phy.Global) and for Weinblatt there were two (33%) (TJC and SJC). Moreland ’02 was found 
to have low risk of ORB (‘(C)’ classification) in all the outcomes considered in this analysis. 
Weinblatt ’07 was found to have no risk of ORB as the classification was FR for all the 
outcomes considered.    
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5.4.7.2 Summary of the results from the original systematic review 
 
In this review, the original study authors applied a FEMA to six of the core outcomes being 
considered. The lower value of heterogeneity index 
2I was calculated for SJC (0%) while 
the higher value of heterogeneity was calculated for outcome TJC (76%). The pooled results 
for each outcome, as reported in the original review, can be found in Table 5.14 (UFMA). 
 
Table 5.14 Meta-analysis results for the Abatacept data set 
Outcome 
Univariate meta-analysis Multivariate meta-analysis 
Mean 
difference 
SE P-value 95% CI 
Mean 
difference 
SE P-value 95% CI 
UFMA MFMA 
TJC -7.28† 0.86 <0.001*** -8.96; -5.59† -5.97 0.81 <0.001*** -7.55; -4.40 
SJC -4.78† 0.56 <0.001*** -5.87; -3.68† -3.23 0.46 <0.001*** -4.14; -2.33 
Pain -12.44† 0.96 <0.001*** -14.32; -10.57† -12.83 0.95 <0.001*** -14.69; -10.97 
Phy.Global -13.29† 0.85 <0.001*** -14.96; -11.61† -13.11 0.85 <0.001*** -14.78; -11.45 
Pat.Global -12.46† 1.04 <0.001*** -14.49; -10.42† -12.49 1.03 <0.001*** -14.51; -10.47 
Function -0.39† 0.05 <0.001*** -0.48; -0.30† -0.39 0.05 <0.001*** -0.48; -0.30 
 URMA MRMA 
TJC -7.31 1.84 <0.001*** -10.92; -3.70 -7.18 1.94 <0.001*** -10.97; -3.38 
SJC -5.11 0.94 <0.001*** -6.94; -3.27 -4.98 1.07 <0.001*** -7.08; -2.88 
Pain -15.13 3.79 <0.001*** -22.56; -7.70 -15.10 3.78 <0.001*** -22.51; -7.70 
Phy.Global -15.75 5.11 0.002** -25.76; -5.74 -15.66 5.13 0.002** -25.71; -5.61 
Pat.Global -14.37 2.96 <0.001*** -20.17; -8.57 -14.38 2.89 <0.001*** -20.05; -8.72 
Function -0.49 0.16 0.003** -0.81; -0.17 -0.49 0.17 0.004** -0.82; -0.15 
† Result from the original meta-analysis performed in the original systematic review 
 
All the outcomes considered are showing a benefit from the combination treatment of 
Abatacept (2 mg/kg and 10 mg/kg) + DMARDs/biologic as the estimate of the MD is lower 
than zero. In particular, the combination therapy of Abatacept (2 mg/kg and 10 mg/kg) + 
DMARDs/biologic is highly effective with regard to pain, Phy.Global and Pat.Global. The 
therapy assessed is mildly effective with regard to TJC and SJC, and finally it is slightly 
effective with regard to function. 
 
5.4.7.3 Summary of the differences between univariate and multivariate meta-analysis 
  
Figure 5.13 shows the forest plots for this systematic review considering all the outcomes 
assessed and excluding the four studies for which the outcomes were missing (Moreland 
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’02, Genovese ’05, Weinblatt ’07, Schiff ’08). When the MFMA model was applied, the 
estimates of the MD decreased for the outcomes TJC, SJC and Phy.Global, suggesting a 
lower efficacy of the combination therapy of Abatacept (2 mg/kg and 10 mg/kg) + 
DMARDs/biologic. For pain and Pat.Global, the estimates of the MD increased, indicating a 
higher efficacy of the combination therapy of Abatacept (2 mg/kg and 10 mg/kg) + 
DMARDs/biologic. For function there is no change in the estimate of the MD comparing the 
UFMA and MFMA models. With the exception of Phy.Global and function, the estimates of 
the MD are characterised by an increase in precision as the Standard Errors calculated for 
the estimates of these outcomes decreased. All the estimates of the MD were extremely 
significant, indicating clear support for combination therapy with Abatacept (2 mg/kg and 10 
mg/kg) + DMARDs/biologic. This happened for both the UFMA and MFMA approaches. 
 
 
 
Additionally, Figure 5.14 shows the forest plots for this systematic review considering all the 
outcomes assessed and excluding the four studies for which the outcomes were missing. 
When we fitted the MRMA, the value was 98.5%, indicating that, across all outcomes, the 
total variation in the meta-analysis is mainly due to between-study heterogeneity; this 
suggests that the REMA model might be appropriate to fit to these data. When the MRMA 
model was applied, the estimates of the MD decreased for the outcomes TJC, SJC, pain 
and Phy.Global, suggesting a lower efficacy of the combination therapy of Abatacept (2 
mg/kg and 10 mg/kg) + DMARDs/biologic. For the outcomes TJC, SJC, Phy.Global and 
function, the estimates of the MD calculated with the MRMA model appear to be less 
Figure 5.13 Abatacept Forest Plots Fixed-Effects 
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precise, as the SEs calculated using the MRMA model are higher than the SEs obtained 
fitting the URMA. For the outcomes pain and Pat.Global, the estimates of the MD calculated 
with the MRMA model appear to be more precise. All the estimates of the MD were 
extremely significant, indicating clear support for combination therapy with Abatacept (2 
mg/kg and 10 mg/kg) + DMARDs/biologic. This happened for both the URMA and MRMA 
approaches. 
 
 
 
5.5 Discussion 
 
This is the first study to consider an assessment of ORB against a well-established core set 
of outcomes. The OMERACT COS (sometimes referred to as the International League of 
Associations for Rheumatology core set of outcomes) was ratified for use in clinical trials for 
rheumatoid arthritis but is also endorsed by the CMSG [30]. Although the uptake of the 
measurement of the COS for rheumatoid arthritis trials has been shown to be increasing 
[91], the reporting of the outcomes for many of these trials remains insufficient, meaning that 
many meta-analyses are unable to include data from all relevant studies. The MVMA 
approach offers one such sensitivity analysis to reduce the potential impact of ORB when 
there are missing trial data for many review outcomes.  
 
Figure 5.14 Abatacept Forest Plots Random-Effects 
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From the results obtained in this study, the MVMA and the UVMA have been applied to 
seven (33%) systematic reviews previously assessed for the presence of ORB. From the 
observation of the results from the UVMA and MVMA, it is possible to see that for three 
(43%) of the systematic reviews analysed there was a change in the direction of the effect, 
comparing results of the UVMA and MVMA models. This happens not for all the outcomes 
considered in the assessment. This change happened for both FEMA and REMA 
approaches for one SR, the SR that studied Leflunomide for the treatment of RA. For this 
SR, the outcome function was presenting a negative estimate (-0.01) of the MD when UVMA 
was applied, while it was showing a positive estimate of the MD when MVMA was applied 
(equal to 0.04 for MFMA and 0.03 for MRMA). The change in the direction of the estimates 
happened only for the FEMA approach for the SR that studied Antimalarials for the 
treatment of RA. For this SR, the outcome function was presenting a negative estimate (-
0.06) of the MD when UFMA was applied, while it was showing a positive estimate of the 
MD (0.10) when MFMA was applied. Furthermore, for the SR that studied Methotrexate for 
the treatment of RA the change in the direction of the estimates happened only for the 
FEMA approach. For this SR, the outcome APR was presenting a negative estimate (-8.95) 
of the MD when UFMA was applied, while it was showing a positive estimate of the MD 
(1.80) when MFMA was applied. From the observation of the results from the UVMA and 
MVMA, it is possible to see that for four (57%) of the systematic reviews analysed there was 
a change in the significance of the estimates, comparing results of the UVMA and MVMA 
models. This happens not for all the outcomes considered in the assessment. With the 
exception of one case, this change was from a significance of the estimates of the UVMA to 
no significance of the estimates of the estimates form the MVMA. For two SRs, this change 
occurred for both FEMA and REMA approaches. These two SRs were Sulfasalazine and 
Auranofin. Observing the results from the Auranofin systematic review [48] for the treatment 
of rheumatoid arthritis, it is possible to see that the change in the significance happened for 
the outcome function, which was presenting a non-significant estimate with the UFMA while 
it was showing a significant estimate with the MFMA. Furthermore, the outcome Pat.Global 
was showing a significant estimate for URMA and a non-significant estimate with the MRMA. 
Commenting on the results from the Sulfasalazine systematic review for the treatment of 
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rheumatoid arthritis, it is possible to determine that the change in the significance happened 
for outcome TJC and pain that were presenting a significant estimate with the UFMA while 
were showing a non-significant estimate with the MFMA. Furthermore, the outcome pain 
was showing a significant estimate for URMA and a non-significant estimate with the MRMA. 
Additionally, the Antimalarials and the Methotrexate systematic reviews for the treatment of 
rheumatoid arthritis were showing a significant estimate for UFMA and a non-significant 
result for the MFMA model. 
 
According to the work of ORB assessment conducted on the 47 outcomes considered in the 
analysed SRs for this application, 20 outcomes (43%) were found to be suspected of high 
risk of bias. Among these outcomes, the direction of the adjustment was in the expected 
direction (toward the null) for 17 (85%) outcomes. For the outcome function, as was 
discussed before, there is a change in the direction of the estimate from a negative estimate 
to a positive estimate of the MD. However, some limitations to this approach need to be kept 
in mind. The first is that the ORB assessment is subjective. The second is that the MVMA 
does not directly model the ORB mechanism; it simply utilises the extra information from the 
w/s correlation to adjust the effect estimates (and this does not necessarily control the 
direction of the change). The third is that MVMA does not distinguish between high/low 
ORB. 
 
With the exception of the Adalimumab Systematic review, all the remaining original reviews 
used FEMA methods for all outcomes in all examples. Of particular interest was the 
observation of the difference in the results between URMA and MRMA models; it is possible 
to say that there are changes in the treatment estimates between URMA and MRMA. For 
example, for the Auranofin systematic review [48] it was seen that the estimates moved 
towards the null for TJC and pain. Furthermore, results showed a shift in treatment effect 
estimates that was in the opposite direction for the global measurements (physician and 
patient), function and APR. Finally, observing the results for the outcome function, the shift 
in direction to a more positive result of the estimate does not suggest ORB. 
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Finally, it has been seen from the results obtained that the MVMA model (fixed and random 
effects) is not always simple to apply to these examples, as there were some issues and 
some limitations in the application of this model. In particular, it needs to be recalled that 
these models are fitted using AD that does not give information about the w/s correlation 
between the outcomes considered in the model. This issue needs to be solved before fitting 
MVMA. As previously highlighted in the methods section, other researchers have defined 
different methods, such as calculating the w/s correlation directly in each study based on the 
availability of IPD, approximating the w/s correlation using biological reasoning or expert 
opinion, and finally using the Pearson correlation method when it is impossible to obtain w/s 
correlation from IPD or from expert opinion [74]. When obtaining the results for this chapter, 
the w/s correlations were calculated based on Pearson correlations calculated at patient 
level from a previous study conducted by Professor Dr. George Wells (unpublished data). 
The Pearson correlations calculated at patient level have been used in the Wei and Higgins 
formula (5.3) described in Section 5.3.5 of this chapter to obtain the desired w/s correlations 
to be used in the MVMA models. 
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Chapter 6 - Discussion 
 
This final chapter provides a summary of the thesis and a discussion of its key findings and 
limitations. This chapter also aims to explain what the work adds to the research field of 
evidence-based synthesis. Recommendations for further work are also provided. 
 
6.1 Overview of the thesis and how it adds to evidence-based synthesis  
 
It was stated in Chapter 1 of this thesis that systematic reviews represent the gold standard 
method for reviewing research literature [1]. Many systematic reviews contain meta-analysis, 
which is the statistical component that is used to synthesise the results of independent 
studies [7]. Meta-analysis and systematic reviews (SR) can make important contributions to 
medical research by showing that there is evidence to support treatments not widely used, 
or that evidence is lacking to support treatments that are in wide use [7].  
 
The reliability of systematic review conclusions is largely based on finding data on a 
complete and unbiased set of studies [7]. Missing data from systematic reviews can heavily 
impact on results and can affect systematic reviews in two ways. Publication bias, where a 
study is not published on the basis of its results, can lead to bias in the analysis of a 
particular outcome in a review, especially if the decision not to submit or publish the study is 
related to the results for that outcome [28]. A second form of missingness comes from 
published studies, for example, when only a subset of the originally recorded outcome 
variables in a trial are selectively reported in the publication based on their results. When the 
decision not to report on certain outcomes is driven by the significance and/or direction of 
the effect size (e.g., non-significant outcomes are reported only as p-value <0.05 or are 
suppressed altogether), then this is referred to as outcome reporting bias (ORB) or selective 
outcome reporting bias [28]. This thesis has considered the problem of ORB. The impact of 
ORB has previously been shown to overturn findings and to overestimate treatment effects 
[28], although in this thesis we consider alternative impact methods to those previously 
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used. Missing participant data [33] may also be considered as a third source of missingness 
within the systematic review process if IPD-MA are performed, which has been examined in 
Chapter 4.    
 
6.1.1 Assessment of ORB in a cohort of systematic reviews for the treatment of rheumatoid 
arthritis 
 
In Chapter 2, the process for assessing ORB in systematic reviews was described, which 
includes the most up-to-date methods and tools available for researchers to use. The 
methods were then applied to a cohort of Cochrane systematic reviews considering 
pharmacological interventions for rheumatoid arthritis. Outcome reporting bias was 
assessed against a well-established set of eight core outcomes, which is commonly known 
as the World Health Organisation (WHO) and International League of Associations for 
Rheumatology (ILAR) core set of outcomes [29]. This core outcome set has not only been 
approved for use in clinical trials for rheumatoid arthritis but is also endorsed by the 
Cochrane Musculoskeletal Group. The use of COS is important for this application of meta-
analysis because it reduces waste in research which in turn can reduce the impact of ORB 
[29].  
 
Although the development of the COS for rheumatoid arthritis has shown that the 
measurement of the outcomes is increasing [29], the reporting of the outcomes for many of 
these trials remains insufficient, meaning that many meta-analyses are unable to include 
data from all relevant studies. Chapter 2 contains the results and the discussion of the work 
on ORB assessment conducted in this thesis when applying the ORBIT classification system 
[28].  
 
The ORB assessment was applied in 21 included reviews, and all contained missing data on 
at least one of the eight outcomes. This assessment has found that ORB was highly 
suspected in 275 (23%) of the 1205 evaluable outcomes from 167 assessable trials. At the 
trial level, missing or incomplete reporting of outcome data for each core outcome ranged 
138 
 
from 41% (tender joint count) to 59% (Phy.Global). For 49.4% of the evaluable outcomes in 
our study, the set of core outcomes was either partially reported or not reported (A to I 
classification). For 23%, at least one core outcome was classified under high suspicion for 
ORB (A, D, E, or G), whereas for 19.6% it was clear the outcomes were measured and 
analysed (A, B, C, D), but the reporting of the outcomes meant that the data could not be 
included in a meta-analysis. Similar to the study reported by Dwan et al. [92], all the reviews 
considered in this study included at least one study that contained missing data in relation to 
at least one of the core outcomes. The results of the work on ORB assessment were 
published in 2014 by Frosi et al. [36]. 
 
6.1.2 Methods for studying the outcome reporting bias issue in systematic reviews 
 
In addressing the issue of ORB, there are two different solutions. The first can be defined as 
a non-statistical solution and consists of contacting trialists to obtain missing outcome data. 
If it is not feasible to obtain the missing data from the trialist, there are solutions that could 
be used, for example, statistical solutions such the maximum bias bound [28], a multivariate 
meta-analysis (MVMA) approach [16], or a model-based correction method [70]. The 
assumption of the maximum bias bound approach is that larger studies (with a small 
standard error) are more likely to be published than smaller studies (with a large standard 
error) [28]. The model-based correction method proposed by Copas et al. [71] assumes that, 
if a paper in the area of interest does not report sufficiently well (or not at all) the particular 
outcome of interest, then either (i) the outcome was measured but failed to show a 
significant treatment effect or (ii) the outcome was simply not measured [71]. Omitting such 
a study from the meta-analysis will lead to a bias in the overall treatment effect in case (i) but 
not in case (ii). If (i) is known to be true, the bias will be in the direction away from the null, 
resulting in overestimation of the treatment effect and exaggeration of significance [71]. 
Previous studies showed that the results from the MVMA approach were encouraging and it 
was found that the ‘borrowing of strength’ through the use of correlation between outcomes 
can reduce the impact of ORB in a meta-analysis [16]. Therefore, the purpose of this thesis 
was to apply MVMA to reduce the impact of outcome reporting bias in randomised controlled 
139 
 
trials for rheumatoid arthritis. Therefore, multivariate meta-analysis was firstly applied to 
some scenarios concerning missing data in simulated SRs with individual participant data, 
and then it was applied to some SRs for the assessment of pharmacological treatment for 
rheumatoid arthritis.  
 
 6.1.3 Simulation of missing data scenarios in individual participant data and application of 
two-stage individual participant data meta-analysis 
 
In Chapter 3 and Chapter 4, an empirically-based individual participant data (IPD) simulation 
study based on the rheumatoid arthritis data was conducted using a fixed-effects meta-
analysis approach. The potential benefits of multivariate meta-analysis were examined over 
standard univariate analyses for a variety of different ORB missing data mechanisms.  
 
In Chapter 4, further simulations were considered to see if any of the benefits of multivariate 
meta-analysis extended to missing participant data within IPD.  
 
Previous research [16] has examined the benefits of bivariate fixed-effects meta-analysis 
(BFMA) over univariate fixed-effects meta-analysis (UFMA) for estimating pooled (treatment) 
effects for multiple outcomes in both complete and missing data scenarios. This work 
contained certain limitations and uncovered a number of questions. One of the limitations 
was that in their simulation work the researchers generated aggregate data (AD) instead of 
considering individual participant data (IPD). The basic assumption when simulating AD is 
that the within-study correlations are the same in each meta-analysis dataset which may not 
be realistic [16].   
 
The IPD meta-analysis simulation study that was performed demonstrated that the MFMA 
was preferential compared to the UFMA across the majority of performance criteria and 
scenarios considered. The benefit was particularly noticeable as the ORB missing data 
mechanism became more severe and the patient-level correlation between the outcomes 
increased.  
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The results from the simulation study were encouraging and, considering the mean square 
error (MSE) as a trade-off between preferred bias and improved precision, then the 
multivariate meta-analysis approach was preferred over the two different univariate 
specifications irrespective of an MCAR or MAR missing data mechanism and two different 
levels of missing data (20% and 40%). The benefit of MFMA when looking at %BoS was 
also clear to see, particularly as the amount of missing data and the patient-level correlation 
between outcomes increases. More BoS occurred in outcomes when the missingness was 
MCAR than when it was MAR.  
 
6.1.4 Application of univariate meta-analysis and multivariate meta-analysis to specific 
examples of systematic reviews assessed 
 
In the final experimental chapter, Chapter 5, the multivariate meta-analysis approach was 
applied to the motivating examples of rheumatoid arthritis. From the observation of the 
results from the UVMA and MVMA, it is possible to see that for three (43%) of the seven 
SRs analysed there was a change in the direction of the effect, comparing results of the 
UVMA and MVMA models. This happens not for all the outcomes considered in the 
assessment. 
 
6.1.4.1 Fixed-effects meta-analysis 
 
According to the assessment of these SRs, the analysed results showed that 20 (43%) of 
the total outcomes considered (47: five SRs considered seven outcomes and 2 SRs 
considered six outcomes therefore 47 come from the calculation 7*5+6*2) were found to be 
at high suspicion of ORB. From the comparison of MFMA and UFMA it is possible to see 
that, for 17 (85%) out of the 20 outcomes suspected to be at high risk of ORB, there is a 
change in the estimates towards the null. Furthermore, the results showed that the precision 
of the estimates increased for 19 (95%) of the outcomes suspected of having a high risk of 
ORB.  
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6.1.4.2 Random-effects meta-analysis 
 
For 17 (85%) out of the 20 outcomes suspected to be at high risk of ORB there is no change 
in the significance of the estimates. From the comparison of MRMA and URMA it is possible 
to see that, for 13 (65%) out of the 20 outcomes suspected to be at high risk of ORB, there 
is a change in the estimates towards the null. Furthermore, the results showed that the 
precision of the estimates increased for 10 (50%) of the outcomes suspected of high risk of 
ORB. For 19 (95%) out of the 20 outcomes suspected to be at high risk of ORB there is no 
change in the significance of the estimates. 
 
6.2 Use of multivariate meta-analysis to limit issues of outcome 
reporting bias 
 
This thesis was mainly dedicated to the investigation of the potential benefits that MVMA 
may offer to address the problem of ORB (and missing participant data) from primary studies 
that plagues many systematic review meta-analyses. 
 
MVMA has many potential advantages over separate univariate meta-analyses [16]. This 
thesis has shown that MVMA allows outcome data to be synthesised jointly in the same 
model; thus, the pooled estimates for all outcomes are obtained simultaneously, whilst 
accounting for their correlation. The BoS across different outcomes given the correlations 
allows for the inclusion of studies with missing outcome data, which would have otherwise 
been lost using standard UVMA methods. This was a particular strength of the MVMA 
method in the presence of ORB, and therefore may lead to more representative inferences 
and potential bias reduction than the standard univariate approach. These benefits may also 
equally translate across to missing participant data if more complex IPD meta-analyses are 
being performed.    
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6.3 Limitations of multivariate meta-analyses 
 
Through the simulation studies, MVMA has been shown to be beneficial compared to 
standard UVMA, particularly in the presence of ORB across a number of different 
performance criteria; however, there are some limitations attached to this approach.  
 
A possible limitation of this work is that this study focused on all Cochrane reviews (up to 
and including September 2012 issue) that had considered only pharmacological 
interventions for the treatment of RA [39]. Despite the scope of the RA COS, there was also 
a suggestion that the COS were being more frequently measured in RA trials that the RA 
COS was not specifically designed for, for example, non-pharmacological treatments [39]. 
However, the reporting of the full RA COS for these intervention types in general remained 
low [39]. For example another study [39] found that for many of the non-pharmacological 
trials the participants included in the study had RA (hence the RA COS was relevant), but 
the nature of the intervention meant that many of the primary investigators were not 
rheumatologists [39].             
 
A methodological limitation of this work of thesis is that univariate analyses are thought to be 
easier to understand and more transparent to the average meta-analyst (who may not have 
a statistical background). MVMA methods for obtaining w/s correlations required for the 
analysis but rarely reported or made available in primary studies may also provide a suitable 
barrier to successful and wide implementation of this approach. The availability of IPD 
means that these w/s correlations can be computed directly (as was performed in the 
simulations study (Chapters 3 and 4)), but these complex review methods are rarely carried 
out due to the availability of IPD, and therefore such correlations may need to be estimated 
as was the case for the applications in Chapter 5. A full review of how to estimate w/s 
correlations for use in MVMA can be found in Wei and Higgins’ paper [74]. Another limitation 
is that the differences in the statistical properties between the univariate and MVMA 
approach are sometimes only marginal, especially when there are no missing data. 
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Perhaps the most notable limitation of the MVMA approach as a method of the reduction of 
the impact or ORB on systematic review conclusions is that the direction of the adjustment 
cannot be controlled by the method (it is a consequence of utilising the w/s correlation).   
 
Finally it is possible to say that typically, ORB overestimates treatment effects when it is 
present (i.e. due to the removal of non-significant results) [28], and therefore a suitable 
adjustment method, under this assumption, would shift the adjusted estimates back towards 
the null, of no treatment effect difference. While this trend was observed in the simulation 
studies, where the true missing data mechanism was known, and the performance 
measures were averaged over many simulations, it was not always observed for a single 
practical application when high risk of ORB was suspected in an outcome. The ORB 
classifications themselves for judging high and low risk of bias can also be subjective, and 
may contribute to this underlying issue, although the sensitivity and specificity of judging 
high/low risk of bias using this classification system has previously been found to be high 
[28]. Notably, a more recent ORB adjustment approach developed by Copas [71] specifically 
directly models the ORB missing data mechanism.     
   
6.4 Further work  
 
This thesis has made a useful contribution to the understanding of MVMA methods as a 
method of ORB adjustment, but many issues remain unaddressed. While the REMA, MVMA 
model was introduced in the applications chapter, for simplicity this approach was not 
investigated as part of a larger simulation study. In the presence of ORB, a FEMA may not 
be a realistic assumption in practice as ORB may hide the true extent of underlying 
heterogeneity, suggesting that a REMA approach could be the default approach in the 
presence of ORB. Considering the REMA, MVMA methods need to be investigated further, 
to see if the same benefits observed in the fixed-effects simulations are still apparent.   
 
Furthermore, there needs to be a comparison of the various ORB adjustment approaches 
(inclusive of MVMA) available to see which method is preferred and which one can be more 
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easily applied. In addition, it would be beneficial to understand more clearly, when MVMA 
should be considered over UVMA.  
  
Assessing ORB for harmful outcomes in reviews has also been considered [69], and an 
investigation into the use of MVMA as an adjustment approach should be considered in this 
situation when the reason for missing outcome data may not be based on statistical 
significance.     
 
6.5 Conclusions 
 
MVMA is not the solution to all ORB-related problems within review meta-analyses, but, 
informed by this thesis, it can unquestionably be seen as a route to address missing 
outcome data. The BoS, reduction in bias and increase in precision can all be seen as 
promising, despite some of the aforementioned challenges with the approach [73].   
 
As well as developing statistical methodology such as MVMA to adjust for ORB, promotion 
of preventative methods should continue.. It has been stated that this is an important step for 
controlling the impact of ORB [29]. The strategies proposed to reduce the impact of ORB 
included trial registration, outcome data banks and online journals with greater space to 
include more information [13].  
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APPENDIX A 
ASSESSMENT OF A COHORT OF SYSTEMATIC REVIEWS OF 
TREATMENTS FOR REHUMATOID ARTHRITIS 
 
List of systematic reviews assessed for the risk of outcome reporting bias 
 Methotrexate monotherapy versus methotrexate combination therapy with non-biologic 
disease modifying antirheumatic drugs for rheumatoid arthritis (Review) [41] 
 Antimalarials for treating rheumatoid arthritis (Review) [46] 
 Azathioprine for treating rheumatoid arthritis (Review) [47] 
 Auranofin versus placebo in rheumatoid arthritis (Review) [48] 
 Cyclophosphamide for treating rheumatoid arthritis (Review) [49] 
 Cyclosporine for treating rheumatoid arthritis (Review) [50] 
 Injectable gold for rheumatoid arthritis (Review) [51] 
 Methotrexate for treating rheumatoid arthritis (Review) [52] 
 Penicillamine for treating rheumatoid arthritis (Review) [53] 
 Sulfasalazine for treating rheumatoid arthritis (Review) [54] 
 Leflunomide for the treatment of rheumatoid arthritis (Review) [55] 
 Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for 
rheumatoid arthritis (Review) [56] 
 Adalimumab for treating rheumatoid arthritis (Review) [57] 
 Abatacept for rheumatoid arthritis (Review) [58] 
 Anakinra for rheumatoid arthritis (Review) [59] 
 Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review) [60] 
 Etanercept for the treatment of rheumatoid arthritis (Review) [61] 
 Infliximab for the treatment of rheumatoid arthritis (Review) [62] 
 Golimumab for rheumatoid arthritis (Review) [63] 
 Tocilizumab for rheumatoid arthritis (Review) [64] 
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 Effects of glucocorticoids on radiological progression in rheumatoid arthritis (Review) 
[65] 
A.1 DMARDs for the treatment of Rheumatoid Arthritis  
 
Table A.1 ORB matrix – Antimalarials for treating rheumatoid arthritis 
Study Eligibility TJC SJC Pain 
Pat. 
Global 
Phy. 
Global 
Function APR RD 
Davis  
’91 
Included 
  (D) (H) (H) (F.R)   
Clark  
’93 
   (C) (C) (FR)  (H) 
Blackburn 
’95 
     (D)  (H) 
HERA 
’95 
       (I) 
Popert  
’61 
Excluded 
(H) (H) (H) (H) (H) (C) (C) (C) 
Scull  
’62 
(F) (F) (H) (H) (H) (H) (H) (F) 
TJC: Tender joint count; SJC: Swollen joint count; Pat.: Patient; Phy.: Physician; APR: acute phase reactant; RD: 
Radiological Damage; FR: Fully reported 
 
 
Table A.2 ORB matrix – Azathioprine for treating rheumatoid arthritis 
Study Eligibility TJC SJC Pain 
Pat. 
Global 
Phy. 
Global 
Function APR RD 
Levy  
‘72 
Included 
 (FR) (H) (H) (H) (FR) (G) (G) 
Urowitz  
‘73 
  (C) (E) (H) (FR)  (FR) 
Woodland 
‘81 
 (FR)  (FR) (B)   (H) 
Barnes  
‘69  
Excluded 
(H) (H) (H) (H) (H) (H) (E) (G) 
Dixon  
‘71  
(G) (G) (H) (H) (H) (A) (H) (H) 
Pedersen 
‘84 
(H) (H) (H) (H) (H) (H) (D) (H) 
TJC: Tender joint count; SJC: Swollen joint count; Pat.: Patient; Phy.: Physician; APR: acute phase reactant; RD: 
Radiological Damage; FR: Fully reported 
 
147 
 
 
Table A.3 ORB matrix – Cyclophosphamide for treating rheumatoid arthritis 
Study Eligibility TJC SJC Pain 
Pat. 
Global 
Phy. 
Global 
Function APR RD 
CCC  
‘70 
Included 
  (H) (C) (E) (FR)   
Townes  
‘76  
  (D) (FR) (FR) (FR)  (D) 
TJC: Tender joint count; SJC: Swollen joint count; Pat.: Patient; Phy.: Physician; APR: acute phase reactant; RD: 
Radiological Damage; FR: Fully reported 
 
 
Table A.4 ORB matrix – Cyclosporine for treating rheumatoid arthritis 
Study Eligibility TJC SJC Pain 
Pat. 
Global 
Phy. 
Global 
Function APR RD 
Dougados  
‘88  
Included 
   (FR) (FR)   (H) 
Tugwell  
‘90 
       (H) 
Forre  
‘94 
        
TJC: Tender joint count; SJC: Swollen joint count; Pat.: Patient; Phy.: Physician; APR: acute phase reactant; RD: 
Radiological Damage; FR: Fully reported 
 
 
 
Table A.5 ORB matrix – Injectable Gold for treating rheumatoid arthritis 
Study Eligibility TJC SJC Pain 
Pat. 
Global 
Phy. 
Global 
Function APR RD 
ERC  
‘60 
Included 
(FR)  (FR)   (FR)  (FR) 
CCC  
‘73 
(FR)  (H) (A) (E) (FR) (FR) (FR) 
Sigler  
‘74 
(C) (C) (H) (H) (H) (C) (C) (FR) 
Ward  
‘83 
(C)  (H)   (C)  (H) 
TJC: Tender joint count; SJC: Swollen joint count; Pat.: Patient; Phy.: Physician; APR: acute phase reactant; 
RD: Radiological Damage; FR: Fully reported 
 
 
 
Table A.6 ORB matrix – Methotrexate for treating rheumatoid arthritis 
Study Eligibility TJC SJC Pain 
Pat. 
Global 
Phy.  
Global 
Function APR RD 
Andersen  
‘85 
Included 
       (H) 
Weinblatt  
‘85 
  (H)     (H) 
Williams  
‘85 
      (C) (H) 
Furst  
‘90 
       (H) 
Pinheiro  
‘93 
 (G)  (H) (H)   (H) 
TJC: Tender joint count; SJC: Swollen joint count; Pat.: Patient; Phy.: Physician; APR: acute phase reactant; RD: 
Radiological Damage; FR: Fully reported 
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Table A.7 ORB matrix – Penicillamine for treating rheumatoid arthritis 
Study Eligibility TJC SJC Pain Pat. 
Global 
Phy.  
Global 
Function APR RD 
Andrews  
‘73 
Included 
 (C) (C)     (A) 
Dixon  
‘75 
(G) (G)  (G) (G) (C)  (A) 
Mery  
‘76 
 (G) (G) (C) (C) (C)  (H) 
Huskisson  
‘76 
(C) (G) (C) (G) (G) (G) (C) (H) 
Hamilton  
‘77 
(G) (G) (G) (G) (G) (C) (C) (A) 
Shiokawa  
‘77 
(E) (E) (G) (G)  (E) (F) (C) 
Williams  
‘83 
     (FR)  (E) 
TJC: Tender Joint Count; SJC: Swollen Joint Count; Pat.: Patient; Phy.: Physician; APR: acute phase reactant; 
RD: Radiological Damage; FR: Fully reported 
 
 
 
 
Table A.8 ORB matrix – Sulfasalazine for treating rheumatoid arthritis 
Study Eligibility TJC SJC Pain 
Pat. 
Global 
Phy. 
Global 
Function APR RD 
Pullar  
‘83 
Included 
(E) (G) (E) (G) (G) (E) (E) (H) 
Williams  
‘88 
  (G)   (FR)  (H) 
Skosey  
‘88 
(A) (A) (C) (C) (C) (C) (C) (H) 
Ebringer  
‘92 
   (D) (D) (D)  (FR) 
Danis  
‘92 
(FR) (G) (FR) (G) (G) (FR) (FR) (H) 
Hannonen  
‘93 
     (C) (D)  
Farr  
‘95 
 (G)  (D) (D) (FR)  (H) 
TJC: Tender Joint Count; SJC: Swollen Joint Count; Pat.: Patient; Phy.: Physician; APR: acute phase reactant; 
RD: Radiological Damage; FR: Fully reported 
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Table A.9 ORB matrix – Methotrexate monotherapy vs. Methotrexate combination 
therapy for treating rheumatoid arthritis 
Study Eligibility TJC SJC Pain 
Pat. 
Global 
Phy. 
Global 
Function APR RD 
Willkins  
’92 
Included 
(FR) (FR)  (G) (FR) (FR) (D) (G) (H) 
Ferraz  
’94 
(FR)   (G) (G)   (H) 
Haagsma  
’94 
(FR) (FR)  (FR) (G) (FR)  (H) 
Tugwell  
’95 
       (H) 
Willkins  
’95 
(FR) (FR)  (G) (FR) (FR) (D) (G) (H) 
O’Dell  
’96 
   (C)   (C)  (G) 
Haagsma  
’97 
 (FR)   (D)   (G) 
Dougados  
’99 
(C) (C)  (D) (C) (C) (C) (C) (C) 
Hanyu  
’99 
(FR) (FR) (G) (G) (FR) (FR)  (G) 
Islam  
’00 
(FR) (FR) (G) (FR) (FR) (FR) (FR) (H) 
Kremer  
’02 
       (H) 
Marchesoni 
’03 
(F) (F)  (F) (F) (F) (F) (F)  
Ichikawa  
’05 
(F) (F)  (F) (F) (F) (F) (F) (FR) 
Lehman  
’05  
       (H) 
Jarett  
’06 
(A) (A)    (G) (A)  
Hetland  
’06 
(E) (F)  (F) (E) (E) (FR) (E) (FR) 
O’Dell  
’06 
(C) (C)  (C) (C) (C) (C) (C) (G) 
Capell  
’07 
(FR) (FR) (FR) (FR) (FR) (FR) (FR) (A) 
Ogrendik  
’07 
(FR) (FR) (FR) (FR) (FR) (FR) (FR) (H) 
Calguneri  
’99 
Excluded 
(FR) (FR) (FR) (FR) (FR) (G) (FR) (G) 
Mottaghi  
’05 
(E) (E) (E) (E) (E) (E) (E) (H) 
TJC: Tender Joint Count; SJC: Swollen Joint Count; Pat.: Patient; Phy.: Physician; APR: acute phase reactant; 
RD: Radiological Damage; FR: Fully reported 
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Table A.10 ORB matrix – Leflunomide for treating rheumatoid arthritis 
Study Eligibility TJC SJC Pain 
Pat. 
Global 
Phy. 
Global 
Function APR RD 
Rozman 
’94a 
Included 
  (G)   (G) (D) (H) 
Mladenovic 
’95 
       (H) 
Emery 
’99 
        
Smolen 
’99 
       (H) 
Strand 
‘99a 
        
Bao 
’00 
     (E)  (H) 
Sharp 
’00 
(E) (E) (E) (E) (E) (E) (E)  
Cohen 
’01 
        
Hu 
’01 
(D) (A) (D) (D) (A) (D) (D) (H) 
Kalden 
’01 
(E) (E) (E) (C) (C) (FR) (C) (D) 
Larsen 
’01 
(E) (E) (E) (E) (E) (E) (C)  
Scott 
’01 
        
Jakez-
Ocampo‘02 
(F) (F) (F) (F) (F) (F) (F) (G) 
Kremer 
’02 
       (H) 
Reece 
’02 
       (H) 
Bao 
’03 
(FR) (FR) (FR) (FR) (FR) (FR) (FR) (H) 
Kremer 
’04 
       (H) 
Mariette 
‘04 
(C) (C) (E) (E) (E) (FR) (C) (H) 
Poor 
’04 
  (E) (E) (E)  (E) (H) 
Dougados 
’05 
   (A) (A)   (G) 
Antony 
’06 
(FR) (FR) (G) (FR) (FR) (FR) (FR) (H) 
Karanikolas 
’06 
(FR) (FR) (FR) (FR) (FR) (FR) (FR) (G) 
Fiehn 
’07 
(A) (A) (G) (E) (G) (G) (C) (H) 
Wislowska 
’07 
   (E) (G)   (H) 
Grijalva 
’07 
Excluded (H) (H) (H) (H) (H) (H) (H) (G) 
TJC: Tender Joint Count; SJC: Swollen Joint Count; Pat.: Patient; Phy.: Physician; APR: acute phase reactant; RD: 
Radiological Damage; FR: Fully reported 
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Table A.11 ORB matrix – Folic Acid for treating rheumatoid arthritis 
Study Eligibility TJC SJC Pain 
Pat. 
Global 
Phy. 
Global 
Function APR RD 
Buckley 
’90 
Included 
(C)  (C)  (C) (C) (C) (H) 
Hanrahan 
’88 
  (FR) (H) (H) (H) (H) (H) 
Morgan 
’90 (FR) (FR) (H) (FR) (FR) (D) (F) (H) 
Joyce 
’91 
  (C) (C) (H) (H) (C) (H) 
Shiroky 
’93 
  (H)  (FR) (FR) (FR) (H) 
Weinblatt 
’93 
  (H)  (FR) (H) (D) (H) 
Morgan 
’94 
  (H)  (FR) (FR) (A) (D) 
Andersen 
’97 Excluded 
(G)  (D)  (D)  (D)  (D)  (D)  (D) (H) 
Morgan 
’98 
(H) (H) (H) (H) (H) (H) (H) (G) 
TJC: Tender Joint Count; SJC: Swollen Joint Count; Pat.: Patient; Phy.: Physician; APR: acute phase reactant; RD: 
Radiological Damage; FR: Fully reported 
 
 
A.2 Biologics for the treatment of Rheumatoid Arthritis  
 
Table A.12 ORB matrix – Adalimumab for treating rheumatoid arthritis 
Study Eligibility TJC SJC Pain Pat. 
Global 
Phy.  
Global 
Function APR RD 
Weinblatt 
’03 
Included 
        (H) 
Furst 
’03 
(F) (F) (F) (F) (F) (F) (F) (H) 
Van de Putte 
’03 
       (H) 
Van de Putte 
’04 
      (C) (H) 
Keystone 
’04 
        
Rau 
’04 
(C) (C) (C) (C) (C) (C) (C) (H) 
TJC: Tender Joint Count; SJC: Swollen Joint Count; Pat.: Patient; Phy.: Physician; APR: acute phase reactant; 
RD: Radiological Damage; FR: Fully reported 
 
 
 
Table A.13 ORB matrix – Anakinra for treating rheumatoid arthritis 
Study Eligibility TJC SJC Pain 
Pat. 
Global 
Phy. 
Global 
Function APR RD 
Bresnihan 
’98 
Included 
(F.R) (FR)  (FR) (FR)    
Cohen 
’02 
(C) (C) (C) (C) (C) (C) (C) (H) 
Fleischman 
’03 
(H) (H) (H) (H) (H) (H)  (H) (H) 
Cohen 
’04 
(FR) (FR) (FR) (FR) (FR)   (I) 
Genovese 
’04 
 (F)  (F)  (F)  (F)  (F)  (F) (F) (I) 
TJC: Tender Joint Count; SJC: Swollen Joint Count; Pat.: Patient; Phy.: Physician; APR: acute phase reactant; RD: 
Radiological Damage; FR: Fully reported 
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Table A.14 ORB matrix – Abatacept for treating rheumatoid arthritis 
Study Eligibility TJC SJC Pain 
Pat. 
Global 
Phy. 
Global 
Function APR RD 
Moreland 
’02 
Included 
(C) (C) (C) (C) (C) (C) (C) (H) 
Kremer 
’03 
      (C) (H) 
Genovese 
’05 
(E) (E) (E) (E) (E) 
 
(E) (H) 
Kremer 
’06 
      (FR)  
Weinblatt 
’06 
(E) (E)     (E) (H) 
Weinblatt 
’07 
 (FR)  (FR)  (FR) (FR)  (FR) (H) 
Schiff 
’08 
 (E)  (E) (E) (E) (E)  (E) (H) 
TJC: Tender Joint Count; SJC: Swollen Joint Count; Pat.: Patient; Phy.: Physician; APR: acute phase reactant; RD: 
Radiological Damage; FR: Fully reported 
 
 
 
 
 
Table A.15 ORB matrix – Golimumab for treating rheumatoid arthritis 
Study Eligibility TJC SJC Pain 
Pat. 
Global 
Phy. 
Global 
Function APR RD 
Kay 
’08 
Included 
(E) (E) (E) (E) (E) (E) (C) (H) 
Kaystone 
’09 
(E) (E) (E) (E) (E)  (E) (H) 
Emery 
’09 
(FR) (FR) (FR) (FR) (FR) (FR) (FR) (H) 
Smolen 
’09 
(FR) (FR) (FR) (FR) (FR)  (FR) (H) 
TJC: Tender Joint Count; SJC: Swollen Joint Count; Pat.: Patient; Phy.: Physician; APR: acute phase reactant; 
RD: Radiological Damage; FR: Fully reported 
 
 
 
 
 
Table A.16 ORB matrix – Certolizumab Pegol for treating rheumatoid arthritis 
Study Eligibility TJC SJC Pain 
Pat. 
Global 
Phy. 
Global 
Function APR RD 
Choy 
‘02  
Included 
(C) (C) (C) (C) (C) (C) (C) (H) 
FAST4WARD 
’05 
(C) (C)  (C) (C)  (C) (H) 
RAPID1 
’05 
(C) (C)  (C) (C)  (C)  
RAPID2 
’07 
(FR) (FR)  (FR) (FR)  (FR)  
TJC: Tender Joint Count; SJC: Swollen Joint Count; Pat.: Patient; Phy.: Physician; APR: acute phase reactant; RD: 
Radiological Damage; FR: Fully reported 
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Table A.17 ORB matrix – Tocilizumab for treating rheumatoid arthritis 
Study Eligibility TJC SJC Pain 
Pat. 
Global 
Phy. 
Global 
Function APR RD 
Choy 
’02 
Included 
(C) (C) (C) (C) (C) (C) (C) (H) 
Nishimoto 
’04 
(C) (C) (C) (C) (C) (C) (C) (H) 
Maini 
’06 
(B) (B) (E) (E) (E) (E) (C) (H) 
Nishimoto 
’07 
(E) (E) (E) (E) (E) (C) (E) (FR) 
Smolen 
’08 
       (H) 
Genovese 
’08 
  (E) (E) (E)   (I) 
Emery 
’08 
  (D) (D) (D)   (H) 
Nishimoto 
’09 
(E) (E) (E) (E) (E) (C)  (H) 
Straub ’06 Excluded (E)  (C)  (H)  (E)  (H)  (H)  (C)  (H) 
TJC: Tender Joint Count; SJC: Swollen Joint Count; Pat.: Patient; Phy.: Physician; APR: acute phase reactant; RD: 
Radiological Damage; FR: Fully reported 
 
 
 
TableA.18 ORB matrix – Infliximab for treating rheumatoid arthritis 
Study Eligibility TJC SJC Pain 
Pat. 
Global 
Phy. 
Global 
Function APR RD 
Maini  
’98 
Included 
  (D) (D) (D) (D)  (H) 
Maini  
’99 
       (H) 
TJC: Tender Joint Count; SJC: Swollen Joint Count; Pat.: Patient; Phy.: Physician; APR: acute phase reactant; RD: 
Radiological Damage; FR: Fully reported 
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Table A.19  ORB matrix – Etanercept for treating rheumatoid arthritis 
Study Eligibility TJC SJC Pain 
Pat. 
Global 
Phy. 
Global 
Function APR RD 
Moreland 
’99 
Included 
(FR) (FR) (FR) (FR) (FR) (FR) (FR) (H) 
Weinblatt 
’99 
(FR) (FR) (FR) (FR) (FR)  (FR) (H) 
Bathon  
‘00 (ERA) 
(E) (E) (E) (E) (E)  (E)  
Klareskog 
‘04 
(TEMPO) 
(E) (E)  (E) (E)  (E)  
Combe 
’06 
(FR) (FR)  (FR) (FR)  (FR) (H) 
Marcora 
’06 
(E) (E) (E) (E) (E)  (FR) (H) 
Emery ‘08 
(COMET) 
(E) (E) (FR) (E) (E)  (E)  
Hu 
’09 
(F) (F) (F) (F) (F) (F) (F) (H) 
Kameda 
’10 
(FR) (FR) (G) (FR) (G)  (FR) (H) 
TJC: Tender Joint Count; SJC: Swollen Joint Count; Pat.: Patient; Phy.: Physician; APR: acute phase reactant; RD: 
Radiological Damage; FR: Fully reported 
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A.3 Glucocorticoids for the treatment of Rheumatoid Arthritis  
 
Table A.20 ORB matrix – Glucocorticoids on radiological progression in rheumatoid 
arthritis 
Study Eligibility TJC SJC Pain 
Pat. 
Global 
Phy.  
Global 
Function APR RD 
Empire  
’55 
Included 
(FR) (FR) (G) (C) (C) (G) (FR) (FR) 
Empire  
’57 
(FR) (FR) (G) (C) (C) (G) (FR)  
Joint  
’59 
(C) (C) (G) (G) (G) (C) (C) (C) 
Joint  
’60 
(C) (C) (G) (G) (G) (C) (C)  
Harris  
’83 
(FR) (FR) (FR) (C) (C) (C) (FR)  
Van Gestel  
’95 
(C) (C) (C) (C) (H) (C) (C)  
Kirwan  
’95 
(C) (D) (C) (G) (G) (C) (C)  
Schaardenburg 
’95 
(C) (C) (G) (G) (G) (C) (C)  
Boers  
’97 
(C) (G) (G) (G) (G) (C) (C)  
Hansen  
’99 
(D) (C) (G) (D) (D) (C) (C)  
Van 
Everdingen  
’02 
(FR) (FR) (FR) (G) (G) (F.R) (FR)  
Capell  
’04 
(FR) (G) (FR) (FR) (FR) (FR) (FR)  
Choy  
’05 
(FR) (FR) (FR) (FR) (FR) (FR) (FR)  
Svensson  
’05 
(F) (F) (F) (F) (H) (C) (C)  
Wassenberg 
’05 
(F) (F) (A) (A) (G) (A) (A)  
Goekoop  
’05 
(G) (G) (G) (G) (G) (FR) (D)  
TJC: Tender Joint Count; SJC: Swollen Joint Count; Pat.: Patient; Phy.: Physician; APR: acute phase reactant; RD: 
Radiological Damage; FR: Fully reported 
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APPENDIX B 
SAS & STATA SCRIPTS FOR THE SIMULATION STUDY ORB 
SCENARIOS 
B.1 Simulation of Individual Participant Data  
RandNormal (N, Mean, Cov); 
n = 5 studies 
N                                                                                                                                                                                            
N1t = 30; N2t = 40; N3t = 50; N4t = 60; N5t = 70; N1p = 30; N2p = 40; N3p = 50; N4p = 60; N5p = 70; 
 
Mean 
Mean1t = {10.0, 8.0, 28.0};  Mean2t = {11.0, 9.0, 29.0}; Mean3t = {12.0, 10.0, 30.0};                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
Mean4t = {13.0, 11.0, 31.0};  Mean5t = {14.0, 12.0, 32.0}; Mean1p = {15.0, 11.0, 34.0};                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
Mean2p = {16.0, 12.0, 35.0}; Mean3p = {17.0, 13.0, 36.0};  Mean4p = {18.0, 14.0, 37.0};                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
Mean5p = {19.0, 15.0, 38.0};  
     
Cov 
 Patient-level correlation = 0  
Cov1t= {49 0 0, 0 25 0, 0 0 121};                                                                                                                                                                                                                                
Cov2t = {64 0 0, 0 36 0, 0 0 144};                                                                                                                                                                                                                               
Cov3t = {81 0 0, 0 49 0, 0 0 169};                                                                                                                                                                                                                               
Cov4t = {100 0 0, 0 64 0, 0 0 196};                                                                                                                                                                                                                              
Cov5t = {121 0 0, 0 81 0, 0 0 225};                                                                                                                                                                                                                              
Cov1p = {64 0 0, 0 36 0, 0 0 144};   
 Cov2p = {81 0 0, 0 49 0, 0 0 169};                                                                                                                                                                                                                               
Cov3p = {100 0 0, 0 64 0, 0 0 196};                                                                                                                                                                                                                              
Cov4p = {121 0 0, 0 81 0, 0 0 225};   
Cov5p = {144 0 0, 0 100 0, 0 0 256};      
 
 Patient-level correlation = 0.2     
Cov1t = {49.0 7.0 15.4, 7.0 25.0 11.0, 15.4 11.0 121.0};                                                                                                                                                                                                         
Cov2t = {64.0 9.6 19.2, 9.6 36.0 14.4, 19.2 14.4 144.0};                                                                                                                                                                                                         
Cov3t = {81.0 12.6 23.4, 12.6 49.0 18.2, 23.4 18.2 169.0};                                                                                                                                                                                                       
Cov4t = {100.0 16.0 28.0, 16.0 64.0 22.4, 28.0 22.4 196.0};                                                                                                                                                                                                      
Cov5t = {121.0 19.8 33.0, 19.8 81.0 27.0, 33.0 27.0 225.0};                                                                                                                                                                                                      
Cov1p = {64.0 9.6 19.2, 9.6 36.0 14.4, 19.2 14.4 144.0};                                                                                                                                                                                                         
Cov2p = {81.0 12.6 23.4, 12.6 49.0 18.2, 23.4 18.2 169.0};                                                                                                                                                                                                       
Cov3p = {100.0 16.0 28.0, 16.0 64.0 22.4, 28.0 22.4 196.0};                                                                                                                                                                                                      
Cov4p = {121.0 19.8 33.0, 19.8 81.0 27.0, 33.0 27.0 225.0};                                                                                                                                                                                                      
Cov5p = {144.0 24.0 40.8, 24.0 100.0 34.0, 40.8 34.0 289.0};       
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 Patient-level correlation = 0.5  
Cov1t = {49.0 17.5 38.5, 17.5 25.0 27.5, 38.5 27.5 121.0};                                                                                                                                                                                                                                
Cov2t = {64.0 24.0 48.0, 24.0 36.0 36.0, 48.0 36.0 144.0};                                                                                                                                                                                                                               
Cov3t = {81.0 31.5 58.5, 31.5 49.0 45.5, 58.5 45.5 169.0};                                                                                                                                                                                                                               
Cov4t = {100.0 40.0 70.0, 40.0 64.0 56.0, 70.0 56.0 196.0};                                                                                                                                                                                                                              
Cov5t = {121.0 49.5 82.5, 49.5 81.0 67.5, 82.5 67.5 225.0};                                                                                                                                                                                                                              
Cov1p = {64.0 24.0 48.0, 24.0 36.0 36.0, 48.0 36.0 144.0};                                                                                                                                                                                                                               
Cov2p = {81.0 31.5 58.5, 31.5 49.0 45.5, 58.5 45.5 169.0};                                                                                                                                                                                                                               
Cov3p = {100.0 40.0 70.0, 40.0 64.0 56.0, 70.0 56.0 196.0};                                                                                                                                                                                                                              
Cov4p = {121.0 49.5 82.5, 49.5 81.0 67.5, 82.5 67.5 225.0};                                                                                                                                                                                                                              
Cov5p = {144.0 60.0 102.0, 60.0 100.0 85.0, 102.0 85.0 289.0};      
 
 Patient-level correlation = 0.8  
Cov1t = {49.0 28.0 61.6, 28.0 25.0 44.0, 61.6 44.0 121.0};                                                                                                                                                                                                                                
Cov2t = {64.0 38.4 76.8, 38.4 36.0 57.6, 76.8 57.6 144.0};                                                                                                                                                                                                                               
Cov3t = {81.0 50.4 93.6, 50.4 49.0 72.8, 93.6 72.8 169.0};                                                                                                                                                                                                                               
Cov4t = {100.0 64.0 112.0, 64.0 64.0 89.6, 112.0 89.6 196.0};                                                                                                                                                                                                                              
Cov5t = {121.0 79.2 132.0, 79.2 81.0 108.0, 132.0 108.0 225.0};                                                                                                                                                                                                                              
Cov1p = {64.0 38.4 76.8, 38.4 36.0 57.6, 76.8 57.6 144.0};                                                                                                                                                                                                                               
Cov2p = {81.0 50.4 93.6, 50.4 49.0 72.8, 93.6 72.8 169.0};                                                                                                                                                                                                                               
Cov3p = {100.0 64.0 112.0, 64.0 64.0 89.6, 112.0 89.6 196.0};                                                                                                                                                                                                                              
Cov4p = {121.0 79.2 132.0, 79.2 81.0 108.0, 132.0 108.0 225.0};                                                                                                                                                                                                                              
Cov5p = {144.0 96.0 163.2, 96.0 100.0 136.0, 163.2 136.0 289.0};  
 
 Patient-level correlation = RA_corr: 0.67 (outcome 1 & outcome 2), 0.55 (outcome 1 & 
outcome 3), 0.38  
Cov1t = {49.0 23.3 42.3, 23.3 25.0 21.1, 42.3 21.1 121.0};                                                                                                                                                                                                                                
Cov2t = {64.0 32.0 52.7, 32.0 36.0 27.6, 52.7 27.6 144.0};                                                                                                                                                                                                                               
Cov3t = {81.0 42.0 64.2, 42.0 49.0 34.9, 64.2 34.9 169.0};                                                                                                                                                                                                                               
Cov4t = {100.0 53.3 76.9, 53.3 64.0 43.0, 76.9 43.0 196.0};                                                                                                                                                                                                                              
Cov5t = {121.0 66.0 90.6, 66.0 81.0 51.8, 90.6 51.8 225.0};                                                                                                                                                                                                                              
Cov1p = {64.0 32.0 52.7, 32.0 36.0 27.6, 52.7 27.6 144.0};                                                                                                                                                                                                                               
Cov2p = {81.0 42.0 64.2, 42.0 49.0 34.9, 64.2 34.9 169.0};                                                                                                                                                                                                                               
Cov3p = {100.0 53.3 76.9, 53.3 64.0 43.0, 76.9 43.0 196.0};                                                                                                                                                                                                                              
Cov4p = {121.0 66.0 90.6, 66.0 81.0 51.8, 90.6 51.8 225.0};                                                                                                                                                                                                                              
Cov5p = {144.0 80.0 112.0, 80.0 100.0 65.3, 112.0 65.3 289.0};                    
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RandNormal (N, Mean, Cov); 
n = 10 studies 
N 
N1t = 10; N2t = 20; N3t = 30; N4t = 40; N5t = 50; N6t = 60; N7t = 70; N8t = 80; N9t = 90; N10t = 100;  
N1p = 10; N2p = 20; N3p = 30; N4p = 40; N5p = 50; N6p = 60; N7p = 70; N8p = 80; N9p = 90; N10p = 100; 
                                                                                                                                                                                               
Mean 
Mean1t = {8.0, 8.0, 20.0}; Mean2t = {9.0, 9.0, 22.0}; Mean3t = {10.0, 9.75, 24.0};                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
Mean4t = {11.0, 10.0, 26.0}; Mean5t = {11.5, 11.0, 28.0}; Mean6t = {12.5, 12.0, 30.0};                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
Mean7t = {13.0, 13.0, 32.0}; Mean8t = {14.0, 13.25, 34.0}; Mean9t = {15.0, 14.0, 36.0};                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
Mean10t = {16.0, 15.0, 38.0};    
Mean1p = {13.0, 11.0, 26.0}; Mean2p = {14.0, 12.0, 28.0}; Mean3p = {15.0, 12.75, 30.0};                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
Mean4p = {16.0, 13.0, 32.0}; Mean5p = {16.5, 14.0, 34.0}; Mean6p = {17.5, 15.0, 36.0};                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
Mean7p = {18.0, 16.0, 38.0}; Mean8p = {19.0, 16.25, 40.0}; Mean9p = {20.0, 17.0, 42.0};                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
Mean10p = {21.0, 18.0, 44.0};         
 
 COV 
 Patient-level correlation = 0 
Cov1t= {49 0 0, 0 25 0, 0 0 121};                                                                                                                                                                                                                                
Cov2t = {64 0 0, 0 36 0, 0 0 144};                                                                                                                                                                                                                               
Cov3t = {81 0 0, 0 49 0, 0 0 169};                                                                                                                                                                                                                               
Cov4t = {100 0 0, 0 64 0, 0 0 196};                                                                                                                                                                                                                              
Cov5t = {121 0 0, 0 81 0, 0 0 225};                                                                                                                                                                                                                              
Cov6t = {144 0 0, 0 100 0, 0 0 289};                                                                                                                                                                                                                             
Cov7t = {169 0 0, 0 121 0, 0 0 324};                                                                                                                                                                                                                             
Cov8t = {196 0 0, 0 144 0, 0 0 361};                                                                                                                                                                                                                             
Cov9t = {225 0 0, 0 169 0, 0 0 400};                                                                                                                                                                                                                             
Cov10t = {256 0 0, 0 196 0, 0 0 441};                                                                                                                                                                                                                            
Cov1p = {64 0 0, 0 36 0, 0 0 144};                                                                                                                                                                                                                               
Cov2p = {81 0 0, 0 49 0, 0 0 169};                                                                                                                                                                                                                               
Cov3p = {100 0 0, 0 64 0, 0 0 196};                                                                                                                                                                                                                              
Cov4p = {121 0 0, 0 81 0, 0 0 225};                                                                                                                                                                                                                              
Cov5p = {144 0 0, 0 100 0, 0 0 256};                                                                                                                                                                                                                             
Cov6p = {169 0 0, 0 121 0, 0 0 324};                                                                                                                                                                                                                             
Cov7p = {196 0 0, 0 144 0, 0 0 361};                                                                                                                                                                                                                             
Cov8p = {225 0 0, 0 169 0, 0 0 400};                                                                                                                                                                                                                             
Cov9p = {256 0 0, 0 196 0, 0 0 441};                                                                                                                                                                                                                             
Cov10p = {289 0 0, 0 225 0, 0 0 484};     
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 Patient-level correlation = 0.2                                                                                                                                                                                                                                                                                                                                                                                                                                               
Cov1t = {49.0 7.0 15.4, 7.0 25.0 11.0, 15.4 11.0 121.0};                                                                                                                                                                                                                                
Cov2t = {64.0 9.6 19.2, 9.6 36.0 14.4, 19.2 14.4 144.0};                                                                                                                                                                                                                               
Cov3t = {81.0 12.6 23.4, 12.6 49.0 18.2, 23.4 18.2 169.0};                                                                                                                                                                                                                               
Cov4t = {100.0 16.0 28.0, 16.0 64.0 22.4, 28.0 22.4 196.0};                                                                                                                                                                                                                              
Cov5t = {121.0 19.8 33.0, 19.8 81.0 27.0, 33.0 27.0 225.0};                                                                                                                                                                                                                              
Cov6t = {144.0 24.0 40.8, 24.0 100.0 34.0, 40.8 34.0 289.0};                                                                                                                                                                                                                             
Cov7t = {169.0 28.6 46.8, 28.6 121.0 39.6, 46.8 39.6 324.0};                                                                                                                                                                                                                             
Cov8t = {196.0 33.6 53.2, 33.6 144.0 45.6, 53.2 45.6 361.0};                                                                                                                                                                                                                             
Cov9t = {225.0 39.0 60.0, 39.0 169.0 52.0, 60.0 52.0 400.0};                                                                                                                                                                                                                             
Cov10t = {256.0 44.8 67.2, 44.8 196.0 58.8, 67.2 58.8 441.0};                                                                                                                                                                                                                            
Cov1p = {64.0 9.6 19.2, 9.6 36.0 14.4, 19.2 14.4 144.0};                                                                                                                                                                                                                               
Cov2p = {81.0 12.6 23.4, 12.6 49.0 18.2, 23.4 18.2 169.0};                                                                                                                                                                                                                               
Cov3p = {100.0 16.0 28.0, 16.0 64.0 22.4, 28.0 22.4 196.0};                                                                                                                                                                                                                              
Cov4p = {121.0 19.8 33.0, 19.8 81.0 27.0, 33.0 27.0 225.0};                                                                                                                                                                                                                              
Cov5p = {144.0 24.0 40.8, 24.0 100.0 34.0, 40.8 34.0 289.0};                                                                                                                                                                                                                             
Cov6p = {169.0 28.6 46.8, 28.6 121.0 39.6, 46.8 39.6 324.0};                                                                                                                                                                                                                             
Cov7p = {196.0 33.6 53.2, 33.6 144.0 45.6, 53.2 45.6 361.0};                                                                                                                                                                                                                             
Cov8p = {225.0 39.0 60.0, 39.0 169.0 52.0, 60.0 52.0 400.0};                                                                                                                                                                                                                             
Cov9p = {256.0 44.8 67.2, 44.8 196.0 58.8, 67.2 58.8 441.0};                                                                                                                                                                                                                             
Cov10p = {289.0 51.0 74.8, 51.0 225.0 66.0, 74.8 66.0 484.0}; 
 
 Patient-level correlation = 0.5      
Cov1t = {49.0 17.5 38.5, 17.5 25.0 27.5, 38.5 27.5 121.0};                                                                                                                                                                                                                                
Cov2t = {64.0 24.0 48.0, 24.0 36.0 36.0, 48.0 36.0 144.0};                                                                                                                                                                                                                               
Cov3t = {81.0 31.5 58.5, 31.5 49.0 45.5, 58.5 45.5 169.0};                                                                                                                                                                                                                               
Cov4t = {100.0 40.0 70.0, 40.0 64.0 56.0, 70.0 56.0 196.0};                                                                                                                                                                                                                              
Cov5t = {121.0 49.5 82.5, 49.5 81.0 67.5, 82.5 67.5 225.0};                                                                                                                                                                                                                              
Cov6t = {144.0 60.0 102.0, 60.0 100.0 85.0, 102.0 85.0 289.0};  
Cov7t = {169.0 71.5 117.0, 71.5 121.0 99.0, 117.0 99.0 324.0};                                                                                                                                                                                                                             
Cov8t = {196.0 84.0 133.0, 84.0 144.0 114.0, 133.0 114.0 361.0};                                                                                                                                                                                                                             
Cov9t = {225.0 97.5 150.0, 97.5 169.0 130.0, 150.0 130.0 400.0};                                                                                                                                                                                                                             
Cov10t = {256.0 112.0 168.0, 112.0 196.0 147.0, 168.0 147.0 441.0};  
Cov1p = {64.0 24.0 48.0, 24.0 36.0 36.0, 48.0 36.0 144.0};                                                                                                                                                                                                                               
Cov2p = {81.0 31.5 58.5, 31.5 49.0 45.5, 58.5 45.5 169.0};                                                                                                                                                                                                                               
Cov3p = {100.0 40.0 70.0, 40.0 64.0 56.0, 70.0 56.0 196.0};    
 Cov4p = {121.0 49.5 82.5, 49.5 81.0 67.5, 82.5 67.5 225.0};                                                                                                                                                                                                                              
Cov5p = {144.0 60.0 102.0, 60.0 100.0 85.0, 102.0 85.0 289.0};                                                                                                                                                                                                                             
Cov6p = {169.0 71.5 117.0, 71.5 121.0 99.0, 117.0 99.0 324.0};                                                                                                                                                                                                                             
Cov7p = {196.0 84.0 133.0, 84.0 144.0 114.0, 133.0 114.0 361.0};                                                                                                                                                                                                                             
Cov8p = {225.0 97.5 150.0, 97.5 169.0 130.0, 150.0 130.0 400.0};  
Cov9p = {256.0 112.0 168.0, 112.0 196.0 147.0, 168.0 147.0 441.0};                                                                                                                                                                                                                             
Cov10p = {289.0 127.5 187.0, 127.5 225.0 165.0, 187.0 165.0 484.0};       
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 Patient-level correlation = 0.8  
Cov1t = {49.0 28.0 61.6, 28.0 25.0 44.0, 61.6 44.0 121.0};                                                                                                                                                                                                                                
Cov2t = {64.0 38.4 76.8, 38.4 36.0 57.6, 76.8 57.6 144.0}; 
Cov3t = {81.0 50.4 93.6, 50.4 49.0 72.8, 93.6 72.8 169.0};                                                                                                                                                                                                                               
Cov4t = {100.0 64.0 112.0, 64.0 64.0 89.6, 112.0 89.6 196.0};                                                                                                                                                                                                                              
Cov5t = {121.0 79.2 132.0, 79.2 81.0 108.0, 132.0 108.0 225.0};   
Cov6t = {144.0 96.0 163.2, 96.0 100.0 136.0, 163.2 136.0 289.0};                                                                                                                                                                                                                             
Cov7t = {169.0 114.4 187.2, 114.4 121.0 158.4, 187.2 158.4 324.0};                                                                                                                                                                                                                             
Cov8t = {196.0 134.4 212.8, 134.4 144.0 182.4, 212.8 182.4 361.0};                                                                                                                                                                                                                             
Cov9t = {225.0 156.0 240.0, 156.0 169.0 208.0, 240.0 208.0 400.0};                                                                                                                                                                                                                             
Cov10t = {256.0 179.2 268.8, 179.2 196.0 235.2, 268.8 235.2 441.0};                                                                                                                                                                                                                            
Cov1p = {64.0 38.4 76.8, 38.4 36.0 57.6, 76.8 57.6 144.0};                                                                                                                                                                                                                               
Cov2p = {81.0 50.4 93.6, 50.4 49.0 72.8, 93.6 72.8 169.0};                                                                                                                                                                                                                               
Cov3p = {100.0 64.0 112.0, 64.0 64.0 89.6, 112.0 89.6 196.0};                                                                                                                                                                                                                                                                                                                                                                                                                                                         
Cov4p = {121.0 79.2 132.0, 79.2 81.0 108.0, 132.0 108.0 225.0};                                                                                                                                                                                                                              
Cov5p = {144.0 96.0 163.2, 96.0 100.0 136.0, 163.2 136.0 289.0};    
Cov6p = {169.0 114.4 187.2, 114.4 121.0 158.4, 187.2 158.4 324.0};                                                                                                                                                                                                                             
Cov7p = {196.0 134.4 212.8, 134.4 144.0 182.4, 212.8 182.4 361.0};                                                                                                                                                                                                                             
Cov8p = {225.0 156.0 240.0, 156.0 169.0 208.0, 240.0 208.0 400.0};  
Cov9p = {256.0 179.2 268.8, 179.2 196.0 235.2, 268.8 235.2 441.0};                                                                                                                                                                                                                             
Cov10p = {289.0 204.0 299.2, 204.0 225.0 264.0, 299.2 264.0 484.0};        
 
 Patient-level correlation = RA_corr: 0.67 (outcome 1 & outcome 2), 0.55 (outcome 1 & 
outcome 3), 0.38  
Cov1t = {49.0 23.3 42.3, 23.3 25.0 21.1, 42.3 21.1 121.0};                                                                                                                                                                                                                                
Cov2t = {64.0 32.0 52.7, 32.0 36.0 27.6, 52.7 27.6 144.0};                                                                                                                                                                                                                               
Cov3t = {81.0 42.0 64.2, 42.0 49.0 34.9, 64.2 34.9 169.0};                                                                                                                                                                                                                               
Cov4t = {100.0 53.3 76.9, 53.3 64.0 43.0, 76.9 43.0 196.0};                                                                                                                                                                                                                              
Cov5t = {121.0 66.0 90.6, 66.0 81.0 51.8, 90.6 51.8 225.0};                                                                                                                                                                                                                              
Cov6t = {144.0 80.0 112.0, 80.0 100.0 65.3, 112.0 65.3 289.0};                                                                                                                                                                                                                             
Cov7t = {169.0 95.3 128.5, 95.3 121.0 76.0, 128.5 76.0 324.0};                                                                                                                                                                                                                             
Cov8t = {196.0 112.0 146.0, 112.0 144.0 87.5, 146.0 87.5 361.0};                                                                                                                                                                                                                             
Cov9t = {225.0 130.0 164.7, 130.0 169.0 99.8, 164.7 99.8 400.0};                                                                                                                                                                                                                             
Cov10t = {256.0 149.3 184.5, 149.3 196.0 112.9, 184.5 112.9 441.0};        
Cov1p = {64.0 32.0 52.7, 32.0 36.0 27.6, 52.7 27.6 144.0};                                                                                                                                                                                                                               
Cov2p = {81.0 42.0 64.2, 42.0 49.0 34.9, 64.2 34.9 169.0};                                                                                                                                                                                                                               
Cov3p = {100.0 53.3 76.9, 53.3 64.0 43.0, 76.9 43.0 196.0};                                                                                                                                                                                                                              
Cov4p = {121.0 66.0 90.6, 66.0 81.0 51.8, 90.6 51.8 225.0};                                                                                                                                                                                                                              
Cov5p = {144.0 80.0 112.0, 80.0 100.0 65.3, 112.0 65.3 289.0};                                                                                                                                                                                                                             
Cov6p = {169.0 95.3 128.5, 95.3 121.0 76.0, 128.5 76.0 324.0};                                                                                                                                                                                                                             
Cov7p = {196.0 112.0 146.0, 112.0 144.0 87.5, 146.0 87.5 361.0};                                                                                                                                                                                                                             
Cov8p = {225.0 130.0 164.7, 130.0 169.0 99.8, 164.7 99.8 400.0};                                                                                                                                                                                                                             
Cov9p = {256.0 149.3 184.5, 149.3 196.0 112.9, 184.5 112.9 441.0};                                                                                                                                                                                                                             
Cov10p = {289.0 169.9 205.3, 169.9 225.0 126.7, 205.3 126.7 484.0};      
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 B.2 First Stage IPD meta-analysis         
   SAS PROC MIXED 
proc mixed cl method=reml data=work.Datasim2;                                                                                                                                                                                                                    
by Simulation Study;                                                                                                                                                                                                                                             
class Outcome id Treated;                                                                                                                                                                                                                                        
  ods listing close;                                                                                                                                                                                                                                             
  ods output solutionf=Fixed;                                                                                                                                                                                                                                    
model Y = Outcome1 Outcome2 Outcome3 Treated*Outcome1 Treated*Outcome2 
Treated*Outcome3/ noint s cl covb corrb;                                                                                                                                                  
repeated Outcome/ type=un subject=id;                                                                                                                                                                                                                            
run;                  
 
B.3 Second Stage IPD meta-analysis 
 
STATA 
Univariate fixed-effects meta-analysis 
mvmeta y S, var(y1) fixed 
mvmeta y S, var(y2) fixed 
mvmeta y S, var(y3) fixed                                                                                                                                                                                                                                                                                                                                                                                                                                       
Multivariate fixed-effects meta-analysis 
mvmeta y S, fixed                       
 
                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                    
 
                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                        
                                                                                                                                                                                                                          
162 
 
APPENDIX C 
MULTIVARIATE META-ANALYSIS FIXED-EFFECTS SIMULATION 
RESULTS ORB SCENARIOS 
 
In the following tables 1 refers to the outcome 1 (TJC), 2 refers to the outcome 2 (SJC) 
and finally 3 refers to the outcome 3 (pain). 
 
 
163 
 
 
Table C.1 Complete case 
Patient  
level 
correlation 
No. 
Studies 
Method 
Bias SEsim Coverage Power MSE Borrowing of Strength 
μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 
0 
 
5 
UFMA/MFMA 
0.044 -0.0001 -0.024 0.852 0.666 1.213 94.0% 96.2% 94.4% 100.0% 99.1% 99.9% 0.729 0.444 1.473 
 10 0.015 -0.003 0.018 0.756 0.625 1.041 93.8% 93.2% 94.5% 100.0% 99.7% 99.9% 0.572 0.391 1.083 
 
0.2 
 
5 
UFMA** 0.044 0.005 -0.014 0.852 0.666 1.222 94.0%  96.2% 93.9% 100.0% 99.3% 99.6% 0.729 0.444 1.494 MFMA vs. UFMA 
MFMA*** 0.038 0.002 -0.017 0.845 0.660 1.212 93.2% 95.8% 93.6% 100.0% 99.4% 99.7% 0.715 0.435 1.469 1.8% 1.9% 1.7% 
10 
UFMA 0.015 0.005 0.018 0.756 0.625 1.044 93.8% 93.2% 94.0% 100.0% 99.7% 100.0% 0.572 0.390 1.091 MFMA vs. UFMA  
MFMA 0.019 -0.005 0.022 0.746 0.616 1.032 93.4% 92.1% 93.0% 100.0% 99.7% 100.0% 0.557 0.379 1.066 2.6% 2.8% 2.3% 
 
0.5 
5 
UFMA 0.044 0.013 0.007 0.852 0.667 1.223 94.0% 96.0% 94.0% 100.0% 99.3% 99.8% 0.729 0.444 1.496 MFMA vs. UFMA 
MFMA 0.037 0.011 0.001 0.844 0.660 1.211 93.3% 95.4% 93.3% 100.0% 99.5% 99.8% 0.714 0.435 1.467 2.0% 2.1% 1.9% 
10 
UFMA 0.015 0.014 0.021 0.756 0.624 1.044 93.8% 94.6% 93.6% 100.0% 99.9% 100.0% 0.572 0.390 1.091 MFMA vs. UFMA 
MFMA 0.018 0.0001 0.024 0.745 0.615 1.030 93.4% 94.0% 93.2% 100.0% 99.9% 100.0% 0.556 0.378 1.062 2.8% 3.1% 2.6% 
0.8 
 
5 
UFMA 0.044 0.022 0.033 0.852 0.667 1.224 94.0% 95.3% 93.6% 100.0% 99.5% 99.8% 0.729 0.446 1.499 MFMA vs. UFMA 
MFMA 0.035 0.020 0.023 0.840 0.657 1.206 93.1% 94.0% 93.0% 100.0% 99.5% 99.7% 0.707 0.432 1.456 2.8% 2.9% 2.9% 
10 
UFMA 0.015 0.016 0.022 0.756 0.624 1.044 93.8% 94.8% 93.9% 100.0% 99.8% 100.0% 0.572 0.390 1.090 MFMA vs. UFMA 
MFMA 0.015 0.005 0.023 0.741 0.611 1.023 92.9% 93.3% 93.1% 100.0% 99.8% 100.0% 0.550 0.373 1.048 3.9% 4.3% 3.9% 
RA_corr* 
5 
UFMA 0.044 0.018 0.010 0.852 0.667 1.223 94.0% 95.8% 93.8% 100.0% 99.5% 99.8% 0.729 0.445 1.495 MFMA vs. UFMA  
MFMA 0.036 0.016 0.005 0.844 0.660 1.211 93.3% 95.3% 93.8% 100.0% 99.6% 99.8% 0.713 0.436 1.468 2.0% 2.0% 1.8% 
10 
UFMA 0.015 0.016 0.022 0.756 0.624 1.044 93.8% 94.4% 93.8% 100.0% 99.9% 100.0% 0.572 0.390 1.090 MFMA vs. UFMA 10 
MFMA 0.017 0.003 0.029 0.745 0.615 1.031 93.1% 93.8% 93.0% 100.0% 99.9% 100.0% 0.556 0.378 1.063 2.9% 3.0% 2.5% 
RA_corr: TJC&SJC: 0.67 TJC&Pain: 0.55 SJC&Pain: 0.38     **UFMA: Univariate fixed-effects meta-analysis     ***MFMA: Multivariate fixed-effects meta-analysis 
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Table C.2 ORB: all studies are excluded that show benefit of alternative treatment irrespective of significance  
Patient  
level 
correlation 
No.  
Studies 
Method 
Bias SEsim Coverage Power MSE Borrowing of Strength 
μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 
0 
 
5 
UFMA/MFMA 
0.008 -0.088 -0.136 0.856 0.675 1.225 94.7% 97.2% 95.4% 100.0% 99.9% 100.0% 0.732 0.464 1.520 
 10 -0.114 -0.273 -0.254 0.765 0.649 1.061 95.3% 94.1% 95.2% 100.0% 100.0% 100.0% 0.598 0.495 1.190 
0.2 
 
5 
UFMA** 0.008 -0.086 -0.139 0.856 0.676 1.236 94.7% 97.1% 94.9% 100.0% 99.8% 100.0% 0.732 0.464 1.547 MFMA vs. UFMA 
MFMA*** 0.002 -0.084 -0.134 0.848 0.669 1.225 93.9% 96.9% 94.8% 100.0% 99.8% 100.0% 0.719 0.455 1.518 1.8% 2.0% 1.8% 
10 
UFMA -0.114 -0.262 -0.258 0.765 0.648 1.065 95.3% 94.5% 95.0% 100.0% 99.9% 100.0% 0.598 0.489 1.201 MFMA vs. UFMA 
MFMA -0.111 -0.256 -0.248 0.755 0.638 1.052 95.0% 93.8% 94.6% 100.0% 99.9% 100.0% 0.583 0.473 1.169 2.5% 3.0% 2.4% 
0.5 
 
5 
UFMA 0.008 -0.077 -0.113 0.856 0.676 1.236 94.7% 96.7% 95.3% 100.0% 99.7% 99.9% 0.732 0.463 1.540 MFMA vs. UFMA 
MFMA 0.009 -0.054 -0.086 0.847 0.666 1.220 93.6% 96.4% 94.8% 100.0% 99.7% 99.9% 0.717 0.447 1.496 2.1% 2.8% 2.4% 
10 
UFMA -0.114 -0.260 -0.258 0.765 0.648 1.065 95.3% 94.1% 94.6% 100.0% 99.9% 100.0% 0.598 0.487 1.201 MFMA vs. UFMA 
MFMA -0.094 -0.204 -0.203 0.753 0.632 1.046 94.8% 94.1% 94.5% 100.0% 99.9% 100.0% 0.575 0.441 1.135 3.1% 4.8% 3.5% 
0.8 
 
5 
UFMA 0.008 -0.065 -0.084 0.856 0.677 1.237 94.7% 96.2% 95.7% 100.0% 99.7% 99.9% 0.732 0.462 1.537 MFMA vs. UFMA 
MFMA 0.011 -0.019 -0.037 0.843 0.661 1.212 93.9% 95.5% 94.7% 100.0% 99.6% 99.7% 0.710 0.437 1.470 3.0% 4.3% 3.8% 
10 
UFMA -0.114 -0.263 -0.275 0.765 0.648 1.066 95.3% 95.2% 95.4% 100.0% 99.9% 100.0% 0.598 0.489 1.212 MFMA vs. UFMA 
MFMA -0.085 -0.136 -0.162 0.748 0.622 1.035 94.3% 95.1% 94.3% 100.0% 99.9% 100.0% 0.567 0.405 1.098 4.3% 7.6% 5.6% 
RA_corr* 
5 
UFMA 0.008 -0.066 -0.097 0.856 0.676 1.234 94.7% 96.7% 95.1% 100.0% 99.7% 99.9% 0.732 0.461 1.532 MFMA vs. UFMA 
MFMA 0.012 -0.036 -0.077 0.846 0.666 1.220 93.9% 96.6% 94.9% 100.0% 99.7% 99.9% 0.716 0.444 1.493 2.2% 2.9% 2.2% 
10 
UFMA -0.114 -0.264 -0.269 0.765 0.648 1.066 95.3% 94.7% 95.0% 100.0% 99.9% 100.0% 0.598 0.490 1.208 MFMA vs. UFMA 
MFMA -0.092 -0.184 -0.210 0.752 0.630 1.048 94.8% 95.0% 94.4% 100.0% 99.9% 100.0% 0.574 0.431 1.142 3.3% 5.3% 3.3% 
*RA_corr: TJC&SJC: 0.67 TJC&Pain: 0.55 SJC&Pain: 0.38     **UFMA: Univariate fixed-effects meta-analysis     ***MFMA: Multivariate fixed-effects meta-analysis 
 
165 
 
 
Table C.3 ORB: 15/20/30% data suppressed from TJC/SJC/Pain respectively if result non-significant  
Patient  
level 
correlation 
No.  
Studies 
Method 
Bias SEsim Coverage Power MSE Borrowing of Strength 
μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 
0 
5 
UFMA/MFMA 
-0.092 -0.219 -0.700 0.882 0.727 1.403 93.3% 94.5% 93.1% 100.0% 99.2% 99.9% 0.786 0.577 2.457 
 10 -0.240 -0.001 -0.005 0.800 0.676 1.169 90.3% 93.0% 94.7% 100.0% 97.6% 98.8% 0.698 0.457 1.366 
0.2 
5 
UFMA** -0.092 -0.208 -0.546 0.882 0.729 1.373 93.3% 95.0% 92.3% 100.0% 99.3% 99.7% 0.786 0.574 2.182 MFMA vs. UFMA 
MFMA*** -0.099 -0.207 -0.531 0.874 0.720 1.356 93.1% 94.3% 92.5% 100.0% 99.4% 99.7% 0.774 0.561 2.122 1.7% 2.1% 2.1% 
10 
UFMA -0.240 -0.422 -0.816 0.800 0.740 1.226 90.3% 85.2% 85.1% 100.0% 99.7% 100.0% 0.698 0.725 2.168 MFMA vs. UFMA 
MFMA -0.235 -0.426 -0.776 0.791 0.728 1.206 90.3% 84.4% 84.1% 100.0% 99.7% 99.8% 0.681 0.712 2.057 2.3% 2.9% 2.8% 
0.5 
5 
UFMA -0.092 -0.204 -0.526 0.882 0.727 1.364 93.3% 94.7% 92.1% 100.0% 99.3% 99.9% 0.786 0.571 2.138 MFMA vs. UFMA 
MFMA -0.093 -0.172 -0.421 0.871 0.709 1.321 93.1% 94.3% 84.0% 100.0% 99.4% 99.8% 0.767 0.532 1.922 2.3% 4.0% 4.8% 
10 
UFMA -0.240 -0.399 -0.825 1.333 0.733 1.224 90.3% 86.4% 92.7% 100.0% 99.8% 99.9% 0.698 0.696 2.179 MFMA vs. UFMA 
MFMA -0.227 -0.361 -0.659 1.156 0.705 1.175 90.2% 86.4% 86.2% 100.0% 99.8% 99.7% 0.671 0.627 1.814 3.0% 5.5% 6.1% 
0.8 
5 
UFMA -0.092 -0.202 -0.490 0.882 0.730 1.368 93.3% 93.3% 93.0% 100.0% 99.5% 99.8% 0.786 0.573 2.112 MFMA vs. UFMA 
MFMA -0.093 -0.120 -0.270 0.867 0.692 1.279 92.7% 93.8% 93.7% 100.0% 99.4% 99.7% 0.761 0.494 1.710 3.0% 7.2% 9.1% 
10 
UFMA -0.240 -0.393 -0.855 0.800 0.733 1.230 90.3% 87.4% 84.4% 100.0% 99.7% 100.0% 0.698 0.691 2.243 MFMA vs. UFMA 
MFMA -0.225 -0.272 -0.499 0.783 0.673 1.125 90.3% 87.2% 87.3% 100.0% 99.5% 100.0% 0.663 0.526 1.516 4.1% 10.1% 11.5% 
RA_corr* 
5 
UFMA -0.092 -0.202 -0.508 0.882 0.728 1.369 93.3% 93.9% 92.1% 100.0% 99.5% 99.8% 0.786 0.570 2.131 MFMA vs. UFMA 
MFMA -0.091 -0.143 -0.401 0.869 0.703 1.327 93.0% 94.3% 92.7% 100.0% 99.4% 99.6% 0.764 0.515 1.923 2.5% 4.9% 4.6% 
10 
UFMA -0.240 -0.387 -0.816 0.800 0.728 1.218 90.3% 86.6% 84.6% 100.0% 99.7% 100.0% 0.698 0.680 2.149 MFMA vs. UFMA 
MFMA -0.225 -0.319 -0.644 0.786 0.692 1.172 89.8% 86.7% 86.6% 100.0% 99.6% 99.8% 0.668 0.580 1.788 3.3% 6.6% 5.8% 
*RA_corr: TJC&SJC: 0.67 TJC&Pain: 0.55 SJC&Pain: 0.38     **UFMA: Univariate fixed-effects meta-analysis     ***MFMA: Multivariate fixed-effects meta-analysis 
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Table C.4 ORB: all studies are excluded that have non-significant results  
Patient 
level 
correlation 
No.  
Studies 
Method 
Bias SEsim Coverage Power MSE Borrowing of Strength 
μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 
0 
 
5 
UFMA/MFMA 
-0.848 -1.172 -1.775 1.045 0.983 1.680 91.7% 86.0% 89.2% 100.0% 100.0% 100.0% 1.810 2.340 5.974 
 10 -1.694 -2.183 -2.764 1.064 1.189 1.647 68.2% 52.6% 61.7% 100.0% 99.8% 100.0% 4.002 6.180 10.351 
 
0.2 
 
5 
UFMA** -0.848 -1.159 -1.786 1.045 0.984 1.696 91.7% 85.9% 88.2% 100.0% 100.0% 100.0% 1.810 2.311 6.066 MFMA vs. UFMA 
MFMA*** -0.838 -1.139 -1.753 1.036 0.969 1.673 91.9% 85.9% 87.1% 100.0% 100.0% 98.7% 1.775 2.235 5.874 1.6% 3.0% 2.4% 
10 
UFMA -1.694 -2.169 -2.790 1.064 1.199 1.657 68.2% 52.4% 61.2% 100.0% 100.0% 100.0% 4.002 6.141 10.529 MFMA vs. UFMA 
MFMA -1.686 -2.136 -2.770 1.055 1.178 1.636 68.2% 52.2% 60.8% 100.0% 99.7% 100.0% 3.957 5.951 10.350 1.7% 3.3% 2.3% 
 
0.5 
 
5 
UFMA -0.848 -1.128 -1.795 1.045 0.987 1.689 91.7% 84.9% 88.2% 100.0% 99.9% 100.0% 1.810 2.246 6.077 MFMA vs. UFMA 
MFMA -0.802 -1.012 -1.612 1.018 0.923 1.602 91.7% 85.7% 88.7% 100.0% 99.4% 100.0% 1.679 1.877 5.167 4.4% 11.4% 8.8% 
10 
UFMA -1.694 -2.149 -2.770 1.064 1.185 1.644 68.2% 53.1% 60.0% 100.0% 100.0% 99.9% 4.002 6.024 10.377 MFMA vs. UFMA 
MFMA -1.645 -1.971 -2.635 1.031 1.088 1.556 68.1% 52.7% 60.9% 100.0% 99.7% 99.8% 3.767 5.070 9.366 5.8% 14.7% 9.6% 
 
0.8 
5 
UFMA -0.848 -1.129 -1.797 1.045 0.990 1.708 91.7% 85.7% 89.8% 100.0% 100.0% 100.0% 1.810 2.254 6.145 MFMA vs. UFMA 
MFMA -0.797 -0.838 -1.413 1.011 0.850 1.523 91.9% 88.8% 90.6% 100.0% 99.8% 99.9% 1.657 1.424 4.316 5.4% 23.1% 17.2% 
10 
UFMA -1.694 -2.142 -2.811 1.064 1.177 1.656 68.2% 54.4% 60.8% 100.0% 99.9% 100.0% 4.002 5.976 10.646 MFMA vs. UFMA 
MFMA -1.608 -1.679 -2.458 1.012 0.949 1.465 68.4% 56.5% 63.0% 100.0% 100.0% 100.0% 3.609 3.719 8.190 8.6% 31.8% 19.4% 
RA_corr* 
5 
UFMA -0.848 -1.137 -1.780 1.045 0.989 1.701 91.7% 85.2% 88.3% 100.0% 99.9% 100.0% 1.810 2.272 6.063 MFMA vs. UFMA 
MFMA -0.793 -0.950 -1.582 1.011 0.902 1.613 92.2% 85.7% 87.3% 100.0% 96.9% 98.1% 1.651 1.715 5.106 5.4% 15.2% 8.8% 
10 
UFMA -1.694 -2.115 -2.751 1.064 1.168 1.626 68.2% 54.2% 60.7% 100.0% 99.8% 100.0% 4.002 5.836 10.215 MFMA vs. UFMA 
MFMA -1.631 -1.847 -2.596 1.019 1.037 1.542 68.1% 55.4% 60.9% 100.0% 99.4% 99.7% 3.697 4.488 9.118 7.7% 19.5% 9.4% 
*RA_corr: TJC&SJC: 0.67 TJC&Pain: 0.55 SJC&Pain: 0.38     **UFMA: Univariate fixed-effects meta-analysis     ***MFMA: Multivariate fixed-effects meta-analysis 
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Table C.5 ORB: all studies are excluded that have non-significant results and show benefit of alternative treatment  
Patient  
level  
correlation 
No.  
Studies 
Method 
Bias SEsim Coverage Power MSE Borrowing of Strength 
μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 
0 
5 
UFMA/MFMA 
-0.848 -1.172 -1.775 1.045 0.983 1.680 91.7% 86.0% 89.2% 100.0% 100.0% 100.0% 1.810 2.340 5.974   
  
  10 -1.694 -2.185 -2.770 1.064 1.189 1.648 68.2% 52.6% 61.7% 100.0% 99.8% 100.0% 4.002 6.189 10.389 
0.2 
5 
UFMA** -0.848 -1.160 -1.786 1.045 0.985 1.696 91.7% 85.9% 88.2% 100.0% 100.0% 100.0% 1.810 2.315 6.066 MFMA vs. UFMA 
MFMA*** -0.838 -1.140 -1.754 1.036 0.969 1.673 91.9% 85.9% 88.2% 100.0% 100.0% 100.0% 1.775 2.239 5.875 1.6% 3.0% 2.4% 
10 
UFMA -1.694 -2.182 -2.800 1.064 1.200 1.657 68.2% 52.2% 61.1% 100.0% 100.0% 100.0% 4.002 6.200 10.586 MFMA vs. UFMA 
MFMA -1.688 -2.149 -2.781 1.055 1.179 1.637 68.1% 51.8% 60.7% 100.0% 99.7% 100.0% 3.962 6.008 10.414 1.7% 3.3% 2.3% 
0.5 
5 
UFMA -0.848 -1.130 -1.795 1.045 0.988 1.689 91.7% 85.0% 88.2% 100.0% 100.0% 100.0% 1.810 2.252 6.077 MFMA vs. UFMA 
MFMA -0.803 -1.015 -1.613 1.018 0.923 1.602 91.7% 85.7% 88.7% 100.0% 99.5% 100.0% 1.681 1.882 5.168 4.4% 11.4% 8.8% 
10 
UFMA -1.694 -2.163 -2.795 1.064 1.186 1.645 68.2% 51.3% 59.6% 100.0% 100.0% 100.0% 4.002 6.084 10.520 MFMA vs. UFMA 
MFMA -1.652 -1.986 -2.663 1.031 1.089 1.558 67.8% 52.1% 62.3% 100.0% 99.7% 99.9% 3.790 5.131 9.516 5.8% 14.7% 9.6% 
0.8 
5 
UFMA -0.848 -1.129 -1.797 1.045 0.990 1.708 91.7% 85.7% 89.8% 100.0% 100.0% 100.0% 1.810 2.254 6.145 MFMA vs. UFMA 
MFMA -0.797 -0.838 -1.413 1.011 0.850 1.523 91.9% 88.8% 90.6% 100.0% 99.8% 99.9% 1.657 1.424 4.316 5.4% 23.1% 17.2% 
10 
UFMA -1.694 -2.152 -2.816 1.064 1.178 1.657 68.2% 54.3% 60.8% 100.0% 100.0% 100.0% 4.002 6.019 10.677 MFMA vs. UFMA 
MFMA -1.614 -1.687 -2.469 1.012 0.950 1.466 68.2% 56.3% 62.9% 100.0% 100.0% 100.0% 3.631 3.748 8.247 8.6% 31.7% 19.3% 
RA_corr* 
5 
UFMA -0.848 -1.141 -1.780 1.045 0.990 1.701 91.7% 85.3% 88.3% 100.0% 100.0% 100.0% 1.810 2.281 6.063 MFMA vs. UFMA 
MFMA -0.794 -0.953 -1.583 1.011 0.902 1.613 92.2% 88.3% 88.6% 100.0% 99.8% 99.6% 1.654 1.722 5.109 5.4% 15.2% 8.8% 
10 
UFMA -1.694 -2.129 -2.770 1.064 1.169 1.627 68.2% 54.0% 60.6% 100.0% 100.0% 100.0% 4.002 5.898 10.320 MFMA vs. UFMA 
MFMA -1.640 -1.861 -2.616 1.019 1.038 1.543 67.7% 54.8% 60.8% 100.0% 99.4% 99.7% 3.730 4.539 9.226 7.7% 19.5% 9.4% 
*RA_corr: TJC&SJC: 0.67 TJC&Pain: 0.55 SJC&Pain: 0.38     **UFMA: Univariate fixed-effects meta-analysis     ***MFMA: Multivariate fixed-effects meta-analysis 
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APPENDIX D 
SAS & STATA SCRIPTS FOR THE SIMULATION STUDY MISSING DATA 
AT PATIENT LEVEL SCENARIOS 
D.1 Simulation of IPD with Missing Data 
 
MISSING COMPLETELY AT RANDOM  
Number of studies equal to 5 
 
 Scenario i: 20% MCAR in the IPD in outcome 1 
data work.T1b; set work.T1; do simulation=1 to 250; if id<=6 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                             
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T2b; set work.T2; do simulation=1 to 250; if id>=14 and id<22 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                             
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T3b; set work.T3; do simulation=1 to 250; if id>=41 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                            
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T4b; set work.T4; do simulation=1 to 250; if id<=12 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                            
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T5b; set work.T5; do simulation=1 to 250; if id>=24 and id<38 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                            
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P1b; set work.P1; do simulation=1 to 250; if id<=36 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                            
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P2b; set work.P2; do simulation=1 to 250; if id>=54 and id<62 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                            
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P3b; set work.P3; do simulation=1 to 250; if id>=91 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                            
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P4b; set work.P4; do simulation=1 to 250; if id<=72 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                          
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P5b; set work.P5; do simulation=1 to 250; if id>=94 and id<108 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                         
end; drop simulation; run;                 
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MISSING COMPLETELY AT RANDOM  
Number of studies equal to 10 
 
 Scenario i: 20% MCAR in the IPD for outcome 1 
data work.T1b; set work.T1; do simulation=1 to 250; if id<=2 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                           
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T2b; set work.T2; do simulation=1 to 250; if id>=9 and id<13 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                        
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T3b; set work.T3; do simulation=1 to 250; if id>=25 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                            
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T4b; set work.T4; do simulation=1 to 250; if id<=8 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                             
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T5b; set work.T5; do simulation=1 to 250; if id>=17 and id<27 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                            
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T6b; set work.T6; do simulation=1 to 250; if id>=49 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                            
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T7b; set work.T7; do simulation=1 to 250; if id<=14 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                            
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T8b; set work.T8; do simulation=1 to 250; if id>=20 and id<36 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                            
end; drop simulation; run;    
data work.T9b; set work.T9; do simulation=1 to 250; if id>=73 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                            
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T10b; set work.T10; do simulation=1 to 250; if id<=20 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                          
end; drop simulation; run;     
data work.P1b; set work.P1; do simulation=1 to 250; if id<=12 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                     
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P2b; set work.P2; do simulation=1 to 250; if id>=16 and id<20 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                            
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P3b; set work.P3; do simulation=1 to 250; if id>=55 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                            
end; drop simulation; run;         
data work.P4b; set work.P4; do simulation=1 to 250; if id<=48 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                            
end; drop simulation; run;        
data work.P5b; set work.P5; do simulation=1 to 250; if id>=67 and id<77 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                            
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P6b; set work.P6; do simulation=1 to 250; if id>=109 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                          
end; drop simulation; run;    
data work.P7b; set work.P7; do simulation=1 to 250; if id<=84 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                         
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P8b; set work.P8; do simulation=1 to 250; if id>=100 and id<116 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                        
end; drop simulation; run;     
data work.P9b; set work.P9; do simulation=1 to 250; if id>=163 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                       
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P10b; set work.P10; do simulation=1 to 250; if id<=120 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                     
end; drop simulation; run;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
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MISSING COMPLETELY AT RANDOM  
Number of studies equal to 5 
 
 Scenario ii: 40% MCAR in the IPD for outcome 1 
data work.T1b; set work.T1; do simulation=1 to 250; if id<=12 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                       
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T2b; set work.T2; do simulation=1 to 250; if id>=12 and id<28 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                      
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T3b; set work.T3; do simulation=1 to 250; if id>=31 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                      
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T4b; set work.T4; do simulation=1 to 250; if id<=24 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                      
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T5b; set work.T5; do simulation=1 to 250; if id>=21 and id<49 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                      
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P1b; set work.P1; do simulation=1 to 250; if id<=42 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                      
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P2b; set work.P2; do simulation=1 to 250; if id>=52 and id<68 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                      
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P3b; set work.P3; do simulation=1 to 250; if id>=81 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                      
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P4b; set work.P4; do simulation=1 to 250; if id<=84 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                     
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P5b; set work.P5; do simulation=1 to 250; if id>=91 and id<119 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                    
end; drop simulation; run;     
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MISSING COMPLETELY AT RANDOM  
Number of studies equal to 10 
 
 Scenario ii: 40% MCAR in the IPD for outcome 1 
data work.T1b; set work.T1; do simulation=1 to 250; if id<=4 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                          
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T2b; set work.T2; do simulation=1 to 250; if id>=6 and id<14 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                        
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T3b; set work.T3; do simulation=1 to 250; if id>=19 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                       
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T4b; set work.T4; do simulation=1 to 250; if id>=25 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                      
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T5b; set work.T5; do simulation=1 to 250; if id>=15 and id<35 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                      
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T6b; set work.T6; do simulation=1 to 250; if id<=24 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                      
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T7b; set work.T7; do simulation=1 to 250; if id>=21 and id<49 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                      
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T8b; set work.T8; do simulation=1 to 250; if id<=32 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                      
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T9b; set work.T9; do simulation=1 to 250; if id>=55 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                      
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T10b; set work.T10; do simulation=1 to 250; if id<=40 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                    
end; drop simulation; run;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
data work.P1b; set work.P1; do simulation=1 to 250; if id<=14 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                      
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P2b; set work.P2; do simulation=1 to 250; if id>=26 and id<34 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                      
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P3b; set work.P3; do simulation=1 to 250; if id>=49 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                      
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P4b; set work.P4; do simulation=1 to 250; if id>=65 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                      
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P5b; set work.P5; do simulation=1 to 250; if id>=65 and id<77 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                      
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P6b; set work.P6; do simulation=1 to 250; if id<=84 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                    
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P7b; set work.P7; do simulation=1 to 250; if id>=91 and id<119 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                    
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P8b; set work.P8; do simulation=1 to 250; if id<=112 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                  
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P9b; set work.P9; do simulation=1 to 250; if id>=145 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                  
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P10b; set work.P10; do simulation=1 to 250; if id<=140 then x1=.;                                                                                                                                                                                                                                                                                                                                                                                                
end; drop simulation; run;                 
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MISSING COMPLETELY AT RANDOM  
Number of studies equal to 5 
 
 Scenario iii: 20% MCAR in the IPD for all outcomes 
data work.T1b; set work.T1; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=6 then x1=.; if id>=11 and id<17 then x2=.; if id>=21 and id<27 then x3=.;                                                                                                                                                                                
end; drop simulation; run;            
data work.T2b; set work.T2; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=8 then x1=.; if id>=14 and id<22 then x2=.; if id>=27 and id<35 then x3=.;                                                                                                                                                                                
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T3b; set work.T3; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=10 then x1=.; if id>=17 and id<27 then x2=.; if id>=33 and id<43 then x3=.;                                                                                                                                                                               
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T4b; set work.T4; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=12 then x1=.; if id>=20 and id<32 then x2=.; if id>=40 and id<52 then x3=.;                                                                                                                                                                               
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T5b; set work.T5; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=14 then x1=.; if id>=24 and id<38 then x2=.; if id>=47 and id<61 then x3=.;                                                                                                                                                                               
end; drop simulation; run;     
 data work.P1b; set work.P1; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=36 then x1=.; if id>=41 and id<47 then x2=.; if id>=51 and id<57 then x3=.;                                                                                                                                                                               
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P2b; set work.P2; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=48 then x1=.; if id>=54 and id<62 then x2=.; if id>=67 and id<75 then x3=.;                                                                                                                                                                               
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P3b; set work.P3; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=60 then x1=.; if id>=67 and id<77 then x2=.; if id>=83 and id<93 then x3=.;                                                                                                                                                                               
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P4b; set work.P4; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=72 then x1=.; if id>=80 and id<92 then x2=.; if id>=100 and id<112 then x3=.;                                                                                                                                                                             
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P5b; set work.P5; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=84 then x1=.; if id>=94 and id<108 then x2=.; if id>=117 and id<131 then x3=.;                                                                                                                                                                            
end; drop simulation; run;          
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MISSING COMPLETELY AT RANDOM  
Number of studies equal to 10 
 
 Scenario iii: 20% MCAR in the IPD for all outcomes  
data work.T1b; set work.T1; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=2 then x1=.; if id=5 and id=6 then x2=.; if id>=9 then x3=.;                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T2b; set work.T2; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=4 then x1=.; if id>=9 and id<13 then x2=.; if id>=17 then x3=.;                                                                                                                                                                                           
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T3b; set work.T3; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=6 then x1=.; if id>=11 and id<17 then x2=.; if id>=21 and id<27 then x3=.;                                                                                                                                                                                
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T4b; set work.T4; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=8 then x1=.; if id>=14 and id<22 then x2=.; if id>=27 and id<35 then x3=.;                                                                                                                                                                                
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T5b; set work.T5; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=10 then x1=.; if id>=17 and id<27 then x2=.; if id>=33 and id<43 then x3=.;                                                                                                                                                                              
end; drop simulation; run;            
data work.T6b; set work.T6; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=12 then x1=.; if id>=20 and id<32 then x2=.; if id>=40 and id<52 then x3=.;                                                                                                                                                                               
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T7b; set work.T7; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=14 then x1=.; if id>=24 and id<38 then x2=.; if id>=47 and id<61 then x3=.;                                                                                                                                                                               
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T8b; set work.T8; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=16 then x1=.; if id>=20 and id<36 then x2=.; if id>=40 and id<56 then x3=.;                                                                                                                                                                               
end; drop simulation; run;         
data work.T9b; set work.T9; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=18 then x1=.; if id>=27 and id<45 then x2=.; if id>=45 and id<63 then x3=.;                                                                                                                                                                               
end; drop simulation; run;  
data work.T10b; set work.T10; do simulation=1 to 250;                                                                                                                                                                                                            
if id<=20 then x1=.; if id>=25 and id<45 then x2=.; if id>=45 and id<65 then x3=.;                                                                                                                                                                               
end; drop simulation; run;      
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MISSING COMPLETELY AT RANDOM  
Number of studies equal to 5 
 
 Scenario iv: 40% MCAR in the IPD for all outcomes 
data work.T1b; set work.T1; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=12 then x1=.; if id>=9 and id<21 then x2=.; if id>=19 then x3=.;                                                                                                                                                                                          
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T2b; set work.T2; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=16 then x1=.; if id>=12 and id<28 then x2=.; if id>=25 then x3=.;                                                                                                                                                                                         
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T3b; set work.T3; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=20 then x1=.; if id>=15 and id<35 then x2=.; if id>=31 then x3=.;                                                                                                                                                                                         
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T4b; set work.T4; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=24 then x1=.; if id>=18 and id<42 then x2=.; if id>=37 then x3=.;                                                                                                                                                                                         
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T5b; set work.T5; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=28 then x1=.; if id>=21 and id<49 then x2=.; if id>=43 then x3=.;                                                                                                                                                                                         
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P1b; set work.P1; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=42 then x1=.; if id>=39 and id<51 then x2=.; if id>=49 then x3=.;                                                                                                                                                                                         
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P2b; set work.P2; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=56 then x1=.; if id>=52 and id<68 then x2=.; if id>=65 then x3=.;                                                                                                                                                                                         
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P3b; set work.P3; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=70 then x1=.; if id>=65 and id<77 then x2=.; if id>=81 then x3=.;                                                                                                                                                                                         
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P4b; set work.P4; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=84 then x1=.; if id>=78 and id<102 then x2=.; if id>=97 then x3=.;                                                                                                                                                                                        
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P5b; set work.P5; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=98 then x1=.; if id>=91 and id<119 then x2=.; if id>=113 then x3=.;                                                                                                                                                                                       
end; drop simulation; run;    
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MISSING COMPLETELY AT RANDOM  
Number of studies equal to 10 
 
 Scenario iv: 40% MCAR in the IPD for all outcomes 
data work.P1b; set work.P1; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=14 then x1=.; if id>=13 and id<17 then x2=.; if id>=17 then x3=.;                                                                                                                                                                                         
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P2b; set work.P2; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=28 then x1=.; if id>=26 and id<34 then x2=.; if id>=33 then x3=.;                                                                                                                                                                                         
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P3b; set work.P3; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=42 then x1=.; if id>=39 and id<51 then x2=.; if id>=49 then x3=.;                                                                                                                                                                                         
end; drop simulation; run;              
data work.P4b; set work.P4; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=56 then x1=.; if id>=52 and id<68 then x2=.; if id>=65 then x3=.;                                                                                                                                                                                         
end; drop simulation; run;   
data work.P5b; set work.P5; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=70 then x1=.; if id>=65 and id<77 then x2=.; if id>=81 then x3=.;                                                                                                                                                                                         
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P6b; set work.P6; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=84 then x1=.; if id>=78 and id<102 then x2=.; if id>=97 then x3=.;                                                                                                                                                                                        
end; drop simulation; run;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
data work.P7b; set work.P7; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=98 then x1=.; if id>=91 and id<119 then x2=.; if id>=113 then x3=.;                                                                                                                                                                                       
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P8b; set work.P8; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=112 then x1=.; if id>=104 and id<136 then x2=.; if id>=129 then x3=.;                                                                                                                                                                                     
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P9b; set work.P9; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=126 then x1=.; if id>=117 and id<153 then x2=.; if id>=145 then x3=.;                                                                                                                                                                                     
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.P10b; set work.P10; do simulation=1 to 250;                                                                                                                                                                                                             
if id<=140 then x1=.; if id>=130 and id<170 then x2=.; if id>=161 then x3=.;                                                                                                                                                                                     
end; drop simulation; run;         
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MISSING COMPLETELY AT RANDOM  
Number of studies equal to 10 
 
 Scenario iv: 40% MCAR in the IPD for all outcomes 
data work.T1b; set work.T1; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=4 then x1=.; if id>=3 and id<7 then x2=.; if id>=7 then x3=.;                                                                                                                                                                                             
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T2b; set work.T2; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=8 then x1=.; if id>=6 and id<14 then x2=.; if id>=13 then x3=.;                                                                                                                                                                                           
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T3b; set work.T3; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=12 then x1=.; if id>=9 and id<21 then x2=.; if id>=19 then x3=.;                                                                                                                                                                                          
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T4b; set work.T4; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=16 then x1=.; if id>=12 and id<28 then x2=.; if id>=25 then x3=.;                                                                                                                                                                                         
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T5b; set work.T5; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=20 then x1=.; if id>=15 and id<35 then x2=.; if id>=31 then x3=.;                                                                                                                                                                                         
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T6b; set work.T6; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=24 then x1=.; if id>=18 and id<42 then x2=.; if id>=37 then x3=.;                                                                                                                                                                                         
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T7b; set work.T7; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=28 then x1=.; if id>=21 and id<49 then x2=.; if id>=43 then x3=.;                                                                                                                                                                                         
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T8b; set work.T8; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=32 then x1=.; if id>=24 and id<56 then x2=.; if id>=49 then x3=.;                                                                                                                                                                                         
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T9b; set work.T9; do simulation=1 to 250;                                                                                                                                                                                                              
if id<=36 then x1=.; if id>=27 and id<63 then x2=.; if id>=55 then x3=.;                                                                                                                                                                                         
end; drop simulation; run;                                                                                                                                                                                                                                       
data work.T10b; set work.T10; do simulation=1 to 250;                                                                                                                                                                                                            
if id<=40 then x1=.; if id>=30 and id<70 then x2=.; if id>=61 then x3=.;                                                                                                                                                                                         
end; drop simulation; run;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
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MISSING AT RANDOM  
Number of studies equal to 5 
 
 Scenario v: 20% MAR in the IPD for outcome 1 
data work.T1b; set work.T1; do simulation=1 to 250; if x1>16.0 then x1=.; 
end; drop simulation; run; 
data work.T2b; set work.T2; do simulation=1 to 250; if x1>17.7 then x1=.; 
end; drop simulation; run; 
data work.T3b; set work.T3; do simulation=1 to 250; if x1>19.5 then x1=.; 
end; drop simulation; run; 
data work.T4b; set work.T4; do simulation=1 to 250; if x1>21.4 then x1=.; 
end; drop simulation; run; 
data work.T5b; set work.T5; do simulation=1 to 250; if x1>23.0 then x1=.; 
end; drop simulation; run; 
data work.P1b; set work.P1; do simulation=1 to 250; if x1>21.8 then x1=.; 
end; drop simulation; run; 
data work.P2b; set work.P2; do simulation=1 to 250; if x1>23.7 then x1=.; 
end; drop simulation; run; 
data work.P3b; set work.P3; do simulation=1 to 250; if x1>25.4 then x1=.; 
end; drop simulation; run; 
data work.P4b; set work.P4; do simulation=1 to 250; if x1>27.2 then x1=.; 
end; drop simulation; run; 
data work.P5b; set work.P5; do simulation=1 to 250; if x1>29.1 then x1=.; 
end; drop simulation; run; 
178 
 
 
MISSING AT RANDOM  
Number of studies equal to 10 
 
 Scenario v: 20% MAR in the IPD for outcome 1 
data work.T1b; set work.T1; do simulation=1 to 250; if x1>14.2 then x1=.;  
end; drop simulation; run;  
data work.T2b; set work.T2; do simulation=1 to 250; if x1>15.7 then x1=.;  
end; drop simulation; run;  
data work.T3b; set work.T3; do simulation=1 to 250; if x1>17.5 then x1=.;  
end; drop simulation; run;  
data work.T4b; set work.T4; do simulation=1 to 250; if x1>19.5 then x1=.;  
end; drop simulation; run;  
data work.T5b; set work.T5; do simulation=1 to 250; if x1>20.6 then x1=.;  
end; drop simulation; run;  
data work.T6b; set work.T6; do simulation=1 to 250; if x1>22.5 then x1=.;  
end; drop simulation; run;  
data work.T7b; set work.T7; do simulation=1 to 250; if x1>23.8 then x1=.;  
end; drop simulation; run;  
data work.T8b; set work.T8; do simulation=1 to 250; if x1>25.9 then x1=.;  
end; drop simulation; run;  
data work.T9b; set work.T9; do simulation=1 to 250; if x1>27.6 then x1=.;  
end; drop simulation; run;  
data work.T10b; set work.T10; do simulation=1 to 250; if x1>29.5 then x1=.;  
end; drop simulation; run;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
data work.P1b; set work.P1; do simulation=1 to 250; if x1>19.9 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                               
data work.P2b; set work.P2; do simulation=1 to 250; if x1>21.5 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                               
data work.P3b; set work.P3; do simulation=1 to 250; if x1>23.5 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                               
data work.P4b; set work.P4; do simulation=1 to 250; if x1>25.0 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                               
data work.P5b; set work.P5; do simulation=1 to 250; if x1>26.5 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                               
data work.P6b; set work.P6; do simulation=1 to 250; if x1>28.2 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                               
data work.P7b; set work.P7; do simulation=1 to 250; if x1>29.7 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                               
data work.P8b; set work.P8; do simulation=1 to 250; if x1>31.7 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                               
data work.P9b; set work.P9; do simulation=1 to 250; if x1>33.5 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                               
data work.P10b; set work.P10; do simulation=1 to 250; if x1>35.1 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run; 
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MISSING AT RANDOM  
Number of studies equal to 5 
 
 Scenario vi : 40% MAR in the IPD for outcome 1 
data work.T1b; set work.T1; do simulation=1 to 250; if x1>11.8 then x1=.;  
end; drop simulation; run;  
data work.T2b; set work.T2; do simulation=1 to 250; if x1>13.0 then x1=.;  
end; drop simulation; run;  
data work.T3b; set work.T3; do simulation=1 to 250; if x1>14.2 then x1=.;  
end; drop simulation; run;  
data work.T4b; set work.T4; do simulation=1 to 250; if x1>15.6 then x1=.;  
end; drop simulation; run;  
data work.T5b; set work.T5; do simulation=1 to 250; if x1>16.7 then x1=.;  
end; drop simulation; run;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
data work.P1b; set work.P1; do simulation=1 to 250; if x1>17.1 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                               
data work.P2b; set work.P2; do simulation=1 to 250; if x1>18.5 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                               
data work.P3b; set work.P3; do simulation=1 to 250; if x1>19.6 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                               
data work.P4b; set work.P4; do simulation=1 to 250; if x1>20.8 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                               
data work.P5b; set work.P5; do simulation=1 to 250; if x1>22.0 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;   
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MISSING AT RANDOM  
Number of studies equal to 10 
 
 Scenario vi : 40% MAR in the IPD for outcome 1 
data work.T1b; set work.T1; do simulation=1 to 250; if x1>10.0 then x1=.;  
end; drop simulation; run;  
data work.T2b; set work.T2; do simulation=1 to 250; if x1>10.9 then x1=.;  
end; drop simulation; run;  
data work.T3b; set work.T3; do simulation=1 to 250; if x1>12.3 then x1=.;  
end; drop simulation; run;  
data work.T4b; set work.T4; do simulation=1 to 250; if x1>13.5 then x1=.;  
end; drop simulation; run;  
data work.T5b; set work.T5; do simulation=1 to 250; if x1>14.3 then x1=.;  
end; drop simulation; run;  
data work.T6b; set work.T6; do simulation=1 to 250; if x1>15.6 then x1=.;  
end; drop simulation; run;  
data work.T7b; set work.T7; do simulation=1 to 250; if x1>16.2 then x1=.;  
end; drop simulation; run;  
data work.T8b; set work.T8; do simulation=1 to 250; if x1>17.8 then x1=.;  
end; drop simulation; run;  
data work.T9b; set work.T9; do simulation=1 to 250; if x1>18.8 then x1=.;  
end; drop simulation; run;  
data work.T10b; set work.T10; do simulation=1 to 250; if x1>20.0 then x1=.;  
end; drop simulation; run;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
data work.P1b; set work.P1; do simulation=1 to 250; if x1>15.1 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                               
data work.P2b; set work.P2; do simulation=1 to 250; if x1>16.3 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                               
data work.P3b; set work.P3; do simulation=1 to 250; if x1>17.7 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                               
data work.P4b; set work.P4; do simulation=1 to 250; if x1>18.9 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                               
data work.P5b; set work.P5; do simulation=1 to 250; if x1>19.3 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                               
data work.P6b; set work.P6; do simulation=1 to 250; if x1>20.6 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                               
data work.P7b; set work.P7; do simulation=1 to 250; if x1>21.4 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                               
data work.P8b; set work.P8; do simulation=1 to 250; if x1>22.8 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                               
data work.P9b; set work.P9; do simulation=1 to 250; if x1>24.1 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                               
data work.P10b; set work.P10; do simulation=1 to 250; if x1>25.3 then x1=.;                                                                                                                                                                                                              
end; drop simulation; run;                                                                                                                                                                                                                                                                                                                                                                                                                                               
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MISSING AT RANDOM  
Number of studies equal to 5 
 
 Scenario vii : 20% MAR in the IPD for all outcomes 
data work.T1b; set work.T1; do simulation=1 to 250; if x1>16.0 then x1=.;  
if x2>12.2 then x2=.; if x3>37.7 then x3=.; end; drop simulation; run;  
data work.T2b; set work.T2; do simulation=1 to 250; if x1>17.7 then x1=.;  
if x2>14.1 then x2=.; if x3>39.0 then x3=.; end; drop simulation; run;  
data work.T3b; set work.T3; do simulation=1 to 250; if x1>19.5 then x1=.;  
if x2>15.9 then x2=.; if x3>40.7 then x3=.; end; drop simulation; run;  
data work.T4b; set work.T4; do simulation=1 to 250; if x1>21.4 then x1=.;  
if x2>17.8 then x2=.; if x3>42.9 then x3=.; end; drop simulation; run;  
data work.T5b; set work.T5; do simulation=1 to 250; if x1>23.0 then x1=.;  
if x2>19.5 then x2=.; if x3>44.4 then x3=.; end; drop simulation; run;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
data work.P1b; set work.P1; do simulation=1 to 250; if x1>21.8 then x1=.;                                                                                                                                                                                                              
if x2>16.0 then x2=.; if x3>44.2 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P2b; set work.P2; do simulation=1 to 250; if x1>23.7 then x1=.;                                                                                                                                                                                                              
if x2>18.0 then x2=.; if x3>46.1 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P3b; set work.P3; do simulation=1 to 250; if x1>25.4 then x1=.;                                                                                                                                                                                                              
if x2>19.6 then x2=.; if x3>47.9 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P4b; set work.P4; do simulation=1 to 250; if x1>27.2 then x1=.;                                                                                                                                                                                                              
if x2>21.6 then x2=.; if x3>49.6 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P5b; set work.P5; do simulation=1 to 250; if x1>29.1 then x1=.;                                                                                                                                                                                                              
if x2>23.3 then x2=.; if x3>52.1 then x3=.; end; drop simulation; run;   
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MISSING AT RANDOM  
Number of studies equal to 10 
 
 Scenario vii : 20% MAR in the IPD for all outcomes 
data work.T1b; set work.T1; do simulation=1 to 250; if x1>14.2 then x1=.;  
if x2>12.3 then x2=.; if x3>29.8 then x3=.; end; drop simulation; run;  
data work.T2b; set work.T2; do simulation=1 to 250; if x1>15.7 then x1=.;  
if x2>14.1 then x2=.; if x3>32.5 then x3=.; end; drop simulation; run;  
data work.T3b; set work.T3; do simulation=1 to 250; if x1>17.5 then x1=.;  
if x2>15.7 then x2=.; if x3>34.9 then x3=.; end; drop simulation; run;  
data work.T4b; set work.T4; do simulation=1 to 250; if x1>19.5 then x1=.;  
if x2>16.8 then x2=.; if x3>37.5 then x3=.; end; drop simulation; run;  
data work.T5b; set work.T5; do simulation=1 to 250; if x1>20.6 then x1=.;  
if x2>18.7 then x2=.; if x3>40.6 then x3=.; end; drop simulation; run;  
data work.T6b; set work.T6; do simulation=1 to 250; if x1>22.5 then x1=.;  
if x2>20.4 then x2=.; if x3>44.3 then x3=.; end; drop simulation; run;  
data work.T7b; set work.T7; do simulation=1 to 250; if x1>23.8 then x1=.;  
if x2>22.1 then x2=.; if x3>47.0 then x3=.; end; drop simulation; run;  
data work.T8b; set work.T8; do simulation=1 to 250; if x1>25.9 then x1=.;  
if x2>23.3 then x2=.; if x3>50.1 then x3=.; end; drop simulation; run;  
data work.T9b; set work.T9; do simulation=1 to 250; if x1>27.6 then x1=.;  
if x2>24.9 then x2=.; if x3>52.9 then x3=.; end; drop simulation; run;  
data work.T10b; set work.T10; do simulation=1 to 250; if x1>29.5 then x1=.;  
if x2>26.8 then x2=.; if x3>55.5 then x3=.; end; drop simulation; run;    
data work.P1b; set work.P1; do simulation=1 to 250; if x1>19.9 then x1=.;                                                                                                                                                                                                              
if x2>16.2 then x2=.; if x3>36.9 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P2b; set work.P2; do simulation=1 to 250; if x1>21.5 then x1=.;                                                                                                                                                                                                              
if x2>17.8 then x2=.; if x3>38.6 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P3b; set work.P3; do simulation=1 to 250; if x1>23.5 then x1=.;                                                                                                                                                                                                              
if x2>19.6 then x2=.; if x3>41.1 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P4b; set work.P4; do simulation=1 to 250; if x1>25.0 then x1=.;                                                                                                                                                                                                              
if x2>20.7 then x2=.; if x3>44.5 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P5b; set work.P5; do simulation=1 to 250; if x1>26.5 then x1=.;                                                                                                                                                                                                              
if x2>22.5 then x2=.; if x3>48.4 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P6b; set work.P6; do simulation=1 to 250; if x1>28.2 then x1=.;                                                                                                                                                                                                              
if x2>24.2 then x2=.; if x3>51.1 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P7b; set work.P7; do simulation=1 to 250; if x1>29.7 then x1=.;                                                                                                                                                                                                              
if x2>26.3 then x2=.; if x3>54.2 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P8b; set work.P8; do simulation=1 to 250; if x1>31.7 then x1=.;                                                                                                                                                                                                              
if x2>27.3 then x2=.; if x3>57.1 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P9b; set work.P9; do simulation=1 to 250; if x1>33.5 then x1=.;                                                                                                                                                                                                              
if x2>28.8 then x2=.; if x3>59.3 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P10b; set work.P10; do simulation=1 to 250; if x1>35.1 then x1=.;                                                                                                                                                                                                              
if x2>30.6 then x2=.; if x3>62.5 then x3=.; end; drop simulation; run;   
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MISSING AT RANDOM  
Number of studies equal to 5 
 
 Scenario viii: 40% MAR in the IPD for all outcomes 
data work.T1b; set work.T1; do simulation=1 to 250; if x1>11.8 then x1=.;  
if x2>9.3 then x2=.; if x3>30.8 then x3=.; end; drop simulation; run;  
data work.T2b; set work.T2; do simulation=1 to 250; if x1>13.0 then x1=.;  
if x2>10.6 then x2=.; if x3>32.0 then x3=.; end; drop simulation; run;  
data work.T3b; set work.T3; do simulation=1 to 250; if x1>14.2 then x1=.;  
if x2>11.9 then x2=.; if x3>33.0 then x3=.; end; drop simulation; run;  
data work.T4b; set work.T4; do simulation=1 to 250; if x1>15.6 then x1=.;  
if x2>13.1 then x2=.; if x3>34.6 then x3=.; end; drop simulation; run;  
data work.T5b; set work.T5; do simulation=1 to 250; if x1>16.7 then x1=.;  
if x2>14.1 then x2=.; if x3>35.6 then x3=.; end; drop simulation; run;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
data work.P1b; set work.P1; do simulation=1 to 250; if x1>17.1 then x1=.;                                                                                                                                                                                                              
if x2>12.4 then x2=.; if x3>37.1 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P2b; set work.P2; do simulation=1 to 250; if x1>18.5 then x1=.;                                                                                                                                                                                                              
if x2>13.8 then x2=.; if x3>38.5 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P3b; set work.P3; do simulation=1 to 250; if x1>19.6 then x1=.;                                                                                                                                                                                                              
if x2>15.0 then x2=.; if x3>39.6 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P4b; set work.P4; do simulation=1 to 250; if x1>20.8 then x1=.;                                                                                                                                                                                                              
if x2>16.2 then x2=.; if x3>40.7 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P5b; set work.P5; do simulation=1 to 250; if x1>22.0 then x1=.;                                                                                                                                                                                                              
if x2>17.6 then x2=.; if x3>42.2 then x3=.; end; drop simulation; run;                                                                                                                                                                                                                                                                                                                                                                                                                                                
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MISSING AT RANDOM  
Number of studies equal to 10 
 
 Scenario viii: 40% MAR in the IPD for all outcomes 
data work.T1b; set work.T1; do simulation=1 to 250; if x1>10.0 then x1=.;  
if x2>9.5 then x2=.; if x3>23.2 then x3=.; end; drop simulation; run;  
data work.T2b; set work.T2; do simulation=1 to 250; if x1>10.9 then x1=.;  
if x2>10.5 then x2=.; if x3>24.9 then x3=.; end; drop simulation; run;  
data work.T3b; set work.T3; do simulation=1 to 250; if x1>12.3 then x1=.;  
if x2>11.5 then x2=.; if x3>27.2 then x3=.; end; drop simulation; run;  
data work.T4b; set work.T4; do simulation=1 to 250; if x1>13.5 then x1=.;  
if x2>12.1 then x2=.; if x3>29.4 then x3=.; end; drop simulation; run;  
data work.T5b; set work.T5; do simulation=1 to 250; if x1>14.3 then x1=.;  
if x2>13.4 then x2=.; if x3>31.8 then x3=.; end; drop simulation; run;  
data work.T6b; set work.T6; do simulation=1 to 250; if x1>15.6 then x1=.;  
if x2>14.6 then x2=.; if x3>34.3 then x3=.; end; drop simulation; run;  
data work.T7b; set work.T7; do simulation=1 to 250; if x1>16.2 then x1=.;  
if x2>15.5 then x2=.; if x3>36.3 then x3=.; end; drop simulation; run;  
data work.T8b; set work.T8; do simulation=1 to 250; if x1>17.8 then x1=.;  
if x2>16.3 then x2=.; if x3>39.0 then x3=.; end; drop simulation; run;  
data work.T9b; set work.T9; do simulation=1 to 250; if x1>18.8 then x1=.;  
if x2>17.2 then x2=.; if x3>40.9 then x3=.; end; drop simulation; run;  
data work.T10b; set work.T10; do simulation=1 to 250; if x1>20.0 then x1=.;  
if x2>18.6 then x2=.; if x3>43.3 then x3=.; end; drop simulation; run;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
data work.P1b; set work.P1; do simulation=1 to 250; if x1>15.1 then x1=.;                                                                                                                                                                                                              
if x2>12.8 then x2=.; if x3>29.5 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P2b; set work.P2; do simulation=1 to 250; if x1>16.3 then x1=.;                                                                                                                                                                                                              
if x2>13.9 then x2=.; if x3>31.2 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P3b; set work.P3; do simulation=1 to 250; if x1>17.7 then x1=.;                                                                                                                                                                                                              
if x2>14.9 then x2=.; if x3>33.0 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P4b; set work.P4; do simulation=1 to 250; if x1>18.9 then x1=.;                                                                                                                                                                                                              
if x2>15.2 then x2=.; if x3>35.7 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P5b; set work.P5; do simulation=1 to 250; if x1>19.3 then x1=.;                                                                                                                                                                                                              
if x2>16.5 then x2=.; if x3>38.2 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P6b; set work.P6; do simulation=1 to 250; if x1>20.6 then x1=.;                                                                                                                                                                                                              
if x2>17.8 then x2=.; if x3>40.6 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P7b; set work.P7; do simulation=1 to 250; if x1>21.4 then x1=.;                                                                                                                                                                                                              
if x2>19.1 then x2=.; if x3>42.7 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P8b; set work.P8; do simulation=1 to 250; if x1>22.8 then x1=.;                                                                                                                                                                                                              
if x2>19.6 then x2=.; if x3>45.0 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P9b; set work.P9; do simulation=1 to 250; if x1>24.1 then x1=.;                                                                                                                                                                                                              
if x2>20.4 then x2=.; if x3>47.2 then x3=.; end; drop simulation; run;                                                                                                                                                                               
data work.P10b; set work.P10; do simulation=1 to 250; if x1>25.3 then x1=.;                                                                                                                                                                                                              
if x2>21.8 then x2=.; if x3>49.5 then x3=.; end; drop simulation; run;     
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D.2 First Stage IPD meta-analysis 
 
SAS 
Proc mixed separate analysis MODEL 
 
proc mixed cl method=reml data=work.Datasim2;                                                                                                                                                                                                                    
by Simulation Study;                                                                                                                                                                                                                                             
class Outcome id Treated;                                                                                                                                                                                                                                        
ods listing close;                                                                                                                                                                                                                                             
ods output solutionf=Fixed1;                                                                                                                                                                                                                                   
model Y = Outcome1 Treated*Outcome1/ noint s cl covb corrb;                                                                                                                                                  
repeated Outcome/ type=un subject=id;                                                                                                                                                                                                                            
run;  
 
proc mixed cl method=reml data=work.Datasim2;                                                                                                                                                                                                                    
by Simulation Study;                                                                                                                                                                                                                                             
class Outcome id Treated;                                                                                                                                                                                                                                        
  ods listing close;                                                                                                                                                                                                                                             
  ods output solutionf=Fixed2;                                                                                                                                                                                                                                    
model Y = Outcome2 Treated*Outcome2/ noint s cl covb corrb;                                                                                                                                                  
repeated Outcome/ type=un subject=id;                                                                                                                                                                                                                            
run;  
 
proc mixed cl method=reml data=work.Datasim2;                                                                                                                                                                                                                    
by Simulation Study;                                                                                                                                                                                                                                             
class Outcome id Treated;                                                                                                                                                                                                                                        
  ods listing close;                                                                                                                                                                                                                                             
  ods output solutionf=Fixed3;                                                                                                                                                                                                                                    
model Y = Outcome3 Treated*Outcome3/ noint s cl covb corrb;                                                                                                                                                  
repeated Outcome/ type=un subject=id;                                                                                                                                                                                                                            
run; 
 
Proc mixed joint analysis MODEL 
proc mixed cl method=reml data=work.Datasim2;                                                                                                                                                                                                                    
by Simulation Study;                                                                                                                                                                                                                                             
class Outcome id Treated;                                                                                                                                                                                                                                        
  ods listing close;                                                                                                                                                                                                                                             
  ods output solutionf=Fixed;                                                                                                                                                                                                                                    
model Y = Outcome1 Outcome2 Outcome3 Treated*Outcome1 Treated*Outcome2 Treated*Outcome3/ noint s cl 
covb corrb;                                                                                                                                                  
repeated Outcome/ type=un subject=id;                                                                                                                                                                                                                            
run;  
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D.3 Second Stage IPD meta-analysis 
 
STATA 
 
Univariate fixed-effects meta-analysis 
 
mvmeta y S, var(y1) fixed 
mvmeta y S, var(y2) fixed 
mvmeta y S, var(y3) fixed                      
                                                                                                                                                                                                                                                                                                                                                                                                                  
Multivariate fixed-effects meta-analysis 
 
mvmeta y S, fixed                       
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APPENDIX E 
MULTIVARIATE META-ANALYSIS FIXED-EFFECTS SIMULATIONS 
RESULTS MISSING COMPLETLY AT RANDOM AND MISSING AT 
RANDOM SCENARIOS 
 
 
In the following tables 1 refers to the outcome 1 (TJC), 2 refers to the outcome 2 (SJC) 
and finally 3 refers to the outcome 3 (pain). 
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Table E.1 Complete case 
Patient  
level 
correlation 
No. 
Studies 
Method 
Bias SEsim Coverage Power MSE Borrowing of Strength 
μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 
0 
 
5 
UFMAj/MFMA 
0.044 -0.0001 -0.024 0.852 0.666 1.213 94.0% 96.2% 94.4% 100.0% 99.1% 99.9% 0.729 0.444 1.473 
 10 0.015 -0.003 0.018 0.756 0.625 1.041 93.8% 93.2% 94.5% 100.0% 99.7% 99.9% 0.572 0.391 1.083 
0.2 
 
5 
UFMAj** 0.044 0.005 -0.014 0.852 0.666 1.222 94.0%  96.2% 93.9% 100.0% 99.3% 99.6% 0.729 0.444 1.494 MFMA vs. UFMA 
MFMA*** 0.038 0.002 -0.017 0.845 0.660 1.212 93.2% 95.8% 93.6% 100.0% 99.4% 99.7% 0.715 0.435 1.469 1.8% 1.9% 1.7% 
10 
UFMAj 0.015 0.005 0.018 0.756 0.625 1.044 93.8% 93.2% 94.0% 100.0% 99.7% 100.0% 0.572 0.390 1.091 MFMA vs. UFMA  
MFMA 0.019 -0.005 0.022 0.746 0.616 1.032 93.4% 92.1% 93.0% 100.0% 99.7% 100.0% 0.557 0.379 1.066 2.6% 2.8% 2.3% 
 
0.5 
5 
UFMAj 0.044 0.013 0.007 0.852 0.667 1.223 94.0% 96.0% 94.0% 100.0% 99.3% 99.8% 0.729 0.444 1.496 MFMA vs. UFMA 
MFMA 0.037 0.011 0.001 0.844 0.660 1.211 93.3% 95.4% 93.3% 100.0% 99.5% 99.8% 0.714 0.435 1.467 2.0% 2.1% 1.9% 
10 
UFMAj 0.015 0.014 0.021 0.756 0.624 1.044 93.8% 94.6% 93.6% 100.0% 99.9% 100.0% 0.572 0.390 1.091 MFMA vs. UFMA 
MFMA 0.018 0.0001 0.024 0.745 0.615 1.030 93.4% 94.0% 93.2% 100.0% 99.9% 100.0% 0.556 0.378 1.062 2.8% 3.1% 2.6% 
0.8 
 
5 
UFMAj 0.044 0.022 0.033 0.852 0.667 1.224 94.0% 95.3% 93.6% 100.0% 99.5% 99.8% 0.729 0.446 1.499 MFMA vs. UFMA 
MFMA 0.035 0.020 0.023 0.840 0.657 1.206 93.1% 94.0% 93.0% 100.0% 99.5% 99.7% 0.707 0.432 1.456 2.8% 2.9% 2.9% 
10 
UFMAj 0.015 0.016 0.022 0.756 0.624 1.044 93.8% 94.8% 93.9% 100.0% 99.8% 100.0% 0.572 0.390 1.090 MFMA vs. UFMA 
MFMA 0.015 0.005 0.023 0.741 0.611 1.023 92.9% 93.3% 93.1% 100.0% 99.8% 100.0% 0.550 0.373 1.048 3.9% 4.3% 3.9% 
RA_corr* 
5 
UFMAj 0.044 0.018 0.010 0.852 0.667 1.223 94.0% 95.8% 93.8% 100.0% 99.5% 99.8% 0.729 0.445 1.495 MFMA vs. UFMA  
MFMA 0.036 0.016 0.005 0.844 0.660 1.211 93.3% 95.3% 93.8% 100.0% 99.6% 99.8% 0.713 0.436 1.468 2.0% 2.0% 1.8% 
10 
UFMAj 0.015 0.016 0.022 0.756 0.624 1.044 93.8% 94.4% 93.8% 100.0% 99.9% 100.0% 0.572 0.390 1.090 MFMA vs. UFMA  
MFMA 0.017 0.003 0.029 0.745 0.615 1.031 93.1% 93.8% 93.0% 100.0% 99.9% 100.0% 0.556 0.378 1.063 2.9% 3.0% 2.5% 
*RA_corr: TJC&SJC: 0.67 TJC&Pain: 0.55 SJC&Pain: 0.38     **UFMAj: Univariate fixed-effects meta-analysis joint model      ***MFMA: Multivariate fixed-effects meta-analysis 
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Table E.2 20% MCAR in one outcome (μ1)  
Patient  
level 
correlation  
No.  
Studies 
Method 
Bias SEsim Coverage Power MSE 
Borrowing of Strength 
μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 
0 
5 
UFMAj/MFMA 0.075 0.010 -0.006 0.946 0.665 1.214 94.4% 93.8% 93.6% 99.9% 99.3% 99.7% 0.900 0.443 1.473 
 
UFMAs/MFMA 0.013 0.013 0.062 0.950 0.667 1.214 95.1% 93.4% 93.2% 99.7% 99.2% 99.3% 0.903 0.445 1.478 
10 
UFMAj/MFMA 0.043 0.003 -0.006 0.836 0.625 1.040 92.8% 94.4% 94.6% 99.9% 99.8% 99.9% 0.701 0.391 1.081 
UFMAs/MFMA 0.035 0.049 -0.065 0.840 0.625 1.040 93.2% 93.9% 94.2% 99.9% 99.4% 99.8% 0.706 0.393 1.087 
0.2 
5 
UFMAj* 0.079 0.022 0.013 0.940 0.665 1.223 94.2% 94.1% 93.4% 99.9% 99.4% 99.5% 0.889 0.443 1.496 Comparison μ1 μ2 μ3 
UFMAs** 0.013 0.014 0.069 0.950 0.667 1.223 95.1% 93.7% 93.2% 99.7% 99.4% 99.2% 0.903 0.446 1.501 MFMA vs UFMAj 2.0% 2.0% 1.9% 
MFMA*** 0.078 0.024 0.012 0.930 0.659 1.211 93.4% 93.9% 93.4% 99.9% 99.5% 99.4% 0.872 0.435 1.468 MFMA vs UFMAs 3.7% 2.2% 1.6% 
10 
UFMAj 0.040 0.009 0.004 0.831 0.625 1.044 93.2% 94.2% 95.2% 99.9% 99.8% 99.9% 0.692 0.391 1.090     
UFMAs 0.035 0.052 -0.047 0.840 0.625 1.045 93.2% 93.8% 95.1% 99.9% 99.5% 99.8% 0.706 0.394 1.094 MFMA vs UFMAj 2.9% 3.0% 2.5% 
MFMA 0.045 0.014 0.001 0.819 0.616 1.031 92.9% 92.9% 94.1% 99.9% 99.9% 99.9% 0.673 0.379 1.062 MFMA vs UFMAs 4.6% 2.7% 2.5% 
0.5 
5 
UFMAj 0.082 0.040 0.044 0.915 0.666 1.223 94.6% 94.0% 94.5% 99.9% 99.6% 99.5% 0.845 0.445 1.498 Comparison μ1 μ2 μ3 
UFMAs 0.013 0.017 0.072 0.950 0.668 1.224 95.1% 94.2% 94.4% 99.7% 99.5% 99.5% 0.903 0.447 1.503 MFMA vs UFMAj 2.1% 2.2% 2.1% 
MFMA 0.082 0.042 0.050 0.906 0.658 1.210 94.2% 93.8% 93.9% 99.9% 99.5% 99.6% 0.827 0.435 1.467 MFMA vs UFMAs 8.8% 2.5% 1.9% 
10 
UFMAj 0.036 0.019 0.017 0.810 0.625 1.044 93.6% 93.9% 95.0% 99.9% 99.7% 99.9% 0.658 0.391 1.091     
UFMAs 0.035 0.051 -0.020 0.840 0.626 1.046 93.2% 94.1% 94.7% 99.9% 99.5% 99.9% 0.706 0.394 1.094 MFMA vs UFMAj 3.1% 3.2% 2.8% 
MFMA 0.041 0.023 0.022 0.798 0.615 1.030 93.1% 92.7% 94.5% 99.9% 99.9% 99.9% 0.638 0.379 1.061 MFMA vs UFMAs 9.5% 3.1% 2.8% 
*UFMAj: Univariate fixed-effects meta-analysis joint model  **UFMAs: Univariate fixed-effects meta-analysis separate model  ***MFMA: Multivariate fixed-effects meta-analysis              
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Table E.2 20% MCAR in one outcome (μ1) 
Patient 
level 
correlation  
No. 
Studies 
Method 
Bias SEsim Coverage Power MSE 
Borrowing of Strength 
μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 
0.8 
5 
UFMAj** 0.083 0.056 0.079 0.879 0.666 1.222 95.1% 95.4% 95.5% 100.0% 99.9% 99.8% 0.780 0.447 1.500 Comparison μ1 μ2 μ3 
UFMAs*** 0.012 0.021 0.067 0.950 0.668 1.225 95.2% 95.3% 95.5% 99.8% 99.7% 99.9% 0.903 0.447 1.504 MFMA vs UFMAj 2.9% 3.1% 3.0% 
MFMA**** 0.084 0.058 0.090 0.867 0.656 1.204 94.3% 95.0% 95.0% 99.9% 99.5% 99.7% 0.758 0.433 1.458 MFMA vs UFMAs 16.5% 3.3% 3.0% 
10 
UFMAj 0.031 0.028 0.032 0.780 0.625 1.044 93.9% 94.1% 94.5% 99.9% 99.6% 99.9% 0.609 0.391 1.092     
UFMAs 0.035 0.043 0.008 0.840 0.626 1.046 93.2% 93.9% 94.5% 99.9% 99.9% 99.9% 0.706 0.394 1.095 MFMA vs UFMAj 4.1% 4.3% 3.9% 
MFMA 0.039 0.031 0.041 0.764 0.611 1.024 93.0% 92.9% 94.1% 99.9% 99.8% 99.9% 0.585 0.375 1.050 MFMA vs UFMAs 17.0% 4.4% 4.1% 
RA_corr* 
5 
UFMAj 0.083 0.049 0.048 0.895 0.666 1.222 94.7% 94.2% 94.1% 99.9% 99.6% 99.5% 0.809 0.446 1.496 Comparison μ1 μ2 μ3 
UFMAs 0.013 0.019 0.067 0.950 0.668 1.224 95.1% 94.0% 93.9% 99.7% 99.6% 99.4% 0.903 0.447 1.502 MFMA vs UFMAj 2.2% 2.2% 1.9% 
MFMA 0.083 0.050 0.049 0.886 0.659 1.210 94.4% 94.9% 93.7% 99.9% 99.6% 99.5% 0.791 0.437 1.467 MFMA vs UFMAs 12.8% 2.4% 1.8% 
10 
UFMAj 0.028 0.048 -0.041 0.794 0.626 1.045 93.7% 93.9% 94.3% 99.9% 99.7% 99.9% 0.632 0.394 1.094     
UFMAs 0.035 0.049 -0.041 0.840 0.626 1.045 93.2% 93.9% 94.3% 99.9% 99.7% 99.9% 0.706 0.394 1.094 MFMA vs UFMAj 3.1% 3.2% 2.6% 
MFMA 0.023 0.044 -0.034 0.782 0.616 1.032 92.5% 92.5% 93.0% 99.9% 99.6% 99.9% 0.612 0.381 1.065 MFMA vs UFMAs 13.3% 3.2% 2.6% 
*RA_corr: TJC&SJC: 0.67 TJC&Pain: 0.55 SJC&Pain: 0.38  **UFMAj: Univariate fixed-effects meta-analysis joint model  ***UFMAs: Univariate fixed-effects meta-analysis separate model  ****MFMA: Multivariate fixed-effects meta-
analysis              
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Table E.3 40% MCAR in one outcome (μ1)  
Patient 
level 
correlation 
No. 
Studies 
Method 
Bias SEsim Coverage Power MSE 
Borrowing of Strength 
μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 
0 
5 
UFMAj/MFMA 0.027 0.013 0.062 1.083 0.667 1.214 94.7% 93.4% 93.2% 99.5% 99.2% 99.3% 1.173 0.445 1.478 
 
UFMAs/MFMA 0.026 0.013 0.062 1.091 0.667 1.214 94.9% 93.4% 93.2% 99.5% 99.2% 99.3% 1.191 0.445 1.478 
10 
UFMAj/MFMA -0.015 0.049 -0.065 0.954 0.625 1.040 92.2% 93.9% 94.2% 99.8% 99.4% 99.8% 0.910 0.393 1.087 
UFMAs/MFMA -0.012 0.049 -0.065 0.962 0.625 1.040 92.8% 93.9% 94.2% 99.8% 99.4% 99.8% 0.926 0.393 1.087 
0.2 
5 
UFMAj* 0.029 0.014 0.069 1.069 0.667 1.223 94.9% 93.7% 93.2% 99.6% 99.4% 99.2% 1.143 0.446 1.501 Comparison μ1 μ2 μ3 
UFMAs** 0.026 0.014 0.069 1.091 0.667 1.223 94.9% 93.7% 93.2% 99.5% 99.4% 99.2% 1.191 0.446 1.501 MFMA vs UFMAj 2.0% 2.0% 1.9% 
MFMA*** 0.024 0.018 0.086 1.058 0.661 1.211 95.0% 93.1% 92.7% 99.4% 99.2% 99.3% 1.120 0.437 1.475 MFMA vs UFMAs 5.9% 2.0% 1.9% 
10      
UFMAj -0.015 0.052 -0.047 0.942 0.625 1.045 92.1% 93.8% 95.1% 99.8% 99.5% 99.8% 0.888 0.394 1.094     
UFMAs -0.012 0.052 -0.047 0.962 0.625 1.045 92.8% 93.8% 95.1% 99.8% 99.5% 99.8% 0.926 0.394 1.094 MFMA vs UFMAj 3.4% 3.2% 2.7% 
MFMA -0.026 0.045 -0.043 0.926 0.615 1.031 91.2% 92.7% 94.1% 99.8% 99.6% 99.8% 0.858 0.380 1.064 MFMA vs UFMAs 7.4% 3.2% 2.7% 
0.5 
5 
UFMAj 0.030 0.017 0.072 1.012 0.668 1.224 95.6% 94.2% 94.4% 99.7% 99.5% 99.5% 1.026 0.447 1.503 Comparison μ1 μ2 μ3 
UFMAs 0.026 0.017 0.072 1.091 0.668 1.224 94.9% 99.5% 94.4% 94.2% 99.5% 99.5% 1.191 0.447 1.503 MFMA vs UFMAj 2.2% 2.2% 2.1% 
MFMA 0.024 0.022 0.087 1.001 0.661 1.211 94.5% 94.0% 93.5% 99.7% 99.5% 99.5% 1.002 0.437 1.474 MFMA vs UFMAs 15.7% 2.2% 2.1% 
10 
UFMAj -0.005 0.051 -0.020 0.894 0.626 1.046 92.4% 94.1% 94.7% 99.9% 99.5% 99.9% 0.799 0.394 1.094     
UFMAs -0.012 0.051 -0.020 0.962 0.626 1.046 92.8% 94.1% 94.7% 99.8% 99.5% 99.9% 0.926 0.394 1.094 MFMA vs UFMAj 3.6% 3.4% 2.9% 
MFMA -0.014 0.043 -0.020 0.878 0.615 1.030 91.3% 92.6% 94.1% 99.9% 99.6% 99.9% 0.770 0.380 1.062 MFMA vs UFMAs 16.8% 3.4% 2.9% 
*UFMAj: Univariate fixed-effects meta-analysis joint model  **UFMAs: Univariate fixed-effects meta-analysis separate model  ***MFMA: Multivariate fixed-effects meta-analysis              
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Table E.3 40% MCAR in one outcome (μ1) 
Patient  
level 
correlation 
No. 
Studies 
Method 
Bias SEsim Coverage Power MSE 
Borrowing of Strength 
μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 
0.8 
5 
UFMAj**  0.029 0.022 0.067 0.926 0.668 1.225 95.2% 95.3% 95.5% 99.9% 99.7% 99.9% 0.858 0.447 1.504 Comparison μ1 μ2 μ3 
UFMAs*** 0.026 0.022 0.067 1.091 0.668 1.225 95.0% 95.6% 95.5% 95.3% 99.7% 99.9% 1.191 0.447 1.504 MFMA vs UFMAj 3.0% 3.1% 3.0% 
MFMA**** 0.025 0.026 0.076 0.912 0.658 1.206 94.8% 94.0% 94.8% 99.8% 99.7% 99.8% 0.832 0.434 1.461 MFMA vs UFMAs 30.0% 3.1% 3.0% 
10 
UFMAj 0.008 0.043 0.006 0.820 0.626 1.046 92.9% 93.8% 94.4% 99.9% 99.9% 99.9% 0.672 0.394 1.095     
UFMAs -0.012 0.043 0.008 0.962 0.626 1.046 92.8% 93.9% 94.5% 99.8% 99.9% 99.9% 0.926 0.394 1.095 MFMA vs UFMAj 4.5% 4.8% 4.1% 
MFMA 0.0004 0.032 -0.004 0.801 0.611 1.024 91.8% 93.1% 93.7% 99.9% 99.6% 99.9% 0.642 0.374 1.049 MFMA vs UFMAs 30.6% 4.7% 4.1% 
RA_corr* 
5 
UFMAj 0.030 0.019 0.067 0.965 0.668 1.224 95.4% 94.0% 93.9% 99.8% 99.6% 99.4% 0.932 0.447 1.502 Comparison μ1 μ2 μ3 
UFMAs 0.026 0.019 0.067 1.091 0.668 1.224 94.9% 94.0% 93.9% 99.5% 99.6% 99.4% 1.191 0.447 1.502 MFMA vs UFMAj 2.3% 2.2% 2.0% 
MFMA 0.025 0.024 0.082 0.954 0.661 1.211 94.8% 94.2% 94.0% 99.8% 99.6% 99.4% 0.910 0.438 1.474 MFMA vs UFMAs 23.5% 2.2% 2.0% 
10 
UFMAj 0.004 0.048 -0.041 0.853 0.626 1.045 92.2% 93.9% 94.3% 99.9% 99.7% 99.9% 0.728 0.394 1.094     
UFMAs -0.012 0.048 -0.041 0.962 0.626 1.045 92.8% 93.9% 94.3% 99.8% 99.7% 99.9% 0.926 0.394 1.094 MFMA vs UFMAj 3.6% 3.4% 2.8% 
MFMA -0.005 0.040 -0.040 0.838 0.615 1.031 91.7% 93.2% 93.5% 99.9% 99.5% 99.9% 0.702 0.380 1.064 MFMA vs UFMAs 24.2% 3.4% 2.8% 
*RA_corr: TJC&SJC: 0.67 TJC&Pain: 0.55 SJC&Pain: 0.38  **UFMAj: Univariate fixed-effects meta-analysis joint model  ***UFMAs: Univariate fixed-effects meta-analysis separate model  ****MFMA: Multivariate fixed-effects 
meta-analysis              
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Table E.4 20% MCAR in all outcomes  
Patient  
level 
correlation 
No. 
Studies 
Method 
Bias SEsim Coverage Power MSE 
Borrowing of Strength 
μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 
0 
5 
UFMAj/MFMA 0.019 0.008 0.082 0.947 0.742 1.349 95.6% 92.4% 93.2% 99.8% 97.1% 99.1% 0.898 0.551 1.826 
 
UFMAs/MFMA 0.018 0.009 0.089 0.951 0.745 1.353 95.5% 92.7% 93.9% 99.7% 97.0% 99.0% 0.904 0.555 1.840 
10 
UFMAj/MFMA 0.014 0.056 -0.083 0.836 0.686 1.154 93.8% 94.1% 94.6% 100.0% 98.3% 99.9% 0.699 0.474 1.338 
UFMAs/MFMA 0.011 0.057 -0.087 0.838 0.688 1.158 94.2% 94.3% 94.9% 100.0% 98.5% 99.9% 0.703 0.477 1.348 
0.2 
5 
UFMAj* 0.015 0.011 0.088 0.941 0.738 1.350 95.3% 93.1% 93.1% 99.9% 97.2% 98.7% 0.887 0.545 1.831 Comparison μ1 μ2 μ3 
UFMAs** 0.018 0.011 0.094 0.951 0.745 1.363 95.5% 93.4% 93.5% 99.7% 97.0% 98.5% 0.904 0.555 1.868 MFMA vs UFMAj 1.9% 2.0% 1.9% 
MFMA*** 0.012 0.012 0.098 0.932 0.730 1.338 94.4% 92.4% 92.9% 100.0% 97.4% 98.7% 0.870 0.533 1.799 MFMA vs UFMAs 3.8% 3.9% 3.8% 
10 
UFMAj 0.020 0.058 -0.065 0.831 0.683 1.152 93.0% 94.0% 95.5% 100.0% 98.5% 99.9% 0.691 0.469 1.330     
UFMAs 0.011 0.063 -0.068 0.838 0.688 1.162 94.1% 94.2% 95.4% 99.9% 98.3% 99.8% 0.703 0.478 1.356 MFMA vs UFMAj 2.8% 3.2% 2.6% 
MFMA 0.020 0.051 -0.063 0.819 0.672 1.136 92.0% 92.3% 94.9% 100.0% 98.6% 99.9% 0.671 0.454 1.295 MFMA vs UFMAs 4.5% 4.7% 4.5% 
0.5 
5 
UFMAj 0.013 0.018 0.090 0.912 0.716 1.309 94.8% 93.9% 93.8% 100.0% 98.4% 99.5% 0.831 0.512 1.722 Comparison μ1 μ2 μ3 
UFMAs 0.017 0.016 0.088 0.951 0.745 1.365 95.5% 94.0% 93.6% 99.7% 97.4% 99.2% 0.904 0.556 1.871 MFMA vs UFMAj 2.1% 2.2% 2.1% 
MFMA 0.028 0.055 -0.034 0.811 0.668 1.124 92.4% 93.6% 95.5% 100.0% 99.2% 100.0% 0.659 0.449 1.265 MFMA vs UFMAs 9.9% 9.8% 10.0% 
10 
UFMAj 0.010 0.021 0.106 0.902 0.708 1.295 94.3% 93.8% 93.6% 100.0% 98.5% 99.5% 0.814 0.501 1.688     
UFMAs 0.011 0.065 -0.037 0.838 0.689 1.163 94.1% 94.0% 94.3% 99.9% 98.3% 99.6% 0.703 0.479 1.355 MFMA vs UFMAj 3.0% 3.6% 2.8% 
MFMA 0.027 0.049 -0.032 0.799 0.656 1.108 91.5% 92.6% 94.2% 100.0% 99.0% 100.0% 0.639 0.432 1.229 MFMA vs UFMAs 9.2% 9.4% 9.2% 
*UFMAj: Univariate fixed-effects meta-analysis joint model  **UFMAs: Univariate fixed-effects meta-analysis separate model  ***MFMA: Multivariate fixed-effects meta-analysis              
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Table E.4 20% MCAR in all outcomes 
Patient  
level 
correlation 
No. 
Studies 
Method 
Bias SEsim Coverage Power MSE 
Borrowing of Strength 
μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 
0.8 
5 
UFMAj** 0.017 0.024 0.080 0.879 0.689 1.263 95.1% 95.1% 95.1% 100.0% 99.2% 99.8% 0.773 0.476 1.603 Comparison μ1 μ2 μ3 
UFMAs*** 0.018 0.021 0.067 0.951 0.745 1.366 95.6% 94.2% 94.9% 99.8% 97.4% 99.3% 0.904 0.555 1.872 MFMA vs UFMAj 2.7% 2.7% 2.8% 
MFMA**** 0.016 0.025 0.093 0.867 0.680 1.245 94.5% 93.5% 94.5% 100.0% 99.1% 99.8% 0.751 0.463 1.559 MFMA vs UFMAs 16.8% 16.6% 16.9% 
10 
UFMAj 0.033 0.045 -0.001 0.781 0.645 1.081 93.0% 94.5% 94.6% 100.0% 99.6% 100.0% 0.611 0.419 1.169     
UFMAs 0.011 0.059 -0.003 0.838 0.689 1.164 94.2% 93.5% 94.1% 100.0% 98.6% 99.8% 0.703 0.479 1.354 MFMA vs UFMAj 3.8% 4.8% 3.6% 
MFMA 0.028 0.039 -0.003 0.766 0.630 1.062 91.7% 92.9% 94.2% 100.0% 99.6% 100.0% 0.588 0.398 1.127 MFMA vs UFMAs 16.5% 16.6% 16.7% 
RA_corr* 
5 
UFMAj 0.015 0.022 0.088 0.894 0.708 1.312 94.9% 94.4% 94.5% 100.0% 98.6% 99.4% 0.800 0.502 1.730 Comparison μ1 μ2 μ3 
UFMAs 0.018 0.018 0.081 0.951 0.745 1.364 95.6% 94.1% 94.2% 99.8% 97.5% 99.3% 0.904 0.556 1.868 MFMA vs UFMAj 2.2% 2.2% 2.0% 
MFMA 0.014 0.024 0.103 0.884 0.701 1.299 94.4% 94.2% 94.3% 100.0% 98.5% 99.4% 0.782 0.491 1.698 MFMA vs UFMAs 13.5% 11.6% 9.3% 
10 
UFMAj 0.032 0.054 -0.056 0.795 0.662 1.127 93.0% 93.9% 95.7% 100.0% 99.1% 99.9% 0.633 0.441 1.273     
UFMAs 0.011 0.062 -0.056 0.838 0.689 1.163 94.1% 93.3% 94.8% 99.9% 98.2% 99.7% 0.703 0.479 1.356 MFMA vs UFMAj 3.0% 3.6% 2.7% 
MFMA 0.030 0.051 -0.051 0.783 0.650 1.111 91.8% 92.8% 95.2% 100.0% 98.7% 99.9% 0.614 0.425 1.238 MFMA vs UFMAs 12.6% 10.9% 8.5% 
*RA_corr: TJC&SJC: 0.67 TJC&Pain: 0.55 SJC&Pain: 0.38  **UFMAj: Univariate fixed-effects meta-analysis joint model  ***UFMAs: Univariate fixed-effects meta-analysis separate model  ****MFMA: Multivariate fixed-effects meta-
analysis              
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Table E.5 40% MCAR in all outcomes  
Patient  
level 
correlation 
No. 
Studies 
Method 
Bias SEsim Coverage Power MSE 
Borrowing of Strength 
μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 
0 
5 
UFMAj/MFMA 0.032 0.019 0.078 1.078 0.840 1.537 94.4% 92.1% 93.6% 99.2% 93.2% 96.8% 1.164 0.706 2.368 
 
UFMAs/MFMA 0.028 0.019 0.078 1.092 0.849 1.557 95.1% 92.7% 93.7% 99.2% 93.2% 96.7% 1.193 0.720 2.430 
10 
UFMAj/MFMA -0.008 0.066 -0.074 0.951 0.781 1.305 91.6% 92.1% 93.3% 99.9% 94.4% 99.2% 0.905 0.614 1.708 
UFMAs/MFMA -0.009 0.067 -0.076 0.968 0.795 1.331 93.7% 93.4% 94.4% 99.9% 94.4% 99.4% 0.938 0.637 1.778 
0.2 
5 
UFMAj* 0.033 0.021 0.074 1.069 0.833 1.534 94.4% 91.5% 93.6% 99.4% 93.5% 97.0% 1.143 0.694 2.357 Comparison μ1 μ2 μ3 
UFMAs** 0.028 0.020 0.077 1.092 0.849 1.568 95.1% 92.6% 93.8% 99.2% 93.6% 96.8% 1.193 0.721 2.464 MFMA vs UFMAj 1.9% 2.2% 1.8% 
MFMA*** 0.035 0.028 0.083 1.058 0.824 1.519 93.9% 91.2% 92.9% 99.3% 93.4% 97.0% 1.121 0.679 2.316 MFMA vs UFMAs 6.0% 5.8% 6.1% 
10 
UFMAj -0.026 0.038 -0.041 0.942 0.773 1.299 91.4% 92.7% 92.9% 99.9% 96.2% 99.2% 0.888 0.600 1.690     
UFMAs -0.007 0.067 -0.043 0.968 0.796 1.337 93.7% 93.9% 94.3% 99.9% 94.8% 99.4% 0.938 0.637 1.789 MFMA vs UFMAj 7.3% 7.9% 8.4% 
MFMA -0.002 0.007 -0.026 0.900 0.736 1.233 83.8% 84.7% 79.9% 98.1% 94.0% 95.9% 0.810 0.541 1.522 MFMA vs UFMAs 12.3% 13.1% 13.6% 
0.5 
5 
UFMAj 0.032 0.026 0.067 1.023 0.797 1.469 94.7% 92.6% 93.4% 99.6% 94.7% 98.1% 1.048 0.636 2.163 Comparison μ1 μ2 μ3 
UFMAs 0.028 0.023 0.071 1.092 0.849 1.569 95.1% 93.5% 94.0% 99.2% 92.5% 97.0% 1.193 0.721 2.467 MFMA vs UFMAj 2.2% 2.4% 2.1% 
MFMA 0.031 0.034 0.076 1.012 0.788 1.453 93.3% 91.0% 92.9% 99.5% 94.4% 98.1% 1.024 0.621 2.118 MFMA vs UFMAs 14.1% 13.9% 14.1% 
10 
UFMAj 0.014 0.037 -0.065 0.901 0.741 1.246 92.4% 93.3% 92.6% 99.8% 97.2% 99.7% 0.813 0.550 1.556     
UFMAs -0.007 0.058 0.004 0.968 0.796 1.338 93.7% 94.5% 93.9% 99.9% 95.5% 99.2% 0.938 0.637 1.790 MFMA vs UFMAj 7.7% 8.3% 8.1% 
MFMA -0.005 0.024 -0.087 0.862 0.706 1.189 83.1% 84.0% 81.0% 98.6% 94.1% 97.8% 0.743 0.499 1.422 MFMA vs UFMAs 19.8% 20.4% 20.2% 
*UFMAj: Univariate fixed-effects meta-analysis joint model  **UFMAs: Univariate fixed-effects meta-analysis separate model  ***MFMA: Multivariate fixed-effects meta-analysis              
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Table E.5 40% MCAR in all outcomes 
Patient  
level 
correlation 
No. 
Studies 
Method 
Bias SEsim Coverage Power MSE 
Borrowing of Strength 
μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 
0.8 
5 
UFMAj** 0.027 0.028 0.065 0.938 0.732 1.349 94.5% 93.9% 94.8% 99.8% 97.7% 99.0% 0.881 0.537 1.823 Comparison μ1 μ2 μ3 
UFMAs*** 0.028 0.030 0.061 1.092 0.848 1.570 95.2% 94.5% 95.2% 99.3% 92.9% 96.7% 1.193 0.721 2.469 MFMA vs UFMAj 2.8% 3.0% 2.7% 
MFMA**** 0.024 0.033 0.072 0.925 0.721 1.330 93.6% 92.6% 93.5% 99.8% 97.8% 98.9% 0.856 0.521 1.775 MFMA vs UFMAs 28.1% 27.6% 28.1% 
10 
UFMAj 0.015 0.055 -0.001 0.830 0.682 1.146 93.2% 93.3% 93.9% 100.0% 98.7% 100.0% 0.689 0.469 1.313     
UFMAs -0.007 0.042 0.047 0.968 0.797 1.339 93.8% 94.2% 94.4% 100.0% 95.0% 99.3% 0.938 0.637 1.794 MFMA vs UFMAj 9.4% 11.2% 8.6% 
MFMA 0.053 0.060 0.072 0.782 0.636 1.085 82.7% 80.9% 83.8% 98.2% 94.8% 97.3% 0.615 0.408 1.183 MFMA vs UFMAs 33.4% 34.9% 33.0% 
RA_corr* 
5 
UFMAj 0.035 0.031 0.077 0.991 0.785 1.478 94.8% 92.9% 93.3% 99.6% 95.2% 97.9% 0.983 0.618 2.191 Comparison μ1 μ2 μ3 
UFMAs 0.028 0.027 0.078 1.092 0.849 1.569 95.1% 93.2% 94.3% 99.2% 92.5% 97.0% 1.193 0.721 2.467 MFMA vs UFMAj 2.4% 2.5% 2.0% 
MFMA 0.033 0.039 0.082 0.979 0.776 1.464 92.8% 92.3% 93.5% 99.7% 95.4% 98.0% 0.959 0.603 2.149 MFMA vs UFMAs 19.6% 16.4% 12.9% 
10 
UFMAj 0.009 0.042 -0.011 0.875 0.731 1.253 92.7% 91.5% 92.1% 99.9% 97.2% 99.3% 0.765 0.536 1.571     
UFMAs -0.009 0.051 -0.018 0.968 0.797 1.338 93.6% 94.4% 93.9% 99.9% 95.3% 99.2% 0.938 0.637 1.790 MFMA vs UFMAj 8.4% 8.8% 8.4% 
MFMA 0.009 -0.004 0.020 0.831 0.692 1.190 81.8% 83.4% 81.2% 98.0% 94.6% 96.9% 0.691 0.478 1.416 MFMA vs UFMAs 25.2% 23.2% 19.6% 
*RA_corr: TJC&SJC: 0.67 TJC&Pain: 0.55 SJC&Pain: 0.38  **UFMAj: Univariate fixed-effects meta-analysis joint model  ***UFMAs: Univariate fixed-effects meta-analysis separate model  ****MFMA: Multivariate fixed-effects meta-
analysis              
 
 
 
197 
 
 
Table E.6 20% MAR in one outcome (μ1)  
Patient 
level 
correlation 
No. 
Studies 
Method 
Bias SEsim Coverage Power MSE 
Borrowing of Strength 
μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 
0 
5 
UFMAj/MFMA 0.301 0.013 0.062 0.724 0.667 1.214 94.0% 93.5% 93.3% 100.0% 99.3% 99.4% 0.615 0.445 1.478 
 
UFMAs/MFMA 0.298 0.013 0.062 0.726 0.667 1.214 93.9% 93.5% 93.3% 100.0% 99.3% 99.4% 0.616 0.445 1.478 
10 
UFMAj/MFMA 0.356 0.049 -0.065 0.643 0.625 1.040 90.2% 94.0% 94.3% 100.0% 99.5% 99.9% 0.540 0.393 1.086 
UFMAs/MFMA 0.356 0.049 -0.065 0.645 0.625 1.040 89.9% 94.0% 94.3% 100.0% 99.5% 99.9% 0.543 0.393 1.087 
0.2 
5 
UFMAj* 0.287 0.014 0.069 0.722 0.667 1.223 93.5% 93.8% 93.3% 100.0% 99.5% 99.3% 0.603 0.446 1.501 Comparison μ1 μ2 μ3 
UFMAs** 0.298 0.014 0.069 0.726 0.667 1.223 93.9% 93.8% 93.3% 100.0% 99.5% 99.3% 0.616 0.446 1.501 MFMA vs UFMAj 2.0% 2.0% 1.9% 
MFMA*** 0.282 0.016 0.078 0.715 0.661 1.211 92.9% 93.2% 92.8% 100.0% 99.5% 99.3% 0.590 0.437 1.473 MFMA vs UFMAs 3.2% 2.0% 1.9% 
10 
UFMAj 0.344 0.052 -0.047 0.641 0.625 1.045 90.1% 93.9% 95.2% 100.0% 99.6% 99.9% 0.529 0.394 1.094     
UFMAs 0.356 0.052 -0.047 0.645 0.625 1.045 89.9% 93.9% 95.2% 100.0% 99.6% 99.9% 0.543 0.394 1.094 MFMA vs UFMAj 2.8% 3.0% 2.5% 
MFMA 0.341 0.049 -0.048 0.632 0.616 1.032 89.9% 93.0% 94.3% 100.0% 99.6% 100.0% 0.515 0.382 1.066 MFMA vs UFMAs 4.0% 3.0% 2.5% 
0.5 
5 
UFMAj 0.228 0.017 0.072 0.719 0.668 1.224 94.7% 94.3% 94.5% 100.0% 99.6% 99.6% 0.569 0.447 1.503 Comparison μ1 μ2 μ3 
UFMAs 0.298 0.017 0.072 0.726 0.668 1.224 93.9% 94.3% 94.5% 100.0% 99.6% 99.6% 0.616 0.447 1.503 MFMA vs UFMAj 2.1% 2.3% 2.2% 
MFMA 0.224 0.019 0.077 0.712 0.660 1.210 94.0% 93.4% 93.3% 100.0% 99.7% 99.5% 0.557 0.436 1.471 MFMA vs UFMAs 4.0% 2.3% 2.2% 
10 
UFMAj 0.281 0.051 -0.020 0.639 0.626 1.046 91.6% 94.2% 94.8% 100.0% 99.6% 100.0% 0.487 0.394 1.094     
UFMAs 0.356 0.051 -0.020 0.645 0.626 1.046 89.9% 94.2% 94.8% 100.0% 99.6% 100.0% 0.543 0.394 1.094 MFMA vs UFMAj 3.0% 3.4% 2.9% 
MFMA 0.277 0.044 -0.026 0.629 0.615 1.030 91.0% 92.6% 94.0% 100.0% 99.7% 100.0% 0.472 0.380 1.062 MFMA vs UFMAs 4.8% 3.4% 2.9% 
*UFMAj: Univariate fixed-effects meta-analysis joint model   **UFMAs: Univariate fixed-effects meta-analysis separate model  ***MFMA: Multivariate fixed-effects meta-analysis 
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Table E.6 20% MAR in one outcome (μ1) 
Patient 
level 
correlation 
No. Studies Method 
Bias SEsim Coverage Power MSE 
Borrowing of Strength 
μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 
 0.8 
5 
UFMAj** 0.119 0.022 0.067 0.754 0.668 1.225 96.0% 95.3% 95.5% 100.0% 99.7% 99.9% 0.583 0.447 1.504 Comparison μ1 μ2 μ3 
UFMAs*** 0.298 0.022 0.067 0.744 0.668 1.225 93.9% 95.3% 95.5% 100.0% 99.7% 99.9% 0.616 0.447 1.504 MFMA vs UFMAj 2.7% 3.4% 3.3% 
MFMA**** 0.120 0.025 0.074 0.726 0.657 1.204 95.4% 94.3% 94.9% 100.0% 99.7% 99.9% 0.568 0.432 1.456 MFMA vs UFMAs 4.9% 3.4% 3.3% 
10 
UFMAj 0.281 0.051 -0.020 0.639 0.626 1.046 91.6% 94.2% 94.8% 100.0% 99.6% 100.0% 0.487 0.394 1.094     
UFMAs 0.356 0.051 -0.020 0.645 0.626 1.046 89.9% 94.2% 94.8% 100.0% 99.6% 100.0% 0.543 0.394 1.094 MFMA vs UFMAj 3.0% 3.4% 2.9% 
MFMA 0.277 0.044 -0.026 0.629 0.615 1.030 91.0% 92.6% 94.0% 100.0% 99.7% 100.0% 0.472 0.380 1.062 MFMA vs UFMAs 4.8% 3.4% 2.9% 
RA_corr* 
5 
UFMAj 0.162 0.019 0.067 0.731 0.668 1.224 95.9% 94.1% 94.0% 100.0% 99.7% 99.5% 0.560 0.447 1.502 Comparison μ1 μ2 μ3 
UFMAs 0.298 0.019 0.067 0.726 0.668 1.224 93.9% 94.1% 94.0% 100.0% 99.7% 99.5% 0.616 0.447 1.502 MFMA vs UFMAj 2.1% 2.4% 2.1% 
MFMA 0.160 0.022 0.075 0.723 0.660 1.211 95.4% 94.0% 94.1% 100.0% 99.7% 99.4% 0.548 0.436 1.471 MFMA vs UFMAs 0.9% 2.4% 2.1% 
10 
UFMAj 0.209 0.048 -0.041 0.649 0.626 1.045 92.1% 94.0% 94.4% 100.0% 99.8% 100.0% 0.464 0.394 1.094     
UFMAs 0.356 0.048 -0.041 0.645 0.626 1.045 89.9% 94.0% 94.4% 100.0% 99.8% 100.0% 0.543 0.394 1.094 MFMA vs UFMAj 2.9% 3.5% 2.8% 
MFMA 0.206 0.042 -0.045 0.639 0.615 1.031 91.9% 92.9% 93.4% 100.0% 99.8% 100.0% 0.451 0.380 1.064 MFMA vs UFMAs 1.8% 3.5% 2.8% 
*RA_corr: TJC&SJC: 0.67 TJC&Pain: 0.55 SJC&Pain: 0.38  **UFMAj: Univariate fixed-effects meta-analysis joint model   ***UFMAs: Univariate fixed-effects meta-analysis separate model  ****MFMA: Multivariate fixed-effects 
meta-analysis              
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Table E.7 40% MAR in one outcome (μ1)  
Patient 
level 
correlation 
No. 
Studies 
Method 
Bias SEsim Coverage Power MSE 
Borrowing of Strength 
μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 
0 
5 
UFMAj/MFMA 0.592 0.013 0.062 0.704 0.667 1.214 84.3% 93.5% 93.3% 100.0% 99.3% 99.4% 0.846 0.445 1.478 
 
UFMAs/MFMA 0.592 0.013 0.062 0.709 0.667 1.214 84.9% 93.5% 93.3% 100.0% 99.3% 99.4% 0.854 0.445 1.478 
10 
UFMAj/MFMA 0.653 0.049 -0.065 0.622 0.625 1.040 77.7% 94.0% 94.3% 100.0% 99.5% 99.9% 0.814 0.393 1.087 
UFMAs/MFMA 0.651 0.049 -0.065 0.628 0.625 1.040 78.5% 94.0% 94.3% 100.0% 99.5% 99.9% 0.818 0.393 1.087 
0.2 
5 
UFMAj* 0.575 0.014 0.069 0.700 0.667 1.223 84.1% 93.8% 93.3% 100.0% 99.5% 99.3% 0.821 0.446 1.501 Comparison μ1 μ2 μ3 
UFMAs** 0.592 0.014 0.069 0.709 0.667 1.223 84.9% 93.8% 93.3% 100.0% 99.5% 99.3% 0.854 0.446 1.501 MFMA vs UFMAj 2.1% 2.1% 2.0% 
MFMA*** 0.569 0.015 0.069 0.693 0.661 1.211 83.5% 93.1% 92.3% 100.0% 99.4% 99.3% 0.804 0.437 1.471 MFMA vs UFMAs 4.5% 2.1% 2.0% 
10 
UFMAj 0.636 0.051 -0.048 0.619 0.625 1.045 78.1% 93.9% 95.2% 100.0% 99.6% 99.9% 0.788 0.394 1.094     
UFMAs 0.651 0.052 -0.047 0.628 0.625 1.045 78.5% 93.9% 95.2% 100.0% 99.6% 99.9% 0.818 0.394 1.094 MFMA vs UFMAj 3.5% 3.3% 2.7% 
MFMA 0.634 0.053 -0.053 0.608 0.615 1.030 77.1% 91.8% 93.7% 100.0% 99.4% 99.9% 0.772 0.381 1.065 MFMA vs UFMAs 6.2% 3.3% 2.7% 
0.5 
5 
UFMAj 0.489 0.017 0.072 0.690 0.668 1.224 87.9% 94.3% 94.5% 100.0% 99.6% 99.6% 0.715 0.447 1.503 Comparison μ1 μ2 μ3 
UFMAs 0.592 0.017 0.072 0.709 0.668 1.224 84.9% 94.3% 94.5% 100.0% 99.6% 99.6% 0.854 0.447 1.503 MFMA vs UFMAj 2.3% 2.5% 2.3% 
MFMA 0.482 0.018 0.069 0.682 0.660 1.210 87.2% 92.9% 93.4% 100.0% 99.6% 99.5% 0.697 0.436 1.468 MFMA vs UFMAs 7.5% 2.5% 2.3% 
10 
UFMAj 0.544 0.051 -0.020 0.610 0.626 1.046 82.2% 94.2% 94.8% 100.0% 99.6% 100.0% 0.668 0.394 1.094     
UFMAs 0.651 0.051 -0.020 0.628 0.626 1.046 78.5% 94.2% 94.8% 100.0% 99.6% 100.0% 0.818 0.394 1.094 MFMA vs UFMAj 3.8% 3.9% 3.3% 
MFMA 0.542 0.051 -0.027 0.599 0.613 1.028 81.1% 93.0% 94.0% 100.0% 99.5% 100.0% 0.652 0.379 1.058 MFMA vs UFMAs 9.0% 3.9% 3.3% 
*UFMAj: Univariate fixed-effects meta-analysis joint model   **UFMAs: Univariate fixed-effects meta-analysis separate model     ***MFMA: Multivariate fixed-effects meta-analysis              
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Table E.7 40% MAR in one outcome (μ1)  
Patient level 
correlation 
No. 
Studies 
Method 
Bias SEsim Coverage Power MSE 
Borrowing of Strength 
μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 
0.8 
5 
UFMAj** 0.289 0.022 0.067 0.712 0.668 1.225 93.6% 95.3% 95.5% 100.0% 99.7% 99.9% 0.590 0.447 1.504 Comparison μ1 μ2 μ3 
UFMAs*** 0.592 0.022 0.067 0.709 0.668 1.225 84.9% 95.3% 95.5% 100.0% 99.7% 99.9% 0.854 0.447 1.504 MFMA vs UFMAj 2.9% 3.9% 3.8% 
MFMA**** 0.288 0.029 0.075 0.701 0.655 1.201 92.8% 94.5% 94.8% 100.0% 99.6% 99.9% 0.575 0.430 1.449 MFMA vs UFMAs 2.0% 3.9% 3.7% 
10 
UFMAj 0.329 0.043 0.008 0.630 0.626 1.046 90.6% 94.0% 94.6% 100.0% 100.0% 100.0% 0.505 0.394 1.095     
UFMAs 0.651 0.043 0.008 0.628 0.626 1.046 78.5% 94.0% 94.6% 100.0% 100.0% 100.0% 0.818 0.394 1.095 MFMA vs UFMAj 4.5% 6.0% 5.4% 
MFMA 0.331 0.046 0.006 0.615 0.607 1.017 88.5% 92.4% 93.2% 99.9% 99.6% 99.9% 0.488 0.370 1.035 MFMA vs UFMAs 3.8% 6.0% 5.4% 
RA_corr* 
5 
UFMAj 0.378 0.019 0.067 0.692 0.668 1.224 91.5% 94.1% 94.0% 100.0% 99.7% 99.5% 0.622 0.447 1.502 Comparison μ1 μ2 μ3 
UFMAs 0.592 0.019 0.067 0.709 0.668 1.224 84.9% 94.1% 94.0% 100.0% 99.7% 99.5% 0.854 0.447 1.502 MFMA vs UFMAj 2.4% 2.7% 2.3% 
MFMA 0.373 0.024 0.070 0.684 0.659 1.209 90.6% 93.6% 94.2% 100.0% 99.6% 99.4% 0.607 0.435 1.467 MFMA vs UFMAs 6.8% 2.7% 2.3% 
10 
UFMAj 0.427 0.048 -0.041 0.613 0.626 1.045 86.9% 94.0% 94.4% 100.0% 99.8% 100.0% 0.558 0.394 1.094     
UFMAs 0.651 0.048 -0.041 0.628 0.626 1.045 78.5% 94.0% 94.4% 100.0% 99.8% 100.0% 0.818 0.394 1.094 MFMA vs UFMAj 3.8% 4.2% 3.3% 
MFMA 0.427 0.049 -0.046 0.601 0.612 1.028 85.8% 93.3% 93.9% 100.0% 99.5% 100.0% 0.544 0.377 1.059 MFMA vs UFMAs 8.3% 4.2% 3.3% 
* RA_corr: TJC&SJC: 0.67 TJC&Pain: 0.55 SJC&Pain: 0.38    **UFMAj: Univariate fixed-effects meta-analysis joint model   ***UFMAs: Univariate fixed-effects meta-analysis separate model    ****MFMA: Multivariate fixed-
effects meta-analysis              
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Table E.8 20% MAR in all outcomes  
Patient 
level 
correlation 
No. 
Studies 
Method 
Bias SEsim Coverage Power MSE 
Borrowing of Strength 
μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 
0 
5 
UFMAj/MFMA 0.301 0.364 0.277 0.724 0.567 1.034 93.6% 88.5% 94.3% 100.0% 99.5% 100.0% 0.615 0.454 1.145 
 
UFMAs/MFMA 0.298 0.365 0.273 0.726 0.568 1.036 93.9% 89.1% 94.2% 100.0% 99.5% 100.0% 0.616 0.457 1.149 
10 
UFMAj/MFMA 0.355 0.530 0.285 0.643 0.344 0.884 89.9% 89.2% 93.3% 100.0% 99.9% 100.0% 0.643 0.399 0.863 
UFMAs/MFMA 0.356 0.344 0.288 0.645 0.532 0.887 89.9% 90.1% 93.3% 100.0% 99.8% 100.0% 0.645 0.401 0.869 
0.2 
5 
UFMAj** 0.295 0.361 0.425 0.723 0.566 1.039 93.5% 88.2% 93.3% 100.0% 99.6% 100.0% 0.609 0.451 1.260 Comparison μ1 μ2 μ3 
UFMAs*** 0.298 0.365 0.434 0.726 0.569 1.044 93.9% 87.7% 93.0% 100.0% 99.6% 100.0% 0.616 0.457 1.279 MFMA vs UFMAj 2.0% 2.1% 2.0% 
MFMA**** 0.292 0.362 0.424 0.715 0.560 1.028 92.9% 87.5% 93.3% 100.0% 99.6% 99.9% 0.597 0.444 1.237 MFMA vs UFMAs 3.0% 3.1% 3.0% 
10 
UFMAj 0.349 0.352 0.373 0.641 0.529 0.886 90.5% 88.9% 93.1% 100.0% 99.9% 100.0% 0.533 0.404 0.924     
UFMAs 0.356 0.354 0.387 0.645 0.532 0.891 89.9% 89.5% 92.7% 100.0% 99.9% 100.0% 0.543 0.409 0.943 MFMA vs UFMAj 3.0% 3.4% 2.8% 
MFMA 0.349 0.353 0.371 0.631 0.520 0.873 88.9% 87.7% 92.7% 100.0% 99.8% 100.0% 0.521 0.395 0.901 MFMA vs UFMAs 4.1% 4.5% 3.8% 
0.5 
5 
UFMAj 0.272 0.344 0.389 0.714 0.560 1.028 93.5% 88.8% 92.9% 100.0% 99.8% 100.0% 0.584 0.432 1.208 Comparison μ1 μ2 μ3 
UFMAs 0.298 0.368 0.433 0.726 0.569 1.045 93.9% 89.3% 91.9% 100.0% 99.5% 100.0% 0.616 0.459 1.279 MFMA vs UFMAj 2.3% 2.4% 2.2% 
MFMA 0.263 0.344 0.381 0.706 0.553 1.016 92.6% 88.5% 92.0% 100.0% 99.8% 100.0% 0.568 0.424 1.178 MFMA vs UFMAs 5.4% 5.6% 5.4% 
10 
UFMAj 0.325 0.340 0.350 0.634 0.524 0.876 91.4% 89.3% 92.5% 100.0% 99.9% 100.0% 0.508 0.390 0.890     
UFMAs 0.356 0.358 0.406 0.645 0.533 0.891 89.9% 89.4% 91.4% 100.0% 99.9% 100.0% 0.543 0.412 0.959 MFMA vs UFMAj 3.3% 3.6% 3.0% 
MFMA 0.315 0.335 0.343 0.624 0.514 0.863 89.9% 89.4% 91.4% 100.0% 100.0% 100.0% 0.488 0.377 0.863 MFMA vs UFMAs 6.4% 6.7% 6.1% 
*RA_corr: TJC&SJC: 0.67 TJC&Pain: 0.55 SJC&Pain: 0.38  **UFMAj: Univariate fixed-effects meta-analysis joint model    ***UFMAs: Univariate fixed-effects meta-analysis separate model   ****MFMA: Multivariate fixed-effects 
meta-analysis              
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Table E.8 20% MAR in all outcomes 
Patient level 
correlation 
No. 
Studies 
Method 
Bias SEsim Coverage Power MSE 
Borrowing of Strength 
μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 
0.8 
5 
UFMAj** 0.241 0.300 0.314 0.708 0.555 1.018 94.0% 90.1% 93.7% 100.0% 99.8% 100.0% 0.559 0.398 1.134 Comparison μ1 μ2 μ3 
UFMAs*** 0.298 0.356 0.411 0.726 0.569 1.044 93.9% 88.7% 92.3% 100.0% 99.5% 100.0% 0.616 0.451 1.259 MFMA vs UFMAj 2.7% 2.9% 2.6% 
MFMA**** 0.235 0.302 0.313 0.698 0.547 1.004 93.7% 89.8% 93.3% 100.0% 99.8% 100.0% 0.543 0.390 1.106 MFMA vs UFMAs 7.6% 7.7% 7.4% 
10 
UFMAj 0.285 0.310 0.293 0.628 0.520 0.840 91.7% 90.9% 92.1% 100.0% 99.9% 100.0% 0.476 0.366 0.868     
UFMAs 0.356 0.347 0.410 0.645 0.533 0.961 89.9% 89.3% 90.2% 100.0% 99.8% 100.0% 0.543 0.404 0.891 MFMA vs UFMAj 3.8% 4.4% 3.6% 
MFMA 0.277 0.305 0.282 0.616 0.508 0.806 90.6% 89.0% 90.9% 100.0% 99.9% 100.0% 0.457 0.351 0.852 MFMA vs UFMAs 8.6% 9.1% 8.4% 
RA_corr* 
5 
UFMAj 0.259 0.329 0.394 0.710 0.558 1.028 93.3% 90.0% 92.8% 100.0% 99.7% 100.0% 0.571 0.420 1.212 Comparison μ1 μ2 μ3 
UFMAs 0.298 0.362 0.432 0.726 0.569 1.044 93.9% 89.7% 92.4% 100.0% 99.7% 100.0% 0.616 0.455 1.275 MFMA vs UFMAj 2.4% 2.4% 2.2% 
MFMA 0.252 0.332 0.389 0.701 0.552 1.017 92.8% 89.3% 92.5% 100.0% 99.7% 100.0% 0.556 0.414 1.185 MFMA vs UFMAs 6.7% 6.2% 5.1% 
10 
UFMAj 0.306 0.326 0.338 0.630 0.523 0.877 91.2% 91.1% 92.4% 100.0% 99.8% 100.0% 0.491 0.379 0.883     
UFMAs 0.356 0.351 0.388 0.645 0.533 0.890 89.9% 90.8% 92.2% 100.0% 99.8% 100.0% 0.543 0.407 0.944 MFMA vs UFMAj 3.4% 3.7% 2.9% 
MFMA 0.292 0.321 0.328 0.619 0.513 0.864 90.8% 90.2% 92.3% 100.0% 99.8% 100.0% 0.469 0.366 0.854 MFMA vs UFMAs 7.7% 7.4% 5.8% 
*RA_corr: TJC&SJC: 0.67 TJC&Pain: 0.55 SJC&Pain: 0.38  **UFMAj: Univariate fixed-effects meta-analysis joint model    ***UFMAs: Univariate fixed-effects meta-analysis separate model   ****MFMA: Multivariate fixed-effects 
meta-analysis              
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Table E.9 40% MAR in all outcome 
Patient 
level 
correlation 
No. 
Studies 
Method 
Bias SEsim Coverage Power MSE 
Borrowing of Strength 
μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 
0 
5 
UFMAj/MFMA 0.595 0.684 0.576 0.703 0.551 1.005 83.9% 74.7% 91.9% 100.0% 98.5% 100.0% 0.848 0.772 1.342 
 
UFMAs/MFMA 0.592 0.683 0.574 0.709 0.556 1.013 84.9% 75.6% 91.6% 100.0% 98.5% 100.0% 0.854 0.776 1.357 
10 
UFMAj/MFMA 0.663 0.624 0.648 0.624 0.516 0.858 76.4% 75.9% 86.1% 100.0% 99.5% 100.0% 0.829 0.655 1.156 
UFMAs/MFMA 0.651 0.620 0.622 0.628 0.518 0.865 78.5% 76.1% 87.6% 100.0% 99.5% 100.0% 0.818 0.653 1.135 
0.2 
5 
UFMAj* 0.591 0.679 0.691 0.702 0.550 1.012 84.0% 73.4% 89.3% 100.0% 98.4% 100.0% 0.842 0.764 1.501 Comparison μ1 μ2 μ3 
UFMAs** 0.592 0.681 0.700 0.709 0.556 1.021 84.9% 74.8% 89.7% 100.0% 98.4% 100.0% 0.854 0.773 1.534 MFMA vs UFMAj 2.3% 2.4% 2.2% 
MFMA*** 0.588 0.677 0.681 0.694 0.544 1.000 82.8% 72.5% 88.4% 100.0% 98.4% 100.0% 0.827 0.755 1.464 MFMA vs UFMAs 4.2% 4.3% 4.1% 
10 
UFMAj 0.659 0.618 0.705 0.622 0.515 0.860 77.5% 77.1% 85.9% 100.0% 99.7% 100.0% 0.822 0.647 1.237     
UFMAs 0.651 0.617 0.704 0.628 0.519 0.869 78.5% 78.2% 86.0% 100.0% 99.7% 100.0% 0.818 0.650 1.249 MFMA vs UFMAj 5.3% 5.8% 4.8% 
MFMA 0.640 0.621 0.674 0.605 0.499 0.839 73.0% 72.5% 81.8% 100.0% 98.7% 100.0% 0.776 0.635 1.158 MFMA vs UFMAs 6.9% 7.2% 6.7% 
0.5 
5 
UFMAj 0.564 0.647 0.630 0.692 0.543 0.997 84.6% 76.6% 90.3% 100.0% 99.1% 100.0% 0.798 0.713 1.391 Comparison μ1 μ2 μ3 
UFMAs 0.592 0.671 0.673 0.708 0.556 1.021 84.8% 75.8% 89.6% 99.9% 98.2% 99.9% 0.853 0.760 1.495 MFMA vs UFMAj 2.7% 2.9% 2.6% 
MFMA 0.558 0.644 0.614 0.683 0.535 0.984 84.5% 74.8% 88.3% 100.0% 99.0% 100.0% 0.778 0.702 1.346 MFMA vs UFMAs 6.7% 6.9% 6.6% 
10 
UFMAj 0.622 0.600 0.651 0.613 0.507 0.847 78.5% 76.6% 85.4% 100.0% 99.7% 100.0% 0.762 0.617 1.142     
UFMAs 0.651 0.612 0.698 0.628 0.519 0.868 78.5% 77.5% 85.3% 100.0% 99.6% 100.0% 0.818 0.644 1.242 MFMA vs UFMAj 5.3% 6.1% 4.8% 
MFMA 0.590 0.610 0.609 0.596 0.491 0.827 74.9% 70.6% 81.6% 99.9% 99.0% 99.8% 0.703 0.614 1.055 MFMA vs UFMAs 9.6% 10.3% 9.3% 
*UFMAj: Univariate fixed-effects meta-analysis joint model  **UFMAs: Univariate fixed-effects meta-analysis separate model  ***MFMA: Multivariate fixed-effects meta-analysis              
 
 
204 
 
 
Table E.9 40% MAR in all outcome 
Patient level 
correlation 
No. 
Studies 
Method 
Bias SEsim Coverage Power MSE 
Borrowing of Strength 
μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 μ1 μ2 μ3 
0.8 
5 
UFMAj** 0.525 0.595 0.577 0.673 0.527 0.967 86.3% 78.6% 90.9% 100.0% 99.6% 100.0% 0.728 0.632 1.267 Comparison μ1 μ2 μ3 
UFMAs*** 0.592 0.660 0.668 0.709 0.556 1.019 84.9% 76.7% 89.8% 100.0% 98.4% 100.0% 0.854 0.744 1.485 MFMA vs UFMAj 3.4% 3.6% 3.3% 
MFMA**** 0.519 0.596 0.568 0.661 0.518 0.951 84.5% 76.8% 89.2% 100.0% 99.6% 100.0% 0.707 0.624 1.226 MFMA vs UFMAs 12.9% 13.2% 13.0% 
10 
UFMAj 0.569 0.580 0.601 0.596 0.492 0.823 80.1% 77.1% 87.4% 100.0% 99.8% 100.0% 0.679 0.579 1.040     
UFMAs 0.651 0.610 0.725 0.628 0.518 0.868 78.5% 77.2% 85.1% 100.0% 99.5% 100.0% 0.818 0.641 1.280 MFMA vs UFMAj 5.7% 6.4% 5.0% 
MFMA 0.552 0.581 0.575 0.578 0.476 0.803 78.3% 74.6% 83.9% 99.9% 99.4% 100.0% 0.639 0.564 0.975 MFMA vs UFMAs 15.0% 15.5% 14.5% 
RA_corr* 
5 
UFMAj 0.549 0.631 0.633 0.684 0.540 0.999 85.4% 76.0% 89.1% 100.0% 99.4% 100.0% 0.769 0.690 1.398 Comparison μ1 μ2 μ3 
UFMAs 0.592 0.665 0.665 0.709 0.556 1.021 84.9% 75.6% 88.9% 100.0% 98.3% 99.9% 0.854 0.751 1.485 MFMA vs UFMAj 2.9% 3.0% 2.6% 
MFMA 0.541 0.628 0.619 0.674 0.532 0.986 84.7% 75.4% 88.3% 100.0% 98.9% 100.0% 0.747 0.677 1.356 MFMA vs UFMAs 9.7% 8.7% 6.7% 
10 
UFMAj 0.596 0.590 0.666 0.606 0.503 0.849 79.3% 76.8% 85.8% 100.0% 99.7% 100.0% 0.722 0.601 1.165     
UFMAs 0.652 0.611 0.697 0.628 0.518 0.868 78.4% 76.6% 86.2% 100.0% 99.9% 100.0% 0.819 0.643 1.240 MFMA vs UFMAj 5.6% 6.1% 4.8% 
MFMA 0.572 0.595 0.646 0.588 0.488 0.828 76.7% 74.1% 82.3% 99.9% 99.1% 99.7% 0.673 0.592 1.104 MFMA vs UFMAs 12.1% 11.4% 8.9% 
*RA_corr: TJC&SJC: 0.67 TJC&Pain: 0.55 SJC&Pain: 0.38  **UFMAj: Univariate fixed-effects meta-analysis joint model  ***UFMAs: Univariate fixed-effects meta-analysis separate model  ****MFMA: Multivariate fixed-effects 
meta-analysis              
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